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 Abstract 
Glutathione S-transferases (GSTs) are a multi-gene family of enzymes involved in the 
detoxification of a wide range of electrophilic compounds and are an integral component to 
antioxidant defence in the mammalian cell. Among GST, the Pi class (GSTP1) is the most 
prominent extrahepatic isoform in humans, and it is well documented that increased 
expression of this enzyme is present in human tumours and can contribute to anticancer drug 
resistance, involving many compounds which are not known substrates for GSTP1. In 
addition to xenobiotic metabolism, GSTP1 has a key and varied role in cell regulation, 
showing to be a modulator of a stress response pathway and has been implicated in mediating 
sulfhydryl homeostasis. 
 
The present study aims to address functions of GSTP1 which are independent of its catalytic 
activity. Initial in vivo studies have identified that targeting a Tyr7Phe substitution in the 
murine Gstp1 gene results in a GSTP1 protein which is devoid of catalytic activity. When 
challenged with a toxic dose of acetaminophen, these mice show a high degree of resistance 
to the hepatotoxic effects of this compound compared to their wild-type counterparts, in part, 
due to a partial recovery of hepatic glutathione levels. The ability of GSTP1 to mediate 
glutathione homeostasis was demonstrated in vitro, where silencing of GSTP1 in a colon 
carcinoma cell line demonstrated increased levels of glutathione disulphide and protein S-
glutathionylation, a reversible post-translational modification involved in thiol protection. 
Subsequent analysis of GSTP1 silencing in this cell line led to the identification of potential 
novel pathways which may be mediated by GSTP1.This study examines the regulatory 
processes mediated by GSTP1 and aims to further our understanding of this protein in the 
aetiology of disease and toxicity. 
Introduction 
 
1 
 
1. Introduction 
Since initial pioneering studies by Freidrich Woehler on the synthesis of urea and Alexandra 
Ure’s observation on the conversion of benzoic acid to hippuric acid in humans in the mid-
19
th
 Century, the understanding of toxicology and drug metabolism has become pivotal in 
understanding how organisms are able to protect themselves against the diverse range of 
chemicals that they are exposed to. The ability of an organism to metabolise compounds is 
essential in survival, not only in avoiding toxicity through the detoxification of chemicals, but 
also in the breakdown of foods and nutrients for growth. Organisms are exposed to a variety 
of chemicals through a number of different routes. For example, oxygen which is necessary 
for cellular respiration is incredibly chemically reactive, often producing oxidative radicals as 
a reaction by-product which can lead to cytotoxicity. As such, a sophisticated system of 
detoxification is necessary in maintaining cellular homeostasis and mediating cytoprotection.   
 
Despite over 150 years of study into drug metabolism, our understanding of the mechanisms 
involved in these processes remains incomplete. Despite their importance in biological 
processes from prokaryotes to eukaryotes, the composition and genetic variation of drug 
metabolising enzymes (DMEs) vary across species, ethnicities and individuals, which 
complicates the ability to predict the metabolism and activity of a given compound. To add 
further complexity, DMEs have been found to possess cellular functions independent of 
metabolism, adding layers of intricacy in understanding how cellular defence systems are 
integrated. The focus of this thesis will describe how one particular group of DMEs, the 
glutathione S-transferases, are involved in regulating cellular functions other than drug 
metabolism and begin to describe the importance of this enzyme in relation to toxicology and 
tumorigenesis. 
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1.1 Drug metabolism 
Metabolism of xenobiotic compounds largely involves the breakdown or inactivation of a 
lipophilic substrate into a more water soluble and readily excretable by-product. Prof. RT 
Williams initially categorised xenobiotic metabolised in 2 distinct phases (Williams, 1972) 
known as Phase I and Phase II, although a third phase has since been added (Figure 1.1). 
Phase I reactions typically involve oxidation, reduction or hydrolytic reactions which leads to 
the functionalization of a substrate. Phase I reactions are catalysed primarily by enzymes 
from the cytochrome P450 (CYP) family of proteins, so called due to a peak at 450nm in the 
reduced carbon monoxide absorption spectrum. CYPs are a diverse family of hemoproteins 
which facilitate the metabolism of a wide range of exogenous compounds as well as 
regulation of a number of endogenous substrates such as retinoic acid (Otto et al., 2003), 
cholesterol (Henderson et al., 2003) and steroid hormones (Miller, 1988). CYPs act as an 
electron acceptor from cytochrome P450 oxidoreductase to catalyse the addition of oxygen 
into a substrate using NAPDH as a cofactor. The multiplicity of CYP family members 
demonstrates a remarkable diversity in their reaction chemistry, despite evolving from a 
common ancestral gene (Nebert et al., 1987). Reactive metabolites formed from this reaction 
are conjugated with an endogenous substrate through a Phase II reaction which typically 
results in the inactivation of the metabolite. The conjugated substrate can then be excreted 
from the body as a polar compound via drug transporters in what can be regarded as a Phase 
III reaction.  Due to the often bulky nature of the conjugating group or acidity of the 
conjugate (as is the case for glutathione conjugation), Phase III reactions involve the efflux of 
a conjugated-metabolite via a drug transporter such as the ATP binding cassette (ABC) 
family of transporters. Drug transporters are ubiquitous throughout the body and form an 
integral component of the detoxification system in a number of organs, often found highly 
expressed in epithelial and endothelial compartments such as the blood brain barrier and the 
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blood-testes barrier. For the purpose of this introduction, this thesis will focus principally on 
Phase II metabolism although references to CYP mediated reactions and the role of drug 
transporters in toxicology are provided (Guengerich, 2008, Fletcher et al., 2010, Coon, 2005).  
 
 
Figure 1.1. A schematic diagram demonstrating the phases of drug metabolism. 
Xenobiotic compounds are typically metabolised in 3 distinct phases of metabolism highlighted in the top 
diagram. Enzymes typically involved in the catalysis of these reactions are described at each stage. An example 
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of drug metabolism is provided in the lower diagram; acetaminophen (APAP) can be conjugated directly to 
form glucuronide and sulphate derivatives or metabolised by cytochrome P450 enzymes into a highly reactive 
N-acetyl-p-benzoquinone imine metabolite. This can then be conjugated to glutathione spontaneously or 
catalytically by glutathione S-transferases (GSTs). FMO, flavin-containing monooxygenase; MRP, multidrug 
resistance protein; OATP2, organic anion transporting polypeptide 2.  
 
1.2 Phase II metabolism 
Phase II reactions involve the addition of a metabolite which utilises a high energy 
intermediate such as UDP-glucuronic acid, 3’-phosphoadenosine-5’-phosphosulfate (PAPS), 
S-Adenosyl-l-methionine (SAM), acyl-Coenzyme A or utilises a reactive nucleophilic centre 
as is the case for glutathione conjugation. These endogenous substrates are catalysed through 
a number of enzymes and can facilitate the conjugation of a diverse set of reactive groups as 
highlighted in Table 1. 
 
In general, Phase II reactions result in the detoxification of a substrate whereby the reactive 
group becomes highly polar allowing it to be readily excreted into the bile or urine. However, 
there are some instances where conjugation may enhance the toxicity of a compound. Short-
chain alkyl halides and dichloromethane still possess electrophilic moieties after glutathione 
conjugation (Wheeler et al., 2001) while the glutathione-platinum conjugate produced after 
cisplatin metabolism is a substrate for γ-glutamyltranspeptidase and cysteine S-conjugate β-
lyase in the proximal tubules, which results in the formation of reactive thiols (Hanigan et al., 
2001).  
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Conjugation 
Reaction 
Enzyme 
Functional 
group 
Enzyme localisation 
Glucuronidation 
UDP-
glucuronosyltransferase 
-OH 
-COOH 
-NH2 
-SH 
Endoplasmic reticulum 
Sulfation Sulfotransferase 
-NH2 
-OH 
Cytosol 
Golgi apparatus 
Methylation 
Methyltransferase 
 
-OH 
-NH2 
-SH 
Cytosol 
Endoplasmic reticulum 
Acetylation N-acetyltransferase 
-NH2 
-OH 
Cytosol 
Glutathione Glutathione S-transferase 
Epoxides 
Organic halides 
Cytosol 
Peroxisomes 
Mitochondria 
Nucleus 
Amino acid  -COOH Mitochondria 
 
Table 1. Phase II conjugation reactions and their enzymes. 
 
Induction of Phase II enzymes can be mediated by a number of dietary compounds such as 
flavonoids (Han et al., 2012), isothiocyanates (Zhang et al., 1992), phenolic compounds such 
as butylated hydroxyanisole (McLellan et al., 1994, McLellan et al., 1992) and green tea 
polyphenols (Khan et al., 1992) which act through an electrophilic mediated stress response 
resulting in activation of the Antioxidant/Electrophile Response Element (ARE/EpRE) 
embedded in the promoter region of Phase II enzymes (Itoh et al., 1997). Typically, induction 
of Phase II enzymes occurs through the binding of a cap’n’collar basic-region leucine zipper 
protein, nuclear factor erythroid 2-related factor 2 (Nrf2) to the ARE which, in a heterodimer 
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complex with a musculo-aponeurotic fibrosarcoma (Maf) protein, act to recruit CREB 
binding proteins and p300 (Zhu and Fahl, 2001) to facilitate the transcription of Phase II 
enzymes along with other genes involved in cytoprotection such as haem oxygenase-1 (HO-
1) (Alam et al., 1999) and glutamate cysteine ligase (GCL) (McWalter et al., 2004). Basally, 
Nrf2 binds to kelch-like ECH associating protein 1 (Keap1) in the cytoplasm (Itoh et al., 
1999), which results in its ubiquitination through an interaction with the E3-based ligase, 
Cullin 3 (Kobayashi et al., 2004, McMahon et al., 2003). The ability of Keap1 to suppress 
Nrf2 activity is redox dependent. Keap1 contains 25 cysteine residues, nearly 1:3 of which 
are flanked by basic amino acid residues which reduces their pKa value, enhancing their 
reactivity (this form of reactivity is discussed further in Chapter 4) (Dinkova-Kostova et al., 
2001). Interaction of these residues with a number of thiol reactive electrophiles (Itoh et al., 
2003) and endogenous signalling molecules (McMahon et al., 2010) results in the 
inactivation of Keap1 and activation of Nrf2, where it can translocate to the nucleus and 
interact with the ARE. Therefore induction of Phase II enzymes can also occur through the 
production of thiol reactive metabolites indirectly produced as a consequence of cellular 
stress, such as the production of reactive oxidative species (ROS) and free radicals. This 
mechanism outlines an adaptive antioxidant system in which Phase II enzymes form a central 
component in the response to cellular stress in addition to their role in drug metabolism. 
 
1.3 Glutathione S-transferases 
Glutathione S-transferases (GSTs; EC 2.5.1.18) are a multi-gene family of enzymes involved 
in the detoxification of a wide range of electrophilic compounds and are an integral 
component to antioxidant defence in the mammalian cell (Hayes and Pulford, 1995). Found 
in multiple cytosolic and membrane-bound forms, GSTs catalyse the conjugation of the 
ubiquitous tripeptide glutathione in its reduced state (GSH), to reactive xenobiotic and 
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endogenous substrates. GSTs were discovered in 1961 as an enzyme conjugating glutathione 
to halogenated aromatic compounds (Combes and Stakelum, 1961, Booth et al., 1961), but 
were soon found to have activity with a wide range of dissimilar substrates (Pabst et al., 
1973). In addition to xenobiotic metabolism, GSTs have a key and varied role in cell 
regulation, including the biosynthesis of many endogenous substrates, response mechanisms 
in oxidative stress and modulation of several signalling pathways. Furthermore, there is 
evidence to suggest that polymorphisms of GSTs are implicated in the aetiology of many 
human diseases such as asthma (A. Sükrü Aynacioglu, 2004, Zhou et al., 2008), liver disease 
(Alexandra Henrion-Caude, 2002), Parkinsonism (Yoritaka et al., 1996) Alzheimer’s (Pinhel 
et al., 2008), cancer (Huang et al., 2009, Mitrunen et al., 2001, Funke et al., 2010, 
Stoehlmacher et al., 2002) and that overexpression of some GST isoenzymes may make a 
significant contribution to the development of tumorigenesis and anticancer drug resistance 
(Goto et al., 1999, Dang et al., 2005, Funke et al., 2010, Black and Wolf, 1991). 
 
1.3.1 GST nomenclature and structure 
There are 3 mammalian classes of GST which share >50% amino acid sequence identities; 
cytosolic (canonical), mitochondrial (Kappa class) and membrane-associated proteins in 
eicosanoid and glutathione metabolism (MAPEG) (Atkinson and Babbitt, 2009). A fourth 
class of GST has been identified in bacteria as a 16kDa polypeptide metalloenzyme known as 
FosA which catalyzes the addition of glutathione to the antibiotic fosfomycin (Arca et al., 
1990). A nomenclature system proposed by Mannervik et al. provides a detailed outline for 
GST designation (Mannervik et al., 1992) and has since been revised (Mannervik et al., 
2005). Enzyme classes are named in Greek and abbreviated with the corresponding Roman 
letter. For example, the class GST Alpha would be abbreviated as GSTA. Cytosolic GSTs are 
dimeric proteins and subunit components are represented by Arabic numerals. GST genes are 
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italicised and allelic variants are represented by lower case letters. If more than one species is 
described, it is prefixed with a lower case letter denoting the species. For example, human 
GSTP1 is described as hGSTP1 and mouse as mGSTP1. An overview of the different classes 
of human GSTs along with details of their substrate reactivity is provided in Table 2. 
 
Of the GST family, the cytosolic class are the most abundant and widely-studied group and 
are categorised according to their amino acid sequence similarities (Mannervik and 
Danielson, 1988, Hayes et al., 2005). To date there are 7 classes of mammalian cytosolic 
GSTs; Alpha, Mu, Pi (Mannervik et al., 1985b), Sigma (Meyer and Thomas, 1995), Theta 
(Meyer et al., 1991), Zeta (Board et al., 1997) and Omega (Board et al., 2000), although other 
forms have been found in different species (Sheehan et al., 2001). Cytosolic GSTs are 
composed of dimers of approximately 25kDa subunits. Each subunit contains two distinct 
domains; a glutathione-binding ‘G-site’ and a hydrophobic ligand binding ‘H-site’ (Reinemer 
et al., 1991, Reinemer et al., 1992, Wilce et al., 1995, Sinning et al., 1993). The G-site is 
found within the N-terminal domain and is highly conserved throughout the classes, 
containing a serine or tyrosine molecule to stabilise glutathione binding (Reinemer et al., 
1991, Wilce et al., 1995). The fold of the N-terminal domain contains a βαβαββα motif which 
is similar to that of the thioredoxin family of enzymes (Figure 1.2) and is important in 
recognising the γ-glutamyl peptide in glutathione binding (Robinson et al., 2004, Atkinson 
and Babbitt, 2009). The C-terminus, composed of mainly α-helices, contains the H-site which 
is not conserved between classes and can accommodate a wide range of electrophilic 
compounds containing a carbon, nitrogen or sulphur functional group (Hayes and Pulford, 
1995). As a result, few ligands can be used to identify individual classes, although the 
structural differences in the H-site domain between GST classes does allow for some 
substrates to be preferentially bound than others. For example, GSTA4 has strong activity 
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towards products of lipid peroxidation such as 4-hydroxynonenal (Zimniak et al., 1992), 
while GSTP1 has preferential activity towards ethacrynic acid (Phillips and Mantle, 1993). 
The nucleophilic substitution of 1-chloro-2,4-dinitrobenzene (CDNB) to S-(2,4-
dinitrophenyl)glutathione can be commonly catalysed by most GSTs as it is relatively small 
and sterically compliant compared to the H-site and can therefore be used as a universal 
substrate for studying GST activity (Habig et al., 1974).   
 
 
 
Figure 1.2. Schematic topology diagram demonstrating the evolution of the N-terminal 
fold of GSTs from thioredoxin. 
Topology diagram showing the N-terminal fold of thioredoxin (A) and canonical GSTs (B). GSTK1 differs 
from the canonical fold of GSTs in that its helical domain is inserted in the α2 connecting helix. α-helices are 
presented in blue and ß-helices in orange. Adapted from Robinson et al 2004. 
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1.3.2 Role in drug metabolism and chemical detoxification 
The predominant action of GSTs is in the detoxification of xenobiotic or endogenous 
compounds. GSTs catalyse the conjugation of reduced glutathione to many electrophilic 
moieties as a glutathionyl thiolate anion (GS⁻). The binding of GSH to GST results in a 
lowering of the pKa of GSH from 9.2 to 6.5 when bound in the active site. This results in the 
stabilisation of GS⁻ which can then spontaneously react with a diverse range of electrophilic 
compounds (Boyland and Chasseaud, 1969, Chasseaud, 1979). A foreign compound can be 
conjugated to GSH catalytically by one of two main metabolic routes; addition and 
nucleophilic substitutions. Addition reactions involve the transfer of a proton from the thiol 
group to the target compound and are common to most reactions catalysed by GSTs such as 
those of epoxides, isothiocyanates, quinones and alkenes (Berhane et al., 1994, Robertson et 
al., 1986, van Ommen et al., 1991, Chasseaud, 1979, Keen et al., 1976). Substitution 
reactions involve the functional group of a compound being replaced with the GSH thiolate 
such as halides (Saavedra et al., 2001). The resulting glutathione-conjugate can be 
transported from the cell into the bile through a variety of transport systems; the ABC family 
multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) (Loe et al., 1998); the 
anion transporter dinitrophenol S-glutathione (DNP-SG ATPase) (Saxena et al., 1992) and a 
Ral binding protein (RLIP76) which has similar structural and functional properties to DNP-
SG ATPase (Awasthi et al., 2000). Awasthi et al have proposed that the two latter systems 
contribute to the majority of glutathione-conjugate transport in the mammalian cell (Awasthi 
et al., 2005). After transportation from the cell, the conjugate is cleaved in the liver or kidney 
by γ-glutamyltranspeptidase and dipeptidases to yield a cysteine conjugate. This substrate 
may then undergo a series of N-acetylation reactions to produce N-acetylcysteine conjugates 
or mercapturic acid (Pabst et al., 1973, Keen and Jakoby, 1978). 
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Enzyme Gene  Chromosome 
location 
Class Residue to 
stabilise 
GS
-
 
thiolate 
anion 
Enzyme 
activity/reaction 
GSTA1 GSTA1 6p12 Cytosolic Tyr9 CDNB; ∆5-ADD, 
BCDE, BPDE, 
Busulfan, 
Chlorambucil, 
DBADE, DBPDE, 
BPhDE, NBD-Cl; N-a-
PhIP; PGE2; PGF2a 
synthase 
GSTA2-2 GSTA2 6p12 Cytosolic Tyr9 CuOOH, DBPDE, 
CDNB, NBD-Cl, 
CuOOH, PGD2 and 
PGF2a synthase 
GSTA3-3 GSTA3 6p12 Cytosolic Tyr9 ∆5-ADD, ∆5-pregnene-
3,20-dione, DBPDE 
GSTA4-4 GSTA4 6p12 Cytosolic Tyr9 COMC-6, EA, 4-
hydroxynonenal, 4-
hydroxydecenal, 
CDNB 
GSTA5-5 GSTA5 6p12 Cytosolic Tyr9 CDNB, 4-
hydroxynonenal, 
trans-nonenal, acrolein 
GSTM1-1 GSTM1 1p13.3 Cytosolic Tyr6 trans-4-phenyl-3-
buten-2-one, BPDE, 
CDE, DBADE, trans-
stilbene oxide, styrene-
7,8-oxide, CDNB, 
AFB1-epoxide 
GSTM2-2 GSTM2 1p13.3 Cytosolic Tyr6 COMC-6, 1,2-
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dichloro-4-
nitrobenzene, 
aminochrome, dopa O-
quinone, 
PGH2→PGE2, CDNB,  
GSTM3-3 GSTM3 1p13.3 Cytosolic Tyr6 BCNU, PGH2→PGE2, 
H2O2 
GSTM4-4 GSTM4 1p13.3 Cytosolic Tyr6 CDNB 
GSTM5-5 GSTM5 1p13.3 Cytosolic Tyr6 CDNB 
GSTP1-1 GSTP1 11q13 Cytosolic Tyr7 acrolein, base 
propenals, BPDE, 
CDE, Chlorambucil, 
COMC-6, EA, 
Thiotepa,  
GST1-1 GSTT1 22q11.2 Cytosolic Ser11 BCNU, butadiene 
epoxide, CH2Cl2, 
EPNP, ethylene oxide 
GST2-2 GSTT2 22q11.2 Cytosolic Ser11 CuOOH, menaphthyl 
sulfate 
GSTZ1-1 GSTZ1 14q24.3 Cytosolic Ser13 dichloroacetate, 
fluoroacetate, 2-
chloropropionate, 
malelyacetoacetate 
GSTO1-1 GSTO1 10q24.3 Cytosolic Cys32 monomethylarsonic 
acid, dehydroascorbic 
acid 
GSTO2-2 GSTO2 10q24.3 Cytosolic Cys32 dehydroascorbic acid 
GSTS1-1 GSTS1/ 
PGDS2 
4q22.3 Cytosolic Tyr7 PGH2→PGD2 
GSTK1-1 GSTK1 7q34 Mitochondria Ser16 CDNB, CuOOH, (S)-
15-hydroperoxy-
5,8,11, 13-
eicosatetraenoic acid 
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FLAP ALOX5AP 13q12 MAPEG Inactive nonenzymatic binding 
of arachidonic acid 
LTC4S LTC4S 5q35 MAPEG Tyr93/ 
Arg104 
LTA4→LTC4 
MGST1 MGST1/ 
PGES1 
9q34.3 MAPEG Arg126 CDNB, CuOOH, 
hexachlorobuta-1,3-
diene, PGH2→PGE2 
MGST2 MGST2 4q28.3 MAPEG Tyr93/ 
Arg104 
CDNB, LTA4→LTC4, 
(S)-5-hydroperoxy-
8,11, 14-cis-6-trans-
eicosatetraenoic acid 
MGST3 MGST3 1q23 MAPEG Tyr93/ 
Arg104 
CDNB, LTA4→LTC4, 
(S)-5-hydroperoxy-
8,11, 14-cis-6-trans-
eicosatetraenoic acid 
 
Table 2. Description of human GSTs and their enzymatic properties. 
Adapted from Hayes et al 2005, Mannervik et al 2005 and Higgins and Hayes 2011. Abbreviations: ∆5-ADD, 
∆5-androstene-3,17-dione; AFB1, aflatoxin B1; BCDE, benzo[g]chrysene diol epoxide; BCNU, 1,3-bis(2-chlo- 
roethyl)-1-nitrosourea; BPDE, benzo[a]pyrene diol epoxide; BPhDE, benzo[c]phenanthrene diol epoxide; CDE, 
chrysene- 1,2-diol 3,4-epoxide; CDNB, 1-chloro-2,4-dinitrobenzene; CH2Cl2, dichloromethane; COMC-6, 
crotonyloxymethyl-2-cyclohexenone; CuOOH, cumene hydroperoxide; DBADE, dibenz[a,h]anthracene diol 
epoxide; DBPDE, dibenzo[a,l]pyrene diol epoxide; EA, ethacrynic acid; EPNP, 1,2-epoxy-3-(p-
nitrophenoxy)propane; LTA4, leukotriene-A4; LTC4, leukotriene-C4; N-a-PhIP, N-acetoxy-2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine; NBD-Cl, 4-chloro-7-nitrobenzofurazan; PGD2, prostaglandin D2; PGE2, 
prostaglandin E2; PGF2a, prostaglandin F2a; PGH2, prostaglandin H2;  
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1.4 GSTP1  
1.4.1 GSTP1 gene and regulation 
Of the major cytosolic classes, GST Pi (π) is the most prominent extra-hepatic GST in 
humans and was originally discovered as a placental isoform (Dao et al., 1984) but was found 
to be largely expressed in most tissues in humans with the exception of the testes (Campbell 
et al., 1990), retina (Singh et al., 1985) and liver (Hiley et al., 1988). GSTP1 is highly 
conserved among species and is involved in a number of metabolic pathways in addition to 
its role in drug metabolism. In most species a single gene codes for GSTP1, GSTP1, which 
contains 7 exons and, in humans, is located on chromosome 11q13.2. There are a few 
organisms which are unusual in that they contain a second gene, Gstp2, upstream of the 
respective Gstp1 gene such as mice and zebrafish, which is discussed further in Chapter 3. 
Like many other Phase II enzymes, GSTP1 is transcriptionally activated through Nrf2 
binding to its ARE as discussed previously. Rats differ slightly as they contain a regulatory 
element known as a GSTP1 Enhancer 1 (GPE1) motif in the 5’ upstream region (Sakai et al., 
1988) which partly resembles an ARE sequence (Favreau and Pickett, 1995, Higgins and 
Hayes, 2011). From in vivo studies in rat liver, GPE1 is bound by transcription factors 
C/EBPα and CA-150 in quiescent liver cells, which suppress GSTP1 transcription. During 
hepatocarcinogenesis, GPE1 is activated through Nrf2 binding (Sakai and Muramatsu, 2007) 
which can also be co-activated through MafK interaction with a histone acetyltransferase, the 
monocytic leukaemia zinc-finger protein (MOZ) (Ohta et al., 2007).   
 
In addition to ARE activation by electrophiles, other regulatory elements have been identified 
in the human GSTP1 gene and its promoter region and are highlighted in Figure 1.3.  Moffat 
et al demonstrated the presence of an AP-1 site embedded in the ARE sequence which was 
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found to be activated by a Fos-Jun complex (Moffat et al., 1994) which supported previous 
observations made by Xia et al on the requirement of an AP-1 binding site for transcriptional 
activity of GSTP1 (Xia et al., 1991). The binding to AP-1 was found to increase after 
stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), hydrogen peroxide, 
doxorubicin and tert-butylhydroquinone (tBHQ) (Duvoix et al., 2004). Further work by 
Moffat and colleagues demonstrated the presence of an active Sp-1 site (Moffat et al., 1996) 
while Xia et al showed that GSTP1 transcription is suppressed upstream by retinoic acid but 
can be induced through an insulin binding site in intron 1 of GSTP1 (Xia et al., 1993). Further 
work from the same group demonstrated that hydrogen peroxide induces GSTP1 transcription 
through a putative NF-κB binding motif upstream of GSTP1 (Xia et al., 1996). In contrast to 
the data provided by Xia and colleagues, Lo et al demonstrated that retinoic acid binding to a 
retinoic acid response element (RARE) in intron 5 of GSTP1 results in increased 
transcriptional activity of a GSTP1*C haplotype (Lo and Ali-Osman, 1997). The same group 
subsequently identified a p53 binding motif in intron 4 of GSTP1 which is thought to be 
transcriptionally active (Lo et al., 2008); the nature of this motif is discussed later in Sub-
chapter 5. 
 
As recently highlighted by Higgins and Hayes, the characterisation of GST genes at a 
molecular level is not as extensive within the literature as their regulation as a result of 
carcinogenesis and chemical stimulation (Higgins and Hayes, 2011). Although a number of 
regulatory motifs have been identified in GSTP1, some are yet to be fully characterised (see 
Chapter 5 (supplementary study)) while a number of regulatory motifs such as the Fork Head 
Protein (FKHD) and Paired box protein Pax-5, Erythroid Krüppel-like Factor (EKLF) 
binding sites have been predicted for human GSTP1 using computational analysis (Vasieva, 
2011). GSTP1 is also subject to regulation through methylation of CpG islands upstream of 
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GSTP1 leading to reduced transcription of GSTP1. This is particularly apparent in prostate 
cancer where GSTP1 expression is absent  (Lee et al., 1994). Treatment of prostate cancer 
cells with a DNA methyltransferase or histone deactetylase (HDAC) inhibitor restores 
GSTP1 expression (Hauptstock et al., 2011, Lin et al., 2001) while it has been demonstrated 
that the treatment of cells with maspin, a serine protease inhibitor, inhibits HDAC1 to restore 
GSTP1 expression (Li et al., 2011). Interestingly, mice in which the murine Gstp gene cluster 
is deleted and replaced with the orthologous human GSTP1 gene demonstrate a CpG 
methylation pattern in mouse liver similar to that of human adult cells (Vaughn et al., 2011). 
However, this did not account for the lack of GSTP1 expression in the livers of these mice 
and therefore other cis-regulatory elements may explain differences in expression. 
 
 
Figure 1.3. Schematic diagram of the human GSTP1 gene and its promoter region with 
regulatory elements highlighted. 
CRE, cAMP response element; ARE, antioxidant response element; RA, retinoic acid, RARE, retinoic acid 
response element. Adapted from Henderson et al 2011. 
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1.4.2 GSTP1 and carcinogenesis 
GSTP1 has attracted much attention because of its apparent role in carcinogenesis and 
anticancer drug resistance. In 1989, Satoh et al. discovered that rats treated with 
dimethylnitrosamine developed hepatic neoplastic foci formation which were GSTP1 
positive, a remarkable finding as rat liver contains very low levels of GSTP1 basally (Satoh et 
al., 1989). Work since then has shown that GSTP1 expression is elevated in most human 
tumours (Howie et al., 1990) and is believed to contribute to anticancer drug resistance as it is 
often found overexpressed in a wide range of cell lines made resistant to a diverse set of 
chemicals, some of which are not known to be GSTP1 substrates (Whelan et al., 1992, 
Wareing et al., 1993, Black et al., 1990). Many cancer drugs form electrophilic species after 
metabolism and are therefore subject to conjugation with GSH. Interestingly, transfection of 
GSTP1 cDNA into GSTP1 null cancer cell lines increased the resistance of a number of 
compounds which are not known substrates for GSTP1 (Moscow et al., 1989, Tew, 1994). 
Similarly, silencing or chemical inhibition of GSTP1 increases the sensitivity of a large 
number of cells to chemically induced apoptosis (Huang et al., 2007, Yu et al., 2009, 
McCaughan et al., 1994) and reduces proliferation of cancer cells (Dang et al., 2005, 
Hokaiwado et al., 2008). In contrast, mice nulled for Gstp1 and Gstp2 demonstrate increased 
tumour formation compared to their wild-type counterparts in response to a wide range of 
carcinogenic and genetic stressors which is discussed further in Chapter 3. As such, there is 
much interest in the role of this enzyme in contributing to cytoprotection and examining 
cellular functions of this enzyme other than drug metabolism.  
 
1.4.3 GSTP1 and redox regulation 
Redox signalling pathways are important in the regulation of cellular and thiol homeostasis, 
perturbations of which can lead to increased oxidative stress and cytotoxicity. Increased 
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production of reactive oxygen species (ROS) can lead to a number of disease states 
associated with increased oxidative stress such as Alzheimer’s disease and has been attributed 
as a major cell signalling pathway in cancer. Cancer cells produce elevated levels of 
peroxides which have been found to contribute to their proliferation and activation of cell 
signalling cascades (Jones, 2008, Szatrowski and Nathan, 1991). Although not regarded as 
the primary enzymes involved in free radical scavenging, GSTs demonstrate activity towards 
a large number of oxidative species, either through direct conjugation of the species, or 
through modification of protein thiols and cell signalling cascades. Recent studies 
surrounding GSTP1-mediated cell regulation suggests that it plays a functional role, not only 
in preventing apoptosis through regulation of cell signalling cascades, but in maintaining 
cellular homeostasis through sulfhydryl protection in the prevention of oxidative stress 
(Townsend et al., 2006, Townsend et al., 2008a). Posttranslational modification of protein 
thiol groups, known as protein S-glutathionylation, is an important mechanism in preventing 
protein oxidation and in maintaining redox control.  Protein S-glutathionylation is an 
interesting area of research in GSTP1 mediated cell regulation and this topic is discussed in 
detail in Chapter 4. 
 
1.4.4 Non-catalytic functions of GSTP1  
There is a growing body of evidence to suggest that GSTP1 can mediate cell regulation 
independently from its catalytic activity. A number of proteins and signalling molecules have 
been found to co-immunoprecipitate or interact with GSTP1 independently of its catalytic 
activity and are highlighted in Table 3. The majority of these interactions are thought to 
prevent against stress-apoptosis in vitro, although there is some in vivo evidence to suggest 
such regulatory pathways are functional basally (Elsby et al., 2003). Although there are a 
relatively small number of peer-reviewed papers describing some of these interactions, a 
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number of targets pertaining to GSTP1 regulation have been described for over a decade and 
are discussed in detail in later chapters of this thesis.  
 
Interacting 
target 
Description References 
Chapters in which 
this function is 
described/discussed 
c-Jun N-terminal 
kinase (JNK) 
GSTP1 binds to JNK as a 
monomer preventing 
phosphorylation of its 
downstream targets. 
(Adler et al., 1999) 
(Wang et al., 2001b) 
(Elsby et al., 2003) 
(Thevenin et al., 
2011) 
Chapter 3 
Chapter 4 
Tumour necrosis 
factor receptor-
associated factor 
2 (TRAF2) 
GSTP1 binds to TRAF2 and 
prevents ASK1 cell induced 
apoptosis. 
(Wu et al., 2006) ND 
Peroxiredoxin 
(Prdx) VI 
GSTP1 heterodimerises with 
PrdxVI resulting in PrdxVI S-
glutathionylation and 
regeneration of its activity. 
(Manevich et al., 
2004) 
(Ralat et al., 2006) 
Chapter 4 
Nitric oxide 
(NO) 
Acts as a NO carrier and forms 
a complex with ferrous irons to 
produce dinitrosyl-
diglutathionyl iron complex 
(DNIC) in transporting cellular 
NO. 
(Lo Bello et al., 2001) 
(Cesareo et al., 2005) 
(Lok et al., 2012) 
 
Chapter 4 
 
Protein thiols 
Catalyses the S-
glutathionylation of cellular 
proteins in response to 
nitrosative and oxidative stress. 
(Townsend et al., 
2008a) 
(Anathy et al., 2012) 
Chapter 4 
Cyclin dependent 
kinase-5 (Cdk5)  
Inhibits Cdk5 activity through 
binding to Cdk5 and indirectly 
(Sun et al., 2011) ND 
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through its peroxidase activity. 
Fanconi anemia 
group C protein 
(FANCC) 
Interaction with FANCC 
inhibits apoptosis and prevents 
oxidation of GSTP1 Cys 
residues. 
(Cumming et al., 
2001) 
ND 
Transglutaminase 
2 (TGM2) 
Binding of GSTP1 with TGM2 
inhibits GSTP1 activity. 
(Piredda et al., 1999) ND 
Human 
Papillomavirus 
(HPV)-16 E7 
HPV-16 E7 can dock to a 
GSTP1 monomer and enhances 
cell survival after UV 
exposure. 
(Mileo et al., 2009) ND 
Death Receptor 
Fas 
Interaction with GSTP1 results 
in Fas S-glutathionylation  
(Anathy et al., 2012) ND 
 
Table 3. Non-catalytic properties of GSTP1. 
The table highlights a number of cellular targets which are believed to interact with GSTP1, some of which are 
discussed in later chapters of the thesis. ND= not described in this thesis. 
 
From Table 3 it is evident that the functions of GSTP1 extend well beyond enzymology and 
are related, either directly or indirectly, to the prevention of apoptosis and promotion of cell 
survival. Although much of the data surrounding GSTP1 cell regulation focuses on JNK 
signalling (see Chapters 3 and 4) Wu et al demonstrated that GSTP1 may possess other 
regulatory functions upstream of the MAP Kinase cascade by binding to tumour necrosis 
factor receptor-associated factor 2 (TRAF2) which prevents its association with apoptosis 
signal-regulating kinase 1 (ASK1) and reduces cell apoptosis (Wu et al., 2006). This followed 
earlier work showing that GSTP1 could coordinate ROS stimulated ASK1 signalling when 
transfected in vitro (Yin et al., 2000), suggesting regulation of these pathways may be 
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oxidative stress dependent. Mileo et al demonstrated that regulation of Map Kinase pathways 
by GSTP1 could be mediated through the binding of GSTP1 as a monomer to the Human 
Papillomavirus (HPV)-16 E7, which greatly reduced the number of apoptotic cells after UV 
treatment and enhanced HaCaT cell survival (Mileo et al., 2009). Interestingly, there is some 
evidence to suggest that GSTP1 may be phosphorylated by epidermal growth factor receptor 
(EGFR) and the Ser/Thr protein kinases, cAMP-dependent protein kinase A and C (PKA and 
PKC), although further studies are required to validate these findings (Lo et al., 2004, 
Okamura et al., 2009).  
 
The identification of non-catalytic functions in other GST classes demonstrates that this is an 
intrinsic function to GST in cell regulation and not exclusive to GSTP1. A number of GST 
isoenzymes are able to bind 15-deoxy-∆12,14prostaglandin J2 (15-d-PGJ2) which prevents its 
translocation to the nucleus and activation of peroxisomal proliferator-activated receptor γ 
(PPARγ) (Paumi et al., 2004). The GSTA isoenzyme has been implicated in the transport of 
bilirubin (Kamisaka et al., 1975, Simons and Jagt, 1980) and steroid synthesis (Johansson and 
Mannervik, 2001) although it is uncertain whether or not these reactions can occur non-
catalytically. As described in Table 3, there is much evidence to suggest GSTP1 can inhibit 
JNK activity in mediating cellular apoptosis (discussed in later chapters). Further evidence to 
support GST regulation of kinase activity is demonstrated through the inhibitory effect of 
GSTM1 on the stress activated MAP Kinase cascade. GSTM1 is the most closely related 
class of GST to Pi and can function as an inhibitory regulator of the MAP Kinase Kinase 
Kinase (MAPKKK) pathway by binding to ASK1 and MAP/ERK Kinase Kinase 1 (MEKK1) 
and protect against ASK1 dependent apoptosis (Cho et al., 2001, Ryoo et al., 2004). The 
extent to which this occurs in vivo requires careful examination as around 50% of the 
Caucasian population are null for GSTM1 and therefore may lack this form of regulation 
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(Hirvonen et al., 1993). Yin et al also demonstrated that GSTs were found to bind to the 
serine protease inhibitor (serpin), Maspin, and that GSTM3 was strongly associated with its 
interaction as determined through a Yeast two hybrid screen (Yin et al., 2005). The key 
finding from these studies is that signalling regulation was found to be independent of their 
glutathione-conjugating abilities, suggesting that the non-catalytic binding of GSTs may 
mediate an important function in protecting cellular proteins and in the regulation of stress 
response signalling pathways. The ability of GSTP1 to function non-catalytically raises 
fundamental questions as to how this enzyme contributes to cell regulation and what role it 
plays in tumorigenesis and cancer progression.  
 
1.5 Aims of study 
It is clear that there are a number of functions relating to GSTP1 that are important in 
mediating anticancer drug resistance and cancer proliferation which are not dependent on its 
catalytic activity. As yet, there are no in vivo models to fully assess the nature of these 
properties, while some of the relationships between GSTP1 and cellular proteins have only 
been postulated in a limited number of cellular models or from individual laboratories. This 
study aims to assess the non-catalytic functions of GSTP1 and examine the extent to which 
they may contribute to cell regulation. The first part of this study describes the 
characterisation of a novel in vivo model in which the catalytic activity of GSTP1 has been 
removed, and assesses the role of this enzyme in response to a well-characterised 
hepatotoxin, acetaminophen. The second part of this thesis will investigate some of the non-
catalytic functions of GSTP1 in vitro, particularly in relation to sulfhydryl homeostasis and 
redox regulation. Finally, this study will aim to examine novel pathways and protein targets 
which may be mediated by GSTP1.  
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2. Materials and Methods 
2.1 Chemicals 
Unless otherwise indicated, all chemicals were purchased from Sigma or VWR. Cell culture 
media was purchased from Invitrogen. 
 
2.2 Animals  
2.2.1 Husbandry 
All animal studies were carried out in accordance with the Animal (Scientific Procedures) 
Act 1986 and approved by the Animal Ethics Committee of the University of Dundee.  Mice 
were housed in open top cages and exposed to a 12 hour light/dark cycle, with ad libitum 
access to water and, unless stated otherwise, RM1 standard animal diet. 
 
Gstp1 wild-type (Gstp1
WT
) and Gstp1/2 null (Gstp1/2
-/-
) mice were generated as previously 
reported (Henderson et al., 1998b) and backcrossed onto a C57/BL6J background for at least 
8 generations.  
 
2.2.2 Sacrifice 
Unless stated otherwise, for all in vivo experiments mice were sacrificed by exposure to a 
rising concentration of carbon dioxide. Where appropriate, blood was taken from cardiac 
punctures into heparinised tubes and centrifuged. The plasma was removed, snap frozen in 
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liquid nitrogen and stored at -80°C. Details of protocols for handling other animal tissues are 
described elsewhere. 
 
2.3 Animal Drug Treatments 
2.3.1 Paracetamol (acetaminophen) 
Paracetamol (APAP) tablets were dissolved by sonication in phosphate buffered saline (PBS) 
at 15mg/ml. Mice were starved for 16 hours prior to APAP administration by oral gavage at 
300mg/kg body weight.  
 
2.3.2 Buthionine sulfoximine  
Buthionine sulfoximine (BSO) was dissolved in sterile water at 30mg/ml. Mice were 
administered a single intraperitoneal (i.p) dose of BSO at either 0.9g/kg or 0.2g/kg body 
weight. 
 
2.4 Generation of GSTP1 Y7F mutant mouse model 
Mice harbouring a tyrosine to phenylalanine mutation at codon 7 in the Gstp1 gene were 
generated by TaconicArtemis, Cologne, Germany. The targeting vector was assembled using 
mouse genomic fragments obtained from the C57Bl/6J RPCIB-731 BAC library which 
introduced a Y7F mutation into exon 2 of the Gstp1 gene, and loxP sites flanking exon 1 to 4 
of the Gstp2 gene, including 1kb of the promoter region. The targeting vector was linearized 
with Sfi I and transfected into C57BL/6NTac mouse embryonic stem (ES) cells, where 
positive clones were identified under puromycin selection. Validation of homologous 
recombinant ES cell clones was performed using Southern blotting and PCR screening. ES 
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cells were injected into the blastocysts of superovulated BALB/c female mice before being 
implanted into pseudopregnant NMRI females. Resultant offspring were assessed for 
chimaerism and highly chimaeric offspring (G0) were subsequently crossed with C57Bl/6J 
females. Germline transmission was identified by the presence of black (C57Bl/6J strain) 
offspring. Mice heterozygous for the targeted locus (Gstp1
WT/Y7F
) were subsequently crossed 
to produce homozygous breeding lines (Gstp1
Y7F/Y7F
).  
 
2.5 Isolation of primary mouse embryonic fibroblasts (MEFs) 
Pregnant female mice were euthanized by cervical dislocation between days 12-14 of 
pregnancy. Embryos were aseptically removed and washed in ice cold PBS. The brain and 
internal organs were removed and the remaining embryo was finely scissor minced and 
incubated at 37°C for 5 minutes in 9ml of Trypsin-EDTA (Invitrogen). 9 ml of MEF medium 
(DMEM, 10% FBS, 2mM L-glutamine and 100U/ml penicillin, 100µg/ml streptomycin) was 
then added to neutralise the Trypsin-EDTA. The mixture was transferred to a 50 ml Falcon 
tube and centrifuged at 800xg for 5 minutes. The supernatant was removed and the pellet was 
resuspended in 5 ml of Trypsin-EDTA and left at 37°C for 10 minutes. MEF medium (20ml) 
was added to disaggregate the tissue and the debris was allowed to settle before plating the 
supernatant onto sterile 15 cm culture dishes. Cells were incubated at 37°C/5% CO2 
overnight. The following morning cells were washed with sterile PBS, replaced with fresh 
MEF medium and incubated overnight. Cells were trypsinised and resuspended into 30 ml of 
MEF medium. 10 ml of suspension was aliquoted into 3x 10cm culture dishes. Over the next 
few days cells were allowed to grow to 95-100% confluency before being seeded for 
experiments or frozen down in 10% DMSO in fetal bovine serum (FBS). 
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2.6 Molecular cloning 
2.6.1 Cloning of Mouse Gstp1WT and Gstp1Y7F constructs 
Full length mouse Gstp1 cDNA was kindly provided by Aileen McLaren, University of 
Dundee. Due to the proximity of the Y7F mutation to the starting codon, site directed 
mutagenesis was performed using a single round of PCR. The Gstp1
Y7F
 mutation was 
introduced into the Gstp1 reading frame, while Nde1 and BamH1 restriction sites were 
introduced at the 5’ and 3’ termini respectively; Gstp1WT primer (CGC ATA TGC CAC CAT 
ACA CCA TTG TCT ACT TCC CAG TTC GAG GGC G), Gstp1
Y7F
 primer (CGC ATA 
TGC CAC CAT ACA CCA TTG TCT TCT TCC CAG TTC GAG GGC G), reverse primer 
(GCG GAT CCC TAC TGT TTG CCA TTG CCA TT). All PCR reactions were performed 
using 5µl Pfu polymerase reaction buffer (20mM Tris pH 8.8, 10mM KCl, 10mM 
(NH4)2SO4, 2mM MgSO4, 0.1% Triton X-100 and 0.1mg/ml nuclease-free BSA), 0.2mM 
dNTP mix, 5ng cDNA, 15 pmol of each primer and 1.5 units of Pfu polymerase. The reaction 
was carried out using a Biometra T3000 Thermocycler as follows; one cycle at 95°C for 30 
seconds followed by 35 cycles of 95°C for 30 seconds, 60°C for 1 minute and 68°C for 1 
minute. The reaction was run on a 1% agarose gel at 100mV for 45 minutes and the PCR 
product was excised and extracted. The PCR product was ligated into pCR
™
-blunt before 
being transformed into One Shot® Top10 Chemically Competent E. Coli cells. 
Transformations were spread onto agar plates containing kanamycin (50µg/ml) and incubated 
overnight. Plasmid DNA was extracted from colonies formed and sequenced to confirm the 
successful addition of restriction sites and introduction of mutation. 
 
From successful colonies, mouse Gstp1
WT
 and Gstp1
Y7F
 inserts were cloned into the Nde1 and 
BamH1 sites of the pET11a vector downstream of the lac operon. Inserts were digested at 
Materials and Methods 
 
27 
 
37°C for 2.5 hours in a buffer containing 1x Promega Buffer D (6mM Tris-HCl pH 7.9, 6mM 
MgCl2, 150mM NaCl, 1mM DTT), 0.1mg/ml BSA, 15 units of Nde1 and 30µl DNA. The 
digest was then heated at 65°C for 10 minutes to inactivate the enzyme. The reaction was 
cleaned and purified using the PureLink
®
 PCR Purification Kit (Invitrogen) according to the 
manufacturer’s protocol, and inserts were eluted in 40µl purified water. Inserts were 
subsequently digested with BamH1 using the same protocol, except using 1x Buffer E (6mM 
Tris-HCl pH 7.5, 6mM MgCl2, 100mM NaCl, 1mM DTT) in place of Buffer D. The 
incubation was run on a 1% agarose gel and the digested insert was excised and extracted. 
The insert was ligated into pET11a using T4 ligase. 3µl of plasmid was transformed into 
BL21-Gold(DE3)pLysS competent E. Coli cells (Stratagene). Colonies formed from the 
transformation were sequenced to determine correct cloning of inserts, and successful 
constructs were used to produce recombinant protein. 
 
2.6.2 Recombinant protein induction and purification 
Bacterial cells containing mouse Gstp1
WT
 and Gstp1
Y7F
 constructs were grown overnight in 
20ml of LB medium at 37°C, 180rpm. An aliquot (5ml) of this culture was added to 500ml of 
LB medium and incubated for 2.5 hours at 37°C, 180rpm. Recombinant protein expression 
was induced with 1mM IPTG for 2 hours before cultures were centrifuged at 4,500rpm for 20 
minutes at 4°C.  A fraction of culture was removed prior and after induction and analysed on 
a SDS-PAGE gel to confirm protein induction. Pellets were resuspended in 15ml of Buffer A 
(50mM Tris-HCl, pH 7.4, 200mM NaCl, 0.5mM DTT). The suspension was mixed with 
lysozyme (100µg/ml) and incubated for 15 minutes at 30°C. Protease inhibitors were added 
and the lysate was rotated for 30 minutes at 4°C. Lysates was sonicated for 3x 1minute 
intervals (14 amp, pulse 10 seconds) with 1 minute on ice between sonications. Lysates were 
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centrifuged at 40,000rpm for 30 minutes at 4°C and the resultant suspension filtered 
(0.45µm).  
 
Purification of recombinant mouse GSTP1 was performed using GSTrap™ FF columns (GE 
Healthcare). Columns were equilibrated with 5 column volumes of water at 1ml/min and then 
5 column volumes of Buffer A at 1ml/min. 100µl lysate was removed from the preparation 
and the remaining lysate was passed over the column at 0.25ml/min and the flow through 
collected. The column was washed with 15 column volumes of Buffer A at 1ml/min. Bound 
protein was eluted from the column using Elution buffer (200mM Tris-HCl pH 7.9, 50mM 
glutathione) and collected in 10x0.5ml fractions. To determine the presence of recombinant 
protein in each fraction, 5µl of each fraction, as well as flow through and lysate taken prior to 
purification were subjected to SDS-PAGE analysis. Recombinant protein was identified 
through Coomassie Blue staining and fractions containing recombinant GSTP1 were isolated 
and combined before being desalted. Desalting columns (BioRad) were equilibrated with 2 
column washes of 50mM Tris pH 7.4. 3ml of lysate containing recombinant GSTP1 was 
added to the column and allowed to flow through. The protein was eluted using 4ml 50mM 
Tris pH 7.4 and stored at -80°C. 
 
2.6.3 GFP-tagging of human GSTP1WT, GSTP1Y7F and GSTP1 V105I constructs 
The open reading frame of human GSTP1, derived from HCT116 cDNA, had previously 
been cloned into pcDNA3.1 and was used as a template for cloning into the peGFP-C3 
vector. Genes cloned into this vector are expressed as fusions to the C-terminus of GFP. The 
cloning strategy was divided into two parts. Initially, silent mutations were introduced into 
the GSTP1 open reading frame to prevent silencing of the gene by shRNA, along with the 
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introduction of EcoR1 and BamH1 restriction sites at the 5’ and 3’ ends, respectively. The 
silent mutations introduce base changes in the shRNA binding region but do not result in a 
change to the amino acid sequence, as shown below: 
 
GSTP1 reading frame           GGA GAC CTC ACC CTG TAC CAG TCC AAT ACC 
Silent mutation         GGA GAC CTC ACT TTA  TAT CAG TCC AAT ACC 
Amino acid                          G        D       L      T       L      Y      Q       S       N       T 
 
The cloning was performed using a two-step PCR procedure as described previously (Landt 
et al., 1990). All PCR reactions were carried under the buffer and cycling conditions 
described for the cloning of mouse Gstp1
WT
 and Gstp1
Y7F
 constructs. The first PCR reaction 
introduced the silent mutations into the GSTP1 open reading frame; silent mutation primer 
(GGA GAC CTC ACT TTA TAT CAG TCC AAT ACC), reverse primer (GAG TCC CCC 
GGA TCC TCA CTG TTT CCC GTT GCC). The base changes resulting in silent mutations 
are underlined. The product from this reaction was run on a 1% agarose gel, excised and 
extracted, and then used as the reverse primer in a second PCR reaction, to generate the wild-
type GSTP1 open reading frame containing silent mutations and restriction sites; forward 
primer (GCC GCC GCA GTC AGA ATT CCC ATG CCG CCC TAC ACC GTG). The 
reaction was ligated into pCR
™
-blunt before transformed into One Shot
®
 Top10 Chemically 
Competent E. Coli cells. Colonies were sequenced, with correct constructs subsequently 
cloned into peGFP-C3. Inserts were digested at 37°C for 3 hours in a buffer containing 1x 
Promega Buffer E (6mM Tris-HCl pH 7.5, 6mM MgCl2, 100mM NaCl, 1mM DTT), 
0.1mg/ml BSA, 20 units of EcoR1, 20 units of BamH1 and 40µl DNA. The digest was then 
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heated at 65°C for 10 minutes to inactivate the enzymes. The reaction was run on a 1% 
agarose gel and the insert was excised and extracted, before ligated into peGFP-C3. 3µl 
plasmid was transformed into NEB 10-beta Competent E. Coli cells (New England BioLabs) 
and colonies sequenced for successful introduction of the GSTP1 open reading frame into 
peGFP-C3 (GSTP1
WT
-GFP). 
 
The second part of the cloning strategy involved introducing Y7F and V105I mutations into 
the GSTP1 open reading frame. This was achieved using the Stratagene QuickChange
™
 Kit 
and the following primers; Y7F (forward, CCG CCC TAC ACC GTG GTC TTC TTC CCA 
GTT CGA GGC CG, reverse CGG CCT CGA ACT GGG AAG AAG ACC ACG GTG TAG 
GGC GG), V105I (forward, GCT GCA AAT ACA TCT CCC TCA TCT ACA CCA ACT 
ATG AGG, reverse CCT CAT AGT TGG TGT AGA TGA GGG AGA TGT ATT TGC 
AGC). The PCR reactions were carried out using the GSTP1
WT
-GFP plasmid as a template 
under the following conditions; 1x QC Reaction Buffer (10mM KCl, 10mM (NH4)2SO4, 
20mM Tris-HCl pH 8.8, 2mM MgSO4, 0.1% Triton X-100, 0.1mg/ml nuclease free BSA), 
125ng each primer, 50ng cDNA, 0.2mM dNTP mix and 2.5 units of PfuTurbo DNA 
polymerase. The reaction was carried out using a Biometra T3000 Thermocycler as follows; 
one cycle at 95°C for 30 seconds followed by 17 cycles of 95°C for 30 seconds, 55°C for 1 
minute and 68°C for 6 minutes. 1µl (10 units) of Dpn I was added to the reaction and left to 
incubate for 1 hour at 37°C. This endonuclease is specific for methylated and 
hemimethylated DNA, digesting the parental DNA template but not the mutated vector. 3µl 
of the reaction was transformed into NEB 10-beta Competent E. Coli cells and colonies 
sequenced for the successful introduction of Y7F and V105I mutations into peGFP-C3 
(GSTP1
Y7F
-GFP
 
and GSTP1
V105I
-GFP respectively). 
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2.6.4 Agarose gel extraction of PCR products 
The extraction of PCR products from agarose gels was performed using the PureLink
®
 Quick 
Gel Extraction Kit according to the manufacturer’s instructions. 
 
2.6.5 DNA sequencing 
DNA sequencing of colonies were analysed using Capillary Electrophoresis by the Genetics 
Core Services, University of Dundee.  
 
2.6.6 Extraction of DNA from bacterial colonies 
Isolation of plasmid DNA from bacterial cultures was performed using the PureLink
™
 Quick 
plasmid Miniprep or HiPure Plasmid Maxiprep kit. For minipreps, bacterial cells were grown 
overnight in 10ml of LB medium containing antibiotic selection. The following morning, 
cultures were pelleted at 3000xg for 10 minutes at 4°C, and plasmid DNA was isolated 
according to the manufacturer’s protocol. For maxipreps, 5ml of culture was grown in 
antibiotic selection for 8 hours before 1ml was transferred to 200ml LB medium containing 
antibiotic selection and grown overnight. The cultures were pelleted at 3000xg for 10 minutes 
at 4°C and plasmid DNA was isolated according to the manufacturer’s protocol. Plasmid 
DNA was stored at -20°C. 
 
2.6.7 Ligation of PCR products into plasmid vectors 
For the ligation of PCR products into the pCR
™
-blunt Vector, 3µl of PCR product was 
incubated with 25ng pCR
™
-Blunt vector, 4 units of  T4 DNA ligase and 1x T4 DNA Ligation 
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buffer (6mM Tris-HCL, pH8, 6mM MgCl2, 5mM NaCl, 0.1mg/ml BSA, 7mM ß-
mercaptoethanol, 0.1mM ATP, 2mM DTT, 1mM spermidine) for 1 hour at 16°C. 
 
For the ligation of PCR products into pET11a and peGFP-C3 vectors, 7µl of PCR product 
was incubated with 3 units of T4 DNA ligase and 1µl of T4 DNA ligase buffer (30mM Tris-
HCL, pH8, 10mM MgCl2, 1mM ATP, 10mM DTT) for 16-18 hours at 16°C. 
 
2.6.8 Transformation of plasmids into bacterial cells 
Ligation product (3µl) was incubated with 50µl of One Shot
®
 Top10, BL21-
Gold(DE3)pLysS or NEB 10-beta Chemically Competent E. Coli cells for 30 minutes on ice. 
Cells were heat shocked for 45 seconds at 42°C before incubated on ice for 2 minutes. 450µl 
of LB medium was added to the cells which were incubated with agitation at 37°C for 1 hour. 
Transformations were spread onto bacterial culture plates with an antibiotic selection and 
incubated overnight. 
 
2.7 Kinetic assays 
The enzymatic activities of recombinant GSTP1 was determined spectrophotometrically at 
25°C, using 1-chloro-2,4-dinitrobenzene (CDNB) as a co-substrate as described by Habig 
(Habig et al., 1974). Kinetic assays were performed in 0.1M potassium phosphate buffer, pH 
6.5. Initially, the linear rate of reaction was determined using variable concentrations of 
protein (0.78-50µg) using fixed concentrations of GSH (10mM) and CDNB (2mM). The 
apparent Km
CDNB
 was determined using a fixed concentration of 10mM GSH and variable 
concentrations of CDNB (0.01–2mM CDNB). The apparent KmGSH was determined using a 
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fixed concentration of CDNB (1mM) and variable concentrations of GSH (0.08-10mM). Vmax 
and Km values were derived fromMichaelis-Menton kinetic curves generated using GraFit 5 
(Erithacus Software). 
 
2.8 Cell culture 
2.8.1 Cells 
HCT116 cells were kindly provided by Dr. Bert Vogelstein (John Hopkins University, 
Baltimore, MD). HCT116 cells were maintained in McCoy’s 5A media supplemented with 
10% FBS and 2mM L-glutamine. SAOS2 and SAOS2/p53 cells were kindly provided by Dr. 
David Meek (University of Dundee). SAOS2 and SAOS2/p53 cells were maintained in 
DMEM supplemented with 10% tet-free FBS and 2mM L-glutamine. 
 
2.8.2 Transfection of HCT116 cells using siRNA 
Transfection of siRNA into HCT116 cells was performed using Lipofectamine RNAiMAX. 
Cells were seeded onto 6 well, 6cm or 10cm tissue culture dishes, so that the density of the 
cells was 30% confluency 24 hours later. Depending on the size of plate to be transfected, 4-
25µl RNAiMAX was incubated with Silencer® select (Ambion) siRNA targeting GSTP1 
(#s306) or a negative control siRNA (#4390843) in Optimem, so that the final concentration 
of siRNA on the cells was 10nM. The reaction was incubated for 20 minutes at room 
temperature before added dropwise to cells. Cells were incubated overnight and media was 
changed the following morning.  
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2.8.3 Generation of GSTP1 stable knock down HCT116 cell line using lentiviral 
mediated shRNA 
Stable knock down of GSTP1 in HCT116 cells was achieved using lentiviral transduction of 
short hairpin RNA constructs (shRNA) followed by clonal selection. For production of 
lentiviral particles, HEK293-T cells were seeded at 3x10
6
 cells per 10cm plate for 70-80% 
confluency 24 hours later. Four separate MISSION shRNA clones (Sigma) targeted against 
different regions of GSTP1 mRNA transcript (2.6µg) were packaged with 26µg of Viral 
Packaging Mix (Sigma) and added to 182µl of serum free medium containing 16µl FuGENE 
transfection reagent. The hairpin sequences of each shRNA construct contain a 21 base stem 
and a 6 base loop which were cloned into the pLKO.1 vector and driven from the pol III U6 
promoter. The Sigma Viral Packaging Mix contains the vesicular stomatitis virus G-protein 
(VSV-G) envelope vector for pseudotyping of lentiviral particles, and a packaging vector 
which encode the virion structural proteins. The transfection cocktail was incubated at room 
temperature for 15 minutes before added dropwise to culture dishes. Medium was replaced 16 
hours post-transfection. The viral supernatant was harvested from cells at 36 and 72 hours 
post-transfection, filtered through 0.45µm filter and stored at -80°C. 
 
For infection of HCT116 cells with lentiviral particles, cells were grown on 10cm culture 
dishes to 20-30% confluency. Polybrene was added to the dishes at a final concentration of 
8µg/ml and increasing concentrations of viral supernatant (10-200µl) was added to cells. 
Cells were incubated for 72 hours before puromycin (3µg/ml) was added for clonal selection. 
Individual clones were picked and knockdown of GSTP1 mRNA was determined by rtPCR. 
Cells were maintained in puromycin selection during culture. Puromycin was removed prior 
to the start of any in vitro experiments.  
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2.8.4 Transfection of plasmid DNA into cells 
Transfection of plasmid DNA into HCT116 cells was performed using Lipofectamine
™
 LTX 
and PLUS
™
 reagents (Invitrogen). Depending on the size of culture dish to be transfected 
1.25-4µg plasmid DNA was incubated with a 1:1 ratio of PLUS
™
 reagent in Optimem for 5 
minutes at room temperature e.g. 2µl of PLUS
™
 reagent would be incubated with 2µg DNA. 
Lipofectamine
™
 LTX reagent was added at a 2.5:1 ratio with DNA and incubated for 30 
minutes at room temperature. The transfection cocktail was added dropwise to cells which 
were grown to 70% confluency. Cell media was replaced after 6 hours, and the cells were 
incubated for a further 18 hours. 
 
2.8.5 Cytotoxicity assays 
HCT116 cells untreated, stably-silenced for GSTP1 or containing a control plasmid were 
seeded into a 96 well plate at 1500 cells per well in 100µl media. 24 hours after seeding, 
100µl media containing a cytotoxic agent was added to each well. All drugs were dissolved 
in DMSO and diluted such that the final concentration of DMSO in the cell media was never 
more than 1%. Cells were incubated with drug for 72 hours before their cell number was 
determined using the ATP assay.  
 
2.8.6 Determination of cell number using the ATP assay 
The numbers of cells in a 96 well plate were determined using the ATP assay. The ATP assay 
is based on Firefly Luciferase catalysis of D-Luciferin, whereby the amount of light emitted 
from the reaction is proportional to the amount of ATP present as a result of its consumption 
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by Luciferin. Media was removed from cells and then incubated for 1 minute in 45µl of 
Somatic cell ATP releasing buffer (Sigma). 30µl of lysate was transferred to a white 96 well-
assay plate. 30µl of ATP Assay Mix, diluted 1:25 in ATP Dilution Buffer (Sigma) was added 
to each well and amount of light emitted was detected on an Orion II Microplate 
Luminometer (Berthold Detection Systems).  
 
2.8.7 UV treatment of cells 
HCT116 cells were seeded into 6cm culture dishes and irradiated with defined doses of UV 
(254nm) using a Stratlinker (Stratagene) 72 hours post transfection of siRNA targeting 
GSTP1 or a control siRNA (10nM). Prior to irradiation cell media was removed and 
incubated at 37°C. Cells were overlaid with warm PBS (1ml) and irradiated. Cells were 
subsequently incubated with the same media removed prior to irradiation for a defined period 
of time. 
 
2.9 Histology 
Animal tissues were excised, washed in PBS and fixed in 4-10% formal saline histological 
fixative (Gurr). Tissues were left rocking gently in fixative for 24 hours at room temperature 
before embedded in paraffin wax. Tissues were cooled on ice for at least 1 hour prior to 
sectioning. For immunohistochemical and histological staining, sections were cut to 5µm and 
transferred to Polysine
®
 slides. 
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2.9.1 Hematoxylin and eosin (H/E) staining 
Tissue sections were deparaffinised in 2x 20 minute washes of xylene and rehydrated through 
2 minute washes in decreasing concentrations of ethanol; 100% (x2), 95%, 90%, 70%, 50% 
ethanol. Sections were incubated for 2 minutes in PBS and then for 2 minutes in Gills 
Hematoxylin, before briefly reduced in acid alcohol. Sections were rinsed for 15 minutes in 
tap water and incubated for 2 minutes in 80% ethanol before stained briefly in eosin Y 
solution. Sections were dehydrated in increasing concentrations of ethanol, incubated in 
xylene solution and then left to dry. Slides were sealed using DPX mounting medium and left 
overnight.    
 
2.9.2 Immunohistochemistry 
Tissue sections were deparaffinised and rehydrated as described under ‘H/E staining’. 
Antigen retrieval was achieved by boiling sections in sodium citrate buffer (0.01M, pH 6.5) 
for 20 minutes and then leaving to cool to room temperature. Endogenous enzymes were 
blocked for 10 minutes in Dual Endogenous Enzyme Block solution (DAKO). Sections were 
blocked in 10% goat serum in 0.1% Tween/PBS (PBST) for 30 minutes, washed in PBST and 
incubated with a primary antibody for 1 hour at room temperature. Secondary antibody and 
substrate-chromogen labelling was achieved using the DAKO EnVision and Dual-Link 
System-HRP kit according to the manufacturers protocol. Sections were washed in PBST and 
counterstained with Haematoxylin solution before dehydrated in increasing concentrations of 
ethanol. Sections were incubated in xylene solution before air dried and sealed using DPX 
mounting medium. 
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2.10 Microscopy 
Fixed and frozen tissue sections were examined, and photomicrographs taken, using an 
AxioCam microscope with Axiovision software (Zeiss). Laser microscopy was performed 
using a LSM 510 confocal microscope (Zeiss). 
 
Immunogold labelling of tissue and electron microscopy (EM) was carried out by the 
Microscopy Facility, College of Life Sciences, University of Dundee. 
 
2.10.1 Immunogold labelling of mouse GSTP1 
Livers from mice treated with APAP were harvested and cut into small pieces in 2% PFA 
solution. Livers were transferred to 30% sucrose solution, frozen and sectioned. The sections 
were collected on pioloform/carbon coated copper grids. For immunogold labelling, sections 
were floated on droplets of solutions in the following protocol. 
 
Sections were washed twice in PBS and blocked with 0.5% Fish Skin Gelatin (FSG) in PBS 
for 10 minutes. Sections were incubated with neat GSTP1 primary antibody for 30 minutes 
before washed 3 times in PBS. Sections were then incubated for 20 minutes with Goat anti-
rabbit gold secondary antibody (1:40). After 6x5 minute washes in PBS and one in distilled 
water, sections were incubated in 2%methyl cellulose/3% uranyl acetate for 2x1minute 
washes and a final 5 minute wash before dried and analysed by EM. 
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2.10.2 Transmission electron microscopy 
1x10
6 
HCT116 cells were seeded onto 10cm plates and transfected with 10nM of siRNA 
targeted for GSTP1, a non-targeting control siRNA or untransfected as described previously. 
72 hours post transfection, cells were fixed using 2% PFA in 0.1M Cacodylate buffer, pH 7.4. 
Cells were post fixed in 1% aqueous osmium and dehydrated in graded alcohols before 
incubated in propylene oxide to remove residual ethanol. Cells were placed in neat resin and 
polymerised at 60°C before analysed by EM. 
 
2.11 Flow Cytometry 
All flow cytometry was performed using a Becton Dickson FACScan (Flow Cytometry Core 
Facility, University of Dundee).  
 
2.11.1 Propidium Iodide (PI) staining 
Cell cycle profiles of HCT116 cells were determined using Propidium Iodide (PI) staining. 
Cells were grown to 70% confluency, trypsinised and pelleted. Cell pellets were washed in 
PBS, pelleted and suspended in residual PBS solution. Cells were fixed in ice cold 70% 
ethanol and incubated at -20°C for at least 30 minutes. After fixation, cells were washed 
twice in PBS containing 1% bovine serum albumin (BSA). Cells were pelleted, resuspended 
in PI solution (50µg/ml propidium iodide, 50µg/ml RNase) prepared in PBS and incubated 
for 20 minutes at room temperature before analysed by flow cytometry.   
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2.11.2 Dichlorodihydrofluorescein Diacetate (H2DCFDA) staining 
H2DCFDA is a reduced fluorescein which is readily converted to a green-fluorescent form in 
the presence of oxidants and therefore can be used as a measure of ROS activity in the cell. 
Cells were grown to 70% confluency and incubated with 10µM H2DCFDA in PBS for 30 
minutes at 37°C. Cells were trypsinised, and washed twice in PBS containing 1% BSA and 
finally resuspended in PBS before analysed by flow cytometry. 
 
2.11.3 Apoptotic assays 
Analysis of apoptotic pathways in HCT116 cells was performed using the Intellicyt 
Multimetric Apoptosis Screening kit. Cells were grown to 70% confluency and stained for a 
number of apoptotic pathways according to the manufacturer’s protocol. Cells were incubated 
in 200µl Caspase 3/7 Detection Reagent, Mitochondrial Integrity Reagent, and Annexin 
V/Cell Viability Reagent. Cells were washed with PBS in between each staining step. For a 
positive control of apoptosis induction, HCT116 cells had been treated with 10µM 
staurosporine for 18 hours. Cells were analysed by flow cytometry using a Becton Dickinson 
LSRFortessa. The excitation wavelengths/peak emissions for the reagents are as follows; 
Caspase 3/7, 488/518; Mitochondrial Integrity, 638/658; Annexin V, 488/575; Cell Viability, 
488/647. 
 
2.12 RNA analysis 
2.12.1 Extraction of RNA from mouse tissue 
RNA was extracted from mouse tissue using TRIzol
®
 and cleaned using RNeasy Minikit 
(Qiagen). Tissue (100mg) was homogenised at room temperature in 1ml of TRIzol
®
. Samples 
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were incubated for 5 minutes at room temperature before centrifuged at 10,000xg at 4°C. 
Chloroform (0.2ml) was then added to the supernatant and mixed thoroughly before 
incubated for 3 minutes at room temperature. Samples were centrifuged at 10,000xg for 15 
minutes at 4°C and the supernatant added to 0.5ml isopropanol. Samples were incubated for 
10 minutes at room temperature and then centrifuged at 10,000xg for 10 minutes at 4°C. The 
pellet was washed with 1ml of 75% ethanol and vortexed. Samples were pelleted again 
before left to air dry. The pellet was dissolved in 100µl RNAse-free water and incubated at 
55°C for 10-15 minutes. The isolated RNA was then cleaned using the RNeasy Minikit 
according to the manufacturer’s instructions. RNA was eluted in 50µl water stored at -70°C. 
 
2.12.2 Extraction of RNA from cell cultures 
RNA was extracted from cell cultures using the PureLink RNA Minikit (Ambion) according 
to the manufacturer’s instructions. RNA was eluted in 50µl water stored at -70°C. 
 
2.12.3 Reverse Transcription (RT) of isolated RNA for synthesis of cDNA 
Reverse Transcription of isolated RNA was performed using the ImPromII Reverse 
Transcription Kit (Promega). Concentrations of RNA were determined 
spectrophotometrically using the NanoDrop ND-8000 Spectrophotometer. Purity of RNA 
was determined by calculating the ratio of absorbance at 260nm and 280nm (260/280 ratio) 
where values of ~2.0 were accepted as pure for RNA.  A secondary measure at 260nm and 
230nm (260/230 ratio) was also used to determined nucleotide purity, where values between 
2.0-2.2 were accepted as pure for RNA. RNA was diluted to 200ng/µl and DNase treated 
with RQ1 DNase. 5µl of RNA was added to 1µl RQ1 buffer (40mM Tris-HCl pH 8.0, 10mM 
MgSO4 and 10mM CaCl2), 1µl RQ1 DNase and 3µl DEPC treated water. The samples were 
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incubated at 37°C for 30 minutes before the reaction was stopped by adding 1µl RQ1 stop 
buffer (2mM EGTA pH 8.0) and incubated at 65°C for 10 minutes. Random primers (1µl) 
were added to 4µl of DNase-treated RNA and incubated at 70°C for 5 minutes and then 
incubated on ice. For reverse transcription of RNA, a master mix composed of the following 
reagents was added to each sample; 4µl ImPromII reaction buffer, 1.2µl MgCl2, 1µl dNTP 
mix, 0.5µl Ribonuclease Inhibitor, 1µl ImPromII Reverse Transcriptase and 7.3µl DEPC 
treated water. The samples were then incubated at 25°C for 5 minutes, 42°C for 1 hour and 
finally 70°C for 15 minutes. cDNA samples were stored at -20°C. 
 
2.12.4 Real Time PCR (Taqman) analysis  
Quantitation of gene expression was performed using the 7500 Real Time PCR System 
(Applied Biosystems). Reverse transcribed cDNA was diluted 1:80 in nuclease-free water 
and 8µl of diluted cDNA was added to a duplex reaction containing 1µl Taqman primer, 12µl 
Taqman Gene Expression Master Mix (Applied Biosystems) and 1µl 18S primer, which 
serves as an endogenous control. For duplex reactions, 18S was VIC-labelled while all other 
Taqman probes were FAM-labelled. The reaction was mixed and added in triplicate to a 
MicroAmp
®
 Optical 96 well plate. The cycling parameters are as follows; 50°C for 2 
minutes, 95°C for 10 minutes and an amplification step of 40 cycles at 95°C for 15 seconds 
followed by 60°C for 1 minute.  
 
Results from Taqman analysis are displayed as fold difference from the control in each 
experiment. The difference in cycle threshold (Ct) values between primer probe and 18S are 
determined (∆Ct) and normalised against the ‘calibrator’ or control sample in each 
experiment (∆∆Ct). The fold difference is determined as 2 to the power of ∆∆Ct (2-∆∆Ct).  
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2.12.5 RNA amplification for microarray profiling 
Generation of biotinylated amplified RNA (cRNA) for hybridization with Illumina
®
 arrays 
was performed using the Illumina
® 
TotalPrep
™
 RNA amplification kit with a T7 Oligo(dT) 
Primer to synthesise cDNA containing a T7 promoter sequence. DNase treated RNA (500ng) 
from HCT116 untreated, HCT116 GSTP1 shRNA 1, HCT116 GSTP1 shRNA 2 and HCT116 
control plasmid was amplified according to the manufacturer’s protocol. cRNA was eluted in 
200µl of nuclease-free water and stored at -20°C. 
 
2.12.6 Gene expression profiling 
Microarray profiling of HCT116 cells stably silenced for GSTP1 was performed using the 
Illumina
® 
HumanHT-12 v4 Expression BeadChip arrays (Wellcome Trust, University of 
Edinburgh). cRNA (750ng) from biological triplicates of HCT116 untreated, HCT116 
GSTP1 shRNA 1, HCT116 GSTP1 shRNA 2 and HCT116 control plasmid was used in the 
array. Data from the array was analysed using Bioconductor 2.2 and normalised using 
quantile normalisation (robust multi-array average, RMA). The data was log2 transformed, 
and differential gene expression was examined between comparison groups using an 
empirical Bayes t test and corrected using Benjamini Hochberg correction. Probes exhibiting 
a p value of <0.05 were considered to be differentially expressed and used for enrichment 
analysis using Metacore pathway (Genego). 
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2.13 Biochemical assays 
2.13.1 Biotinylation of glutathione ethyl ester (BioGEE) 
BioGEE is a cell-permeable glutathione analogue which is transiently incorporated into 
proteins under conditions of oxidative stress and can therefore be used as marker of protein 
S-glutathionylation. Biotinylation of glutathione ethyl ester was prepared as previously 
described (Sullivan et al., 2000). 25mM sulfo-LC-NHS-biotin (Pierce) was added to 25mM 
glutathione ethyl ester (Sigma) and dissolved in 3ml of 100mM NaHCO3 pH 8.5. The pH of 
the solution was adjusted to 7.2 with NaOH and incubated at room temperature for 2 hours. 
After 2 hours, 300µl of 1M Tris pH 7.2 was added to the solution to quench remaining 
biotinylation reagent and left to incubate overnight at 4°C before stored at -20°C. 
 
For detection of protein S-glutathionylation in vitro, cells were incubated with 0.4mM 
BioGEE for 1 hour. Cells were then washed in ice cold PBS and harvested in RIPA buffer 
(50mM Tris pH 7.4, 150mM NaCl, 1% Igepal-630, 5mM EDTA, 0.1% SDS, 0.5% sodium 
deoxycholate) supplemented with 25mM N-ethylmaleimide. Biotinylated proteins were 
analysed as neat lysates by immunoblotting or purified using streptavidin-coupled 
Dynabeads
®
 (Invitrogen) prior to immunoblotting.  
 
2.13.2 Co-immunoprecipitation of proteins 
For immunoprecipitation of biotinylated proteins, 40µl of streptavidin-coated Dynabeads
®
 
were washed 3 times in RIPA lysis buffer before incubated with 0.25-0.5µg/µl of protein 
lysate at 4°C for 1 hour under gentle rotation. Beads were separated from unbound protein 
lysates using a DynaMag
™
 magnet (Invitrogen) and were washed 4 times in RIPA wash 
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buffer. Biotinylated proteins were separated from streptavidin beads by heating the samples 
at 95°C for 5 min in 1x LDS Sample buffer (Invitrogen) in non-reducing conditions.     
 
For the immunoprecipitation of GFP-tagged GSTP1 constructs, cells were lysed in NP40 
buffer (10mM Tris-HCl pH 7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP40) and left on ice 
for 30 minutes, with extensive pipetting every 10 minutes. Lysates were centrifuged for 10 
minutes at 13,000xg at 4°C and the supernatant removed. Protein lysate (2.5mg/ml) was 
incubated with 25µl GFP-Trap
® 
-M beads (Chromotek) and incubated for 2 hours at 4°C 
under gentle rotation. Beads were separated from unbound protein lysates using a DynaMag
™
 
magnet and were washed 4 times in NP-40 wash buffer. Immunocomplexes were separated 
from the beads by boiling in 1xLDS sample buffer for 10 minutes in reducing conditions. 
 
2.13.3 Precipitation of proteins 
Protein lysates were mixed with 4 volumes of ice cold acetonitrile and incubated on ice for 30 
minutes. Lysates were centrifuged at 12,000rpm for 15 minutes at 4°C. Pellets were washed 
with fresh acetonitrile before centrifuged at 12,000rpm for 5 minutes at 4°C. Pellets were 
allowed to dry before resuspended in a suitable buffer solution for subsequent downstream 
applications.   
 
2.13.4 Determination of protein concentration 
The protein concentration of biological samples was determined spectrophotometrically using 
the Bradford Protein Assay (Bradford, 1976). For all assays, a working solution of Bradford 
Reagent (BioRad) was diluted 1:5 in water. Standards were prepared in duplicate containing 
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1ml of 0, 2, 4, 6, 8µg/ml BSA in Bradford Reagent. Protein lysates from samples were 
diluted in Bradford Reagent to a final volume of 1ml. Samples were mixed and incubated at 
room temperature for 5 minutes. The absorbance of each sample was measured at 590nm and 
the concentration in each sample was calculated against the standards. 
 
2.13.5 Measurement of reduced and disulphide glutathione 
Levels of total and reduced glutathione (GSH) were determined using a modification of the 
Tietze protocol (Tietze, 1969) as described by Rahman et al (Rahman et al., 2006). Levels of 
glutathione disulphide (GSSG) were determined using a modification of the Griffith protocol 
(Griffith, 1980). All steps were performed on ice unless stated otherwise. Glutathione levels 
were determined spectrophotometrically, using the sulfhydryl reagent 5,5’-dithio-bis (2-
nitrobenzoic acid) (DTNB, also referred to as Ellman’s reagent). DTNB oxidises GSH, 
forming GSSG and a TNB chromophore which can be measured at 412nm. The rate of TNB 
formation is proportional to the sum of GSH and GSSG present. Levels of GSSG are 
determined using GSSG reductase and monitoring NADPH spectrophotometrically. The 
levels of GSSG can be measured as described for GSH after treatment with 2-vinylpyridine, 
which covalently binds GSH and not GSSG (Rahman et al., 2006). 
 
To determine the levels of GSH/GSSG in vivo, mouse liver samples were harvested and 
washed in ice cold PBS. 0.25M sucrose (2ml) was then added to approximately 100mg of 
tissue and homogenised; 500µl of homogenate was retained for protein determination. 2x 
extraction buffer (1.5ml; 0.2M potassium phosphate buffer pH 7.5, 10mM EDTA, 10% meta-
phosphoric acid, 1.2% 5-sulfosalicyclic acid, 0.2% Triton X-100, 0.2% NP-40) was added to 
the remaining homogenate. Acidification and deproteinization of biological samples is 
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necessary to prevent oxidation of GSH and to inhibit the activity of γ-glutamyl transpeptidase 
which catalyses the transfer of glutathione to various molecules resulting in a loss of both 
GSH and GSSG. Homogenates were centrifuged at 3,000xg for 4 minutes at 4°C and 500µl 
of the aqueous upper layer was neutralised with 1ml of 1M Tris (pH 7.5) and used to 
determine GSH/GSSG levels.  
 
To determine the levels of glutathione in vitro, cells were trypsinised and pelleted at 3,000xg 
for 4 minutes at 4°C. Pellets were washed in ice cold PBS, centrifuged and resuspended in 
250µl 0.25M sucrose. An aliquot (50µl) of cell suspension was removed and used to 
determine protein concentration. Extraction buffer (excluding metaphosphoric acid) was 
added (200µl) to the sucrose suspension and centrifuged at 3,000xg for 4 minutes at 4°C. The 
supernatant was removed and used to determine GSH/GSSG levels.  
 
Stock solutions of DTNB (4mg per 6ml), glutathione reductase (20 units per 6ml) and ß-
NADPH (4mg/6ml) were prepared in KPE buffer (0.1M potassium phosphate buffer 
supplemented with 5mM EDTA). For determination of total and reduced levels of GSH, 
samples were diluted (1:20 for tissues, 1:5 for cells) and 20µl was dispensed in triplicate into 
a 96 well plate. GSH standards were prepared at 26.4, 13.2, 6.6, 3.3, 1.65, 0.825 and 
0.4125µM in standard buffer (0.25M sucrose, 2x extraction buffer, 1M Tris (pH 7.5)). 20µl 
of each standard was dispensed in triplicate into a 96 well plate. DTNB and glutathione 
reductase (60µl of each) were added to each well and left for 2 minutes at room temperature. 
ß-NADPH (60µl) was added after 2 minutes and the velocity (mOD/min) of the reaction at 
412nm was calculated. The increment in concentration of GSH was calculated and measured 
against the standard concentrations to determine total GSH concentration in the sample. 
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For determination of GSSG, 6µl of 2-vinylpyridine (diluted 1:10 in KPE buffer) was added to 
300µl of homogenate and left at room temperature for 1 hour. Triethanolamine (18µl; diluted 
1:6 in KPE) was added and left for 10 minutes in order to neutralise excess 2-vinylpyridine. 
Determination of GSSG was as described for GSH, with the following changes; 2% 1:10 2-
vinylpyridine and 6% 1:6 triethanolamine is added to the standard buffer, samples are 
measured against GSSG standards at the concentrations described for GSH and samples are 
not diluted prior to analysis.  
 
2.13.6 Measurement of mitochondrial respiration 
Oxygen consumption and levels of glycolysis were determined using the XF24 Analyser 
(Seahorse Biosciences). Cells were seeded at 20,000 cells per well in 100µl media into a XF 
24 TC well plate and incubated at 37°C/5% CO2 for 1 hour to allow cells to adhere. DMEM 
or McCoy’s 5A Medium (150µl) was added to each well and the cells were incubated 
overnight at 37°C/5% CO2. At the same time, 1ml XF Calibrant solution, pH 7.4, was added 
to each well of a Seahorse Bioscience 24-well utility plate, the XF Sensor Cartridge placed on 
top and incubated at 37°C in a non-carbon dioxide incubator. The following morning, cells 
were gently washed in cell media before incubated in 825µl of unbuffered DMEM (8.3g/L 
DMEM base, 32mM NaCl, 25mM glucose, 1mM sodium pyruvate, 2mM GlutaMax-1, 42µM 
Phenol red, pH 7.4) for 1 hour at 37°C in a non-carbon dioxide incubator. During this period, 
100µM of 2,4-dinitrophenol (DNP) dissolved in 75µl unbuffered media was added to one 
port of each well of the XF Sensor Cartridge and calibrated inside the XF Analyser. The cell 
plate was loaded onto the Analyser, mixed for 2 minutes, paused for 10 minutes followed by 
5 cycles of mixing for 3 minutes, paused for 2 minutes and measured for 2.5 minutes. DNP 
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was then injected and the plate went through 2 cycles of mixing for 3 minutes, paused for 2 
minutes and measured for 2.5 minutes. 
 
2.13.7 Isolation of cytosol from mouse tissue 
Cytosolic fractions were prepared from tissues as previously described with modifications 
(McLellan and Hayes, 1987). Tissue (100-200mg) was homogenised in 3 volumes of 
potassium chloride phosphate buffer (0.1M potassium phosphate pH 7.4, 0.1mM EDTA, 
150mM potassium chloride, protease inhibitor (Roche)) and centrifuged at 11,000xg for 20 
minutes at 4°C. The supernatant was removed and centrifuged at 100,000xg for 80 minutes at 
4°C. The supernatant (cytosolic fraction) was removed and the pellet (micosomal fraction) 
was resuspended in sucrose buffer (0.25M sucrose in potassium chloride phosphate buffer 
supplemented with protease inhibitor (Roche)) and stored at -80°C.  
 
2.13.8 Isolation of mitochondria from HCT116 cells 
Mitochondria were isolated from cells using the Mitochondrial Isolation Kit for Cultured 
Cells (Pierce). 1x10
6 
HCT116 cells were seeded onto 10cm culture dishes and transfected 
with 10nM of siRNA targeted for GSTP1, a non-targeting control siRNA or untransfected as 
described previously. Cells were trypsinised 72 hours later and centrifuged at 800xg for 5 
minutes and homogenised using a Dounce homogeniser. Mitochondria were isolated using 
differential centrifugation according to the manufacturer’s protocol and stored at -80°C.  
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2.13.9 Immunoblotting 
Immunoblotting was performed as previously described (Henderson and Wolf, 1992) with 
modifications. Protein lysates from cells and tissues were prepared at 0.5-2µg/µl in a sample 
buffer containing 1x LDS loading buffer (Invitrogen) and 10% ß-mercaptoethanol. For 
samples run under non-reducing conditions, ß-mercaptoethanol was omitted. Samples were 
boiled at 95°C for 5 minutes prior to loading onto gels. Protein (5-30µg) was resolved on 10-
12% SDS-polyacrylamide gels at 100mV for 1.5-3 hours depending on the size of the protein 
of interest. Proteins were transferred onto Protean nitrocellulose membranes at 100mV for 80 
minutes and visualised using Ponceau S solution (Sigma). Membranes were briefly washed in 
TBST buffer (50mM Tris, 150mM NaCl, 0.1% Tween 20, pH 7.9) before blocked in 5-10% 
non-fat dry milk in TBST for 1 hour at room temperature. For immunoblotting of phospho-
antibodies and biotinylated proteins, membranes were blocked in 5% BSA in place of milk 
for 1 hour at room temperature. Milk contains casein, a phospho-protein, causing high 
background with phospho-antibodies and due to the presence of endogenous biotin in non-fat 
dry milk, it should not be used for biotinylated proteins. Membranes were washed 3 times in 
TBST before incubated with a primary antibody (Appendices I) overnight at 4°C. Antibodies 
were prepared in 5-10% non-fat dry milk in TBST. Phospho-antibodies were prepared in 5% 
BSA in TBST. Membranes were washed 3 times in TBST and incubated with secondary 
antibody prepared in 5% non-fat dry milk for 1 hour at room temperature. Membranes were 
washed 4-5 times in TBST before visualised using a chemiluminescent kit (ECL, Millipore) 
and Konica Minolta autoradiographic film. 
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2.13.10 Two-dimensional gel electrophoresis 
Biotinylated proteins from HCT116 cells were analysed by two-dimensional gel 
electrophoresis as previously described with modifications (Berkelman and Stenstedt, 1998). 
Protein lysate (100µg) was precipitated using acetonitrile and pellets were resuspended in 
100µl of isoelectric focusing (IEF) buffer containing 7M urea, 2M thiourea, 4% CHAPS, 
12µl/ml Destreak, 5µl/ml Bio-Lyte ampholytes and 0.002% bromophenol blue. Sample 
loading was performed by overnight in-gel rehydration of Immobilised pH Gradient (IPG) 
ReadyStrips
™
 pH3-10 NL, pH4-7 or pH5-8. 20µg of sample was used for silver stain analysis 
and 70µg of sample used for Western blotting. IEF was performed at 20°C using a Protean 
IEF Cell (BioRad) according to the following parameters; 250V for 15minutes, 4,000V for 2 
hours, 4,000V for 20,000Vhours, hold at 500V. Voltage ramping was linear and the current 
limit did not exceed 50µA/strip.  
 
Immobilized pH gradient (IPG) strips were equilibrated in buffer (EQ buffer) containing 
0.37M Tris, 6M urea, 2% SDS, 30% glycerol pH 8.8. For analysis of proteins using silver 
staining, strips were washed 3x 5 minutes in EQ buffer containing 130mM DTT, followed by 
washing 3x 5 minutes in EQ buffer containing 135mM iodoacetamide. For analysis of 
biotinylated proteins using western blotting, DTT was omitted from the buffer. IPG strips 
were resolved on 10-12% SDS-polyacrylamide gels at 80mV for 2-3 hours and analysed by 
silver staining or western blotting. 
 
2.13.11 Silver staining 
Silver staining of SDS-polyacrylamide gels was performed using the SilverQuest staining kit 
(Invitrogen). Gels were briefly washed in ultrapure water before fixed overnight in a solution 
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containing 40% ethanol, 10% acetic acid and 50% ultrapure water. Gels were then stained 
according to the manufacturer’s instructions. 
 
2.14 Statistical analysis 
All results are expressed as mean ± standard deviation. ANOVA, Student’s t-test and the 
Mann-Whitney test are used where parametric and non-parametric analyses are indicated. 
Non-normality was determined using the Shapiro-Wilk test. All statistical analysis was 
performed using SPSS statistical software (University of Dundee). 
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3. Chapter 3: Non-catalytic functions of GSTP1 in mediating 
resistance to acetaminophen-induced hepatotoxicity  
 
Introduction 
GSTP1 plays an important role in cell physiology, the precise mechanism(s) of which are yet 
to be fully characterised. There are a growing number of in vitro studies highlighting 
functions of GSTP1 independent of its catalytic properties, yet little in vivo evidence to 
corroborate these findings. This chapter will begin to assess some of the non-catalytic 
properties of GSTP1 using a novel transgenic mouse model in which the activity of mouse 
GSTP1 (mGSTP1) has been made catalytically redundant. Preliminary studies will examine 
basal function of GSTP1 and assess whether its catalytic activity contributes to the 
hepatotoxic effects of acetaminophen.   
 
3.1 In vivo characterisation of GSTP1 through the use of Gstp1/2-/- mice  
Transgenic models provide a powerful tool in characterising the functions of a gene in vivo. 
Mice have a more comparable GST isozyme composition to humans than other laboratory 
animals such as the rat (Gupta et al., 1990) which makes them ideal candidates in modelling 
GSTs in transgenic research. A number of GST classes have been deleted in vivo which has 
led to the identification of several interesting phenotypes. For a thorough overview on the use 
of transgenic models in GST research please refer to a recent review by Henderson  and 
Wolf, 2011 (Henderson and Wolf, 2011). In contrast to most other organisms, mice have 2 
Gstp genes, Gstp1 and Gstp2 which are located on chromosome 19 and lie in tandem 2.5kb 
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apart. GSTP2 is catalytically weaker than GSTP1 and transcribed at a lower level despite 
differing by six amino acids and sharing 97% sequence identity (Bammler et al., 1995). The 
genes encoding GSTP1 and GSTP2 have been knocked out, resulting in Gstp1 null (Gstp1
-/-
) 
and Gstp1/2 null (Gstp1/2
-/-
) mice bred, initially, on a 129xMF1 background (Henderson et 
al., 1998b). To date, the function of GSTP1 has only been assessed in comparison to Gstp1/2
-
/-
 mice. The Gstp1 gene and exons 5-7 of the Gstp2 gene have been replaced by an IRES-
ßGEO element, the targeting construct shown in Figure 3.1. GSTP2 contains very little 
catalytic activity in its native form and truncation of the Gstp1 gene shows no catalytic 
activity towards CDNB (Henderson et al., 1998a). No transcript or protein expression of the 
truncated Gstp2 gene could be identified as determined by Western or Northern Blotting 
(Henderson et al., unpublished). Gstp1/2
-/- 
null mice are viable, phenotypically healthy with 
no apparent state of stress or illness and have no apparent defect in reproductive capabilities, 
the only apparent difference being a greater body weight and lung size compared to their 
wild-type counterparts (Henderson et al., 1998a), the reason for which remains unclear. With 
the complete deletion of a single class of GST, one might expect an adaptive mechanism to 
compensate through increased expression of other GST classes. Whilst other GST knock out 
models have observed some form of compensatory changes (Fernandez-Canon et al., 2002) 
this is not apparent at a protein level in Gstp1/2
-/-
 mice (Henderson et al., 1998b, 
Kitteringham et al., 2003). Despite a lack of protein induction, it has been observed that there 
is significant increase in other GST mRNA levels and other antioxidant response genes upon 
deletion of GSTP1 (Henderson et al., 2005, Elsby et al., 2003). 
 
Like other GST knockout mouse models, Gstp1/2
-/-
 mice only appear to exhibit differences in 
phenotype in response to chemical or genetic stress. Upon exposure to chemical agents, the 
deletion of GSTP1 can have detrimental effects in vivo, often, but not exclusively, associated 
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with an ability to suppress inflammatory responses. In a study by Henderson et al. Gstp1/2
-/-
 
mice were treated with 7,12-dimethylbenz anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA), used respectively as skin tumorigenic inducing and 
promoting agents. The authors found that Gstp1/2
-/-
 mice developed a significantly higher 
number of papillomas compared to wild-type animals; an average of 9.94 papillomas per 
animal compared to 2.89 in wild-type mice (P<0.001). Later studies suggested that the role of 
GSTP1 in supressing inflammation may account for these observations, as Gstp1/2
-/-
mice 
crossed onto mice harbouring H-ras mutations in the skin (Tg.Ac mice) showed increased 
nitrotyrosine formation and upregulation of a number of inflammatory genes compared with 
their wild-type counterparts when treated with TPA (Henderson et al., 2011). This has 
considerable implications in humans, where GSTP1 expression and catalytic activity is far 
higher in female skin and may lead to sex differences in the metabolism of polycyclic 
aromatic hydrocarbons (PAHs) depending on the level of exposure (Singhal et al., 1993). 
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Figure 3.1. Targeting strategy for the deletion of the murine Gstp cluster, taken, with 
permission, from Henderson et al, 2005. 
A) Target gene cluster B) Targeted deletion of Gstp1 and Gstp2; En2a, splice acceptor site; IRES, internal 
ribosome entry site; lacZ, β-galactosidase reporter; pA, simian virus 40 polyadenylation site.  
 
GSTP1 expression also has a profound effect in the protection against pulmonary 
carcinogens. In the human lung, GSTP1 is the most prominent GST but this is not the case in 
rodents, where the expression of GST Mu and Alpha classes are higher. It is clear however, 
that GSTP1 expression is an important factor in lung pathophysiology. Ritchie et al 
demonstrated that Gstp1/2
-/-
 mice treated with the PAH agents benzo[a]pyrene (BaP), 3-
methylcholanthrene (3-MC) and the carbamate urethane, developed more papillomas on the 
lung surface than wild-type mice and had increased BaP DNA adduct formation (Ritchie et 
al., 2007). GSTP1 is known to be involved in the metabolism of different PAHs (Sundberg et 
al., 1998, Hu et al., 1997, Whyatt et al., 2000) and therefore may explain the difference in 
sensitivity towards these agents in Gstp1/2
-/-
 mice. Pulmonary expression of GSTP1 also 
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appears to attenuate inflammatory responses in mice. Zhou et al demonstrated that Gstp1/2
-/-
 
mice challenged with ovalbumin to induce airway inflammation show increased eosinophilia 
and goblet cell hyperplasia compared to wild-type mice, while Schroer et al, showed 
increased oxidative stress in Gstp1/2
-/- 
mice subjected to an allergen challenge (Zhou et al., 
2008, Schroer et al., 2011). A potential mechanism of GSTP1 cytoprotection in pulmonary 
disease was highlighted by Schroer et al as GSTP1 was found to be downregulated in 
children with asthma.  
 
These studies form part of a larger body of evidence which suggests that suppression of 
inflammatory signalling may be one mechanism by which GSTP1 functions in vivo. Gstp1/2
-
/-
 mice crossed onto mice heterozygous for mutations in the adenomous polyposis coli (Apc) 
gene have a higher incidence and multiplicity of colon adenomas than their wild-type 
counterparts, and demonstrate an induction of a number of inflammatory genes and formation 
of nitrotyrosine adducts (Ritchie et al., 2009). The Apc
min
 mouse model carries a missense 
mutation at codon 850 of the Apc gene, resulting in small intestinal adenoma development 
through activation of Wnt signalling driven by ß-catenin (Su et al., 1992) and therefore 
bypasses practical and metabolic problems associated with chemically induced 
carcinogenesis. By crossing Gstp1/2
-/-
 mice onto Apc
min
 mice, the authors managed to define 
a phenotype of GSTP1 which is independent of chemical stress and metabolism. The 
mechanism behind the suppression of inflammatory response remains unclear but may be 
related to the regulation of the mitogen-activated protein kinases (MAPKs). A model of 
GSTP1 mediated cell regulation was proposed by Adler et al, when, using mouse embryonic 
fibroblasts (MEFs), the group identified that GSTP1 binds to c-Jun N-terminal kinase (JNK) 
preventing downstream phosphorylation of its target substrates (Adler et al., 1999).  JNK is 
an upstream modulator of the transcription factor AP-1 and is intrinsically controlled to 
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phosphorylate c-Jun in the presence of stressors such as ionising and UV irradiation, heat 
shock, growth factors, inflammatory cytokines or oxidative stress (Westwick et al., 1994, 
Cano et al., 1994, Hibi et al., 1993). Under basal conditions, GSTP1 binds to the C-terminus 
of JNK in its monomeric form, preventing phosphorylation of c-Jun by JNK (Wang et al., 
2001b). In times of oxidative stress, the GSTP1 monomer oligomerizes and dissociates from 
JNK, which becomes phosphorylated and activates the MAPK pathway and subsequent stress 
responses. Studies using MEFs and 3T3 fibroblast cells suggests that the JNK2 isoform 
contributes to JNK stability whereas the JNK1 isoform activates downstream activity 
(Sabapathy et al., 2004). Constitutive JNK signalling may then lead to the recycling of 
GSTP1 transcription as the phosphorylated c-Jun forms a complex with other transcription 
factors such as c-Fos to form the AP-1 complex which binds to the AP-1 promoter on the 
GSTP1 gene (Moffat et al., 1994). Subsequent in vivo work has demonstrated that Gstp1/2
-/-
 
mice bred on a 129xMF1 background express higher basal levels of JNK in liver and lungs 
and also express increased levels of an AP-1 target antioxidant gene, Haem Oxygenase-1 
(HO-1) and the ARE regulated phase II gene, UDP-glucuronosyltransferase 1A6 (Elsby et al., 
2003).  Gstp1/2
-/- 
mice administered cyclophosphamide show a larger increase in bladder 
toxicity and acrolein adduct formation compared to wild-type mice and demonstrate 
increased JNK activity, in part due to an inability to metabolise acrolein in the absence of 
GSTP1 (Conklin et al., 2009). Gstp1/2
-/-
 mice have been found to have higher levels of 
myeloproliferation through increased levels of JNK and signal transducer and activator of 
transcription (STAT) molecules, particularly in bone marrow cells, and have higher levels of 
circulating leukocytes than their wild-type counterparts (Gate et al., 2004). 
 
Despite extensive research into this mechanism, a lack of consistency and detail across in 
vitro and in vivo models demonstrates that GSTP1 regulation of JNK signalling cannot be a 
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universal mechanism to explain GSTP1-associated phenotypes (discussed further in ‘Results 
Chapter 4’ and ‘Discussion’). As discussed below, Gstp1/2-/- mice are resistant to the 
hepatotoxic effects of acetaminophen and show increased resistance to the nephrotoxic 
effects of cisplatin (Townsend et al., 2008b). The latter phenotype can be rationalised through 
increased production of cysteine S-conjugate β-lyase in the proximal tubule, as a result of 
increased cisplatin conjugation, which results in the formation of reactive thiols. However, 
this phenotype is not translated clinically or in vitro, as GSTP1 has been shown to attenuate 
cisplatin efficacy (Peklak-Scott et al., 2008) while the use of a GSTP1 inhibitor, ethacrynic 
acid, increases the sensitivity of tumour cells to cisplatin (Wang et al., 2007). The role of 
GSTP1 in mediating cytoprotection appears more complex than its function in enzymology 
but cannot be solely explained through the regulation of JNK.  
 
3.2 Acetaminophen 
Initially identified as the metabolite derived from acetanilide and phenacetin (Brodie and 
Axelrod, 1948a, Brodie and Axelrod, 1948b) acetaminophen has been widely used since the 
1950s as an analgesic and antipyretic compound. At therapeutic doses (500mg) 
acetaminophen is well tolerated but can cause hepatic necrosis and acute liver failure at 
higher doses. The metabolism of acetaminophen is well established with around 80-90% of 
the parent compound typically conjugated with sulphate or glucoronide and excreted in the 
urine (Forrest et al., 1982, Clements et al., 1984). Around 5% of acetaminophen is oxidised in 
a cytochrome P450 directed manner, with CYP2E1, CYP3A4 and CYP1A2 isoforms 
catalysing the majority of CYP-mediated reactions (Raucy et al., 1989, Patten et al., 1993). 
Hepatotoxicity as a result of acetaminophen overdose was first established in 1966 (Davidson 
and Eastham, 1966), the toxicity of which is directly linked to increased production of a 
reactive metabolite from CYP-mediated reactions, N-acetyl-p-benzoquinone imine (NAPQI). 
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At non-toxic doses, NAPQI is conjugated to the tripeptide glutathione, to form 3-glutathion-
S-yl-acetaminophen (Hinson et al., 1982), which can be catalysed by GSTP1 or non-
enzymatically conjugated (Coles et al., 1988). At toxic doses, glucoronidation and sulfation 
pathways become saturated, leading to increased NAPQI production and depletion of hepatic 
glutathione levels. The electrophilic NAPQI can arylate a number of thiol containing peptides 
and proteins (Bartolone et al., 1987) and activate stress response genes, leading to DNA 
damage (Ray et al., 1993), increased ALT/AST production (Pumford et al., 1989), 
mitochondrial damage (Burcham and Harman, 1991, Weis et al., 1992) and changes in 
calcium homeostasis (Moore et al., 1985, Ray et al., 1993), resulting in hepatic necrosis. 
Inhibition of activation of these pathways or administration of cysteine containing 
compounds such as N-acetyl-cysteine can be used as effective treatment against 
acetaminophen overdose (Gunawan et al., 2006, Smilkstein et al., 1988).   
 
Mice are particularly sensitive to the hepatotoxic effects of acetaminophen compared to other 
laboratory animals, in part due to a rapid depletion of hepatic glutathione after acetaminophen 
treatment (Green et al., 1984). The sensitivity of mice towards acetaminophen appears to be 
strain specific as Harrill et al demonstrated a range of ALT serum responses and differential 
changes in gene expression after a single dose of acetaminophen from a panel of 36 inbred 
mouse strains (Harrill et al., 2009a). Using this model, Harrill et al went on to perform a 
whole-genome association analysis to identify that polymorphisms in the Cd44 gene in mice 
correlated well with tissue necrosis, and later identified that polymorphisms in the 
orthologous human gene, CD44, show comparable sensitivity traits to acetaminophen in a 
human cohort (Harrill et al., 2009b). Despite its functional role in catalysing glutathione 
conjugation of NAPQI, there is little evidence to suggest that polymorphisms in the GSTP1 
gene may confer differences in susceptibility to acetaminophen treatment. This is not 
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surprising, as slight changes in catalytic activity due to polymorphic variations may have 
little effect on the conjugation of glutathione to NAPQI if non-enzymatic reactions can also 
take place in acetaminophen overdose. However, there is some evidence to suggest that 
asthma induced by prenatal exposure to acetaminophen may be influenced by polymorphisms 
in GSTP1 (Perzanowski et al., 2010).  
 
The role of GSTP1 in mediating acetaminophen metabolism becomes more complex as, 
paradoxically, Gstp1/2
-/- 
mice appear to be more resistant to the hepatotoxic effects of 
acetaminophen than their wild-type counterparts. Using acetaminophen as a model compound 
for hepatotoxicity, Henderson et al, demonstrated that after a single dose of acetaminophen, 
Gstp1/2
-/-
 mice had lower levels of plasma ALT and very little hepatic necrosis compared to 
their wild-type counterparts, which showed significant increases in ALT and substantial 
hepatic necrosis at 24 and 48 hours after dosing (Henderson et al., 2000). The difference in 
sensitivity was attributed to increased hepatic glutathione regeneration after acetaminophen 
treatment in Gstp1/2
-/- 
mice, as no difference was observed in the pharmacokinetic 
metabolism or conjugation of the parent compound. This suggests that covalent binding of 
acetaminophen may not be the only mechanism of toxicity and that regulation of other 
cellular pathways involved in acetaminophen induced hepatotoxicity may be mediated by 
GSTP1. Therefore, in vivo modelling of a catalytically inactive GSTP1 protein may aid in 
elucidating these pathways associated with hepatotoxicity in mice. 
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3.3 Structure and Kinetics of GSTP1 - Identification of Tyr7 as target for non-
catalytic mouse model 
Reinemer et al first identified the three dimensional structure of GSTP1 using cytosolic 
extracts isolated from pig lung and showed that GSTP1 is composed of a dimer with two 
identical subunits of 23 kDa (Reinemer et al., 1991). The three-dimensional structures have 
since been characterised for human (Reinemer et al., 1992) (Figure 3.2) and mouse (Parraga 
et al., 1998) GSTP1. The ability of GSTP1 to dimerize appears critical for the stability of its 
tertiary structure (Erhardt and Dirr, 1995). Similarly to other cytosolic GSTs, dimerization is 
facilitated through ionic, hydrogen bonding and a hydrophobic ‘lock and key’ motif between 
its subunits, of which Tyr50 appears to be a key residue in mediating hydrophobic 
interactions. Although in vitro experiments have demonstrated heterodimerization between 
GSTP1 and GSTM1 (Pettigrew and Colman, 2001), it is unlikely that this occurs in vivo. 
Despite only around 23 residues being conserved amongst cytosolic GST classes, GSTP1 is 
structurally similar to the Alpha and Mu class of GSTs but differs in its C-terminal region, 
possessing a highly exposed electrophilic binding site that expresses both hydrophilic and 
hydrophobic interactions (Ji et al., 1997). There is evidence to suggest that GSTP1 can exist 
as a stable monomer and in its reduced form can interact with several proteins such as JNK 
and PrdxVI (Monaco et al., 1999, Manevich et al., 2004, Adler et al., 1999).  In HaCaT cells, 
increased cell survival and inhibition of JNK phosphorylation is associated with stabilisation 
of GSTP1 monomers by the Human Papillomavirus-16 E7 protein (Mileo et al., 2009). 
However, there is contrasting evidence to show if monomeric GSTP1 has any catalytic 
function with some reports suggesting a lack of catalytic functionality of GSTP1 monomers 
(Abdalla et al., 2002), whilst others suggesting dimerization stabilises the catalytic function 
but is not required for catalysis (Huang et al., 2008a).  
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Figure 3.2. Three dimensional structure of hGSTP1-1 in complex with glutathione. 
A) Dimeric structure of human GSTP1-1. Helix α2 is highly flexible within GSTP1-1 and can modulate 
glutathione binding and catalysis (Oakley et al., 1997). B) Position of tyrosine 7 (highlighted in yellow) in 
relation to glutathione within the N-terminal domain of GSTP1-1.  
 
Activation of glutathione by GSTP1 is mediated through a tyrosine (Tyr7) present within its 
active site (Reinemer et al., 1991) and is conserved in all cytosolic GSTs (Mannervik et al., 
1985a). Kinetic studies using recombinant human GSTP1 demonstrated that Tyr7 contributes 
predominantly to the catalysis of substrates rather than their binding as mutational studies in 
which tyrosine is substituted to a phenylalanine demonstrates large decreases in catalytic 
activity, yet very little change in substrate affinity (Kolm et al., 1992, Cesareo et al., 2005). 
Its catalytic function is thought to be mediated through protonation of a phenolic hydroxyl 
group present in the tyrosine molecule (Kolm et al., 1992) which stabilises the glutathione 
anion (GS
-
) by activating its sulphur group through hydrogen bonding (Stenberg et al., 1991). 
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Although structurally similar, phenylalanine lacks this phenolic hydroxyl group and therefore 
catalysis cannot occur. Later studies have argued against the tyrosinate hypothesis as the 
proton acceptor and suggested that a water molecule found within the G-site accepts and 
transfers the thiol proton (Parraga et al., 1998).  
 
A number of key residues involved in GSTP1-mediated catalysis and substrate binding have 
been identified and are highlighted in Table 4. Mutation of residues within the lock and key 
motif of GSTP1 (Tyr50) produces large decreases in catalytic activity (Kcat) towards a 
number of substrates (Hegazy et al., 2004), but the inability of GSTP1 to dimerize accurately 
as a result of the mutations deems the lock and key motif an unsuitable target for in vivo 
modelling of the non-catalytic properties of GSTP1. Other substitutions affecting 
dimerization were similarly disregarded as potential targets. In 1995, Bammler et al, neatly 
identified that the differences in catalytic activity between mouse GSTP1 and the non-
catalytic protein GSTP2, was largely dependent on 2 key amino acid substitutions, located 
within the H-binding site (Val10) and N-terminal domain (Arg11) of GSTP1 (Bammler et al., 
1995). Site-directed mutagenesis of these sites resulted in large decreases in catalytic activity, 
with Val10Ser demonstrating an 80% loss in activity while Arg11Pro a 97% loss in activity. 
Although Val10Ser resulted in modest changes in affinity for glutathione and CDNB, 
Arg11Pro resulted in reduced affinity for both glutathione and CDNB and therefore was 
dismissed as a possible target for in vivo modelling.  
 
The advantage for targeting a Tyr7 in the development of a non-catalytic GSTP1 mouse 
model is that as Tyr7 is crucial for the catalytic activity of GSTP1 but is not required for 
Results Chapter 3 
 
65 
 
substrate binding, mutation of Tyrosine to Phenylalanine may result in a protein which is 
devoid of catalytic activity yet retains its ability to bind glutathione and other substrates. 
 
Element Mutation Comments 
Advantage as 
a mutation 
target 
Disadvantage as 
a mutation 
target 
Reference 
GSH 
catalysis / 
binding 
GSTP1 (10 
mutations) 
Stable monomer. 10 
mutations - L49Q, 
Y50E, L61Q, L63E, 
A87E, A88K, L89E, 
M92E, G96K, 
C102Q – loss of 
catalytic activity, 
retained affinity for 
several H-site 
compounds. 
Stable and has 
complete loss 
of catalytic 
activity 
Problems with 
dimerization and 
introduction of 10 
mutations may be 
problematic. 
(Abdalla 
et al., 
2002) 
 
Tyr 7 (Y7F) 
Tyr 7 important for 
catalysis. Large 
decrease in GSH 
Kcat. Moderate 
increase in GSH 
Km. 
Largest 
decrease in 
catalytic 
activity 
Key site in 
glutathionylation 
of proteins 
(Kong et 
al., 1992)   
(Kolm et 
al., 1992)  
(Cesareo 
et al., 
2005) 
(Townsen
d et al., 
2008a) 
Tyr50 
(Y50A) 
Reduction in GSH 
Kcat but increase in 
GSH Km. 
Heterodimer of 
mutant and wild-
type similarly 
reduces Kcat but 
only slight increase 
in Km. 
Loss of 
catalytic 
activity in 
mutant and 
heterodimer. 
Role in GSH 
stability. 
Loss of GSH 
affinity. Affects 
dimerization. 
Heterodimer not 
practical in vivo 
(Hegazy et 
al., 2004) 
Substrate 
binding 
Val10 
(V10G) 
(V10S) 
Reduced catalytic 
activity towards EA 
(V10G) and CDNB 
(V10G, V10S), GSH 
Km unchanged 
Large 
reduction in 
Kcat of 
substrates with 
hardly no loss 
Only compounds 
tested are CDNB 
and EA – unsure 
of effect on other 
substrates 
(Micaloni 
et al., 
2000) 
(Bammler 
et al., 
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(V10G, V10S) 
 
in GSH 
affinity 
1995) 
Arg11 
(R11P) 
Decreased CDNB 
Kcat, increased 
CDNB Km. GSH 
Km increased. 
Largest 
decrease in 
Kcat of all 
substrate 
mutations 
Large loss of 
GSH affinity. 
Uncertain of 
effect on other 
substrates. 
(Bammler 
et al., 
1995) 
Tyr50 
(Y50A) 
Reduction in 
substrate and GSH 
Kcat but increase in 
Km towards CDNB 
(aromatic 
nucleophilic 
displacement) and 
PEITC (addition 
reaction). 
Decrease in 
kcat for several 
types of 
reactions 
Affects 
dimerization 
(Hegazy et 
al., 2004) 
Val104 
(V104G) 
Decrease CDNB 
Kcat, increase GSH 
km. 
Mutation has 
implications in 
human 
polymorphism
s and in altered 
transformation 
of various 
compounds. 
Not potential site 
to study non-
catalytic 
mechanisms as 
decrease in Kcat 
is only moderate. 
(Bammler 
et al., 
1995) 
(Abel et 
al., 2004) 
Tyr108 
(Y108F) 
 
Reduced Kcat 
towards ethacrynic 
acid, no change in 
GSH Km. Reduced 
Kcat towards EPNP. 
Important site for 
catalysis and binding 
of epoxide 
substrates. Little 
effect on CDNB, 
DCNB, cumene 
hydroperoxide 
DTNB, 4NQO and 
Δ5-androstene 3,17-
dione. 
Reduction in 
substrate kcat 
with minimal 
decrease in 
GSH affinity 
Has little effect 
on a variety of 
compounds. 
(LoBello 
et al., 
1997) 
(Park et 
al., 2005) 
Dimerization 
Tyr50 
(Y50A) 
Key residue in lock-
and-key motif. Not 
strongest contributor 
in dimerization of 
A key residue 
with regards to 
GSH stability. 
Decrease in 
Not strongest 
residue with 
regards to 
dimerization 
(Hegazy et 
al., 2004) 
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GSTP1-1 but 
important for 
thermal stability of 
dimer. 
GSH and 
substrate kcat 
for several 
types of 
reactions 
Arg70 
(R70Q) 
Mutation increases 
GSH Km compared 
to wild-type and 
affects dimer 
stability. No change 
for CDNB Km. 
Removing charge 
lowers enzymatic 
activity. 
Minimal effect 
on substrate 
Km. 
Large loss of 
GSH affinity and 
large effect on 
dimer stability. 
(Huang et 
al., 2008b) 
Arg74 
(R74Q) 
Not determinant of 
GSH stability. Small 
increase towards 
GSH Km of R74Q 
mutant. No change 
for CDNB Km. 
Removing charge 
lowers enzymatic 
activity and 
diminishes 
dimerization. 
Minimal effect 
on substrate 
Km. 
Diminished 
dimerization will 
effect GSTP1 
regulation in vivo 
(Huang et 
al., 2008b) 
Asp90 
(D90N) 
Not determinant of 
GSH stability. 
Conserved in 
GSTP1. Mutation 
causes no change for 
CDNB Km. 
Removing charge 
lowers enzymatic 
activity and 
diminishes 
dimerization. 
Minimal effect 
on substrate 
Km. 
Diminished 
dimerization will 
effect GSTP1 
regulation in vivo 
(Huang et 
al., 2008b) 
Asp94 
(D94N) 
No change for 
CDNB Km. Marked 
increase in GSH 
Km. Removing 
charge lowers 
enzymatic activity 
and shifts 
Minimal effect 
on substrate 
Km. Decreased 
enzymatic 
activity. 
Large loss of 
GSH affinity and 
large effect on 
dimer stability. 
(Huang et 
al., 2008b) 
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equilibrium towards 
monomer. 
 
Table 4. Mutation of residues in GSTP1 that confer differences in kinetic and binding 
properties. 
 
However, the consequence of this mutation in the regulation of cellular proteins is somewhat 
complex and difficult to predict. Whilst groups have demonstrated that the Y7F mutant is as 
efficient as wild-type GSTP1 in inhibiting high basal JNK activity and c-Jun-mediated 
transactivation (Adler et al., 1999, Townsend et al., 2008a), the Y7F mutant does not appear 
to form complexes with PrdxVI (Ralat et al., 2006) and has diminished ability to 
glutathionylate cellular proteins (Townsend et al., 2008a). 
 
To ensure that a Y7F substitution would result in decreased catalytic activity in mouse 
GSTP1, recombinant mouse GSTP1 harbouring the wild-type or Y7F mutation was produced 
and used in kinetic studies against GSH and CDNB to determine catalytic rates and substrate 
affinity. Table 5 highlights the kinetic data of GSTP1
WT
 and GSTP1
Y7F
 recombinant proteins. 
GSTP1
Y7F
 shows a marked decrease in its catalytic rate (Vmax) against GSH and CDNB when 
compared against wild-type GSTP1. This correlates with previous reports that a Y7F 
mutation greatly reduces the catalytic activity of GSTP1. It also demonstrates a more marked 
reduction in catalytic activity than mutations associated with catalytic differences between 
GSTP1 and GSTP2 as observed by Bammler et al (Bammler et al., 1995). While the affinity 
of GSTP1
Y7F
 for CDNB remains unchanged there is a slight increase in its affinity for GSH. 
However, the kinetic data show that a Y7F substitution would be a promising model to use in 
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the development of a non-catalytically functioning GSTP1 protein which retains its ability to 
bind to substrates. 
 
Kinetic parameters
1
 
Protein Km
GSH
 Vmax
GSH
 Km
CDNB
 Vmax
CDNB
 
GSTP1
WT
 0.65±0.1 397±20 0.55±0.1 447±39 
GSTP1
Y7F
 0.31±0.05
**
 4.4±0.17
***
 0.67±0.1
ns
 3.9±0.2
***
 
1
 Km:µM; Vmax:∆
340nm/min/mg
 
 
Table 5. Apparent kinetic parameters of mouse GSTP1
WT
 and GSTP1
Y7F
 towards 1-
chloro-2,4-dintrobenzene (CDNB) and glutathione (GSH). 
Data are provided for the kinetic parameters of recombinant protein, where affinity (Km ) is shown as µM  and 
the Vmax as the rate of change at 340nm/min/mg protein. Data are provided as mean ± standard deviation (n=4) 
where ns, not statistically significant, ** P value <0.01, *** P value <0.001.  
 
3.4 Generation and design of Gstp1Y7F mouse model 
The data generated from the recombinant studies demonstrate that targeting the Tyr7 residue 
would provide the best model for examining the non-catalytic function of GSTP1 in vivo. A 
mouse model was designed in which Y7F was constitutively knocked into exon 2 of the 
mouse Gstp1 gene using a BAC transgene (Figure 3.3) as described in ‘Materials and 
Methods’. Neomycin and puromycin resistance sites used for clonal selection have been 
flanked by FRT and F3 sites, respectively, which are then removed after Flp recombination to 
avoid any alteration of gene function (Scacheri et al., 2001). Despite the relatively low 
transcription and catalytic activity of GSTP2, there are some concerns that it may have a role 
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in cell regulation in a non-catalytic capacity. To circumvent any role GSTP2 may play in cell 
regulation and cytoprotection, loxP sites were introduced flanking exons 1 to 4 of the Gstp2 
gene, allowing for conditional deletion of Gstp2 using Cre recombination. This would allow 
for a mouse model solely dependent on the non-catalytic properties of Gstp1. However, in 
order to control against the effects of Gstp2 against their wild-type counterparts, all data 
presented here utilises Gstp1
Y7F
 mice harbouring a Gstp2 gene.      
 
3.5 Characterisation of Gstp1Y7F mice 
3.5.1 Protein expression  
Gstp1
Y7F
 mice show no abnormal phenotype during development, suggesting that the 
catalytic function of GSTP1 is not essential for survival. Although some reports suggest 
Gstp1/2
-/-
 mice bred on a 129xMF1 background develop a higher incidence of spontaneous 
tumours, particularly lung adenomas (Gate et al., 2005), we found no evidence for this in 
Gstp1/2
-/-
 or Gstp1
Y7F
 mice bred on a C57Bl/6J background up to 18 weeks of age (data not 
shown). Despite reports of increased lung size in Gstp1/2
-/-
 mice compared to wild-type mice 
bred on a 129xMF1 background (Henderson et al., 1998a), we found no evidence of this in 
either transgenic mouse model bred on a C57Bl/6J background. The only differences 
observed were sex-related, with female Gstp1/2
-/-
 mice having a larger brain size than their 
male counterparts and female Gstp1
Y7F
 mice having a larger thymus than their male 
counterparts (Table 6). The differences in organ:weight ratios in this instance has not been 
examined further.  
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Figure 3.3. Targeting strategy for the generation of a GSTP1
Y7F
 mouse model.  
The diagram shows the introduction of Y7F into exon 2 of the Gstp1 gene which is downstream of the Gstp2 
gene. Exons 1-4 of Gstp2 are flanked by LoxP sites (purple arrows) allowing conditional deletion of Gstp2 
using Cre recombination. Green arrow, FRT site. blue arrow, F3 site. 
 
GSTP1 is expressed largely in the livers of mice, particularly in male mice (Henderson et al., 
1998b). For this reason, male mice are the ideal model to use when examining the function of 
GSTP1 compared to a knockout system. The expression of GSTP1 from the livers of 
Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice were analysed by Western blotting (Figure 3.4). We 
can clearly observe the presence of GSTP1 in the livers of Gstp1
WT
 and Gstp1
Y7F
 mice and 
demonstrate that they are expressed at comparable levels, suggesting that GSTP1 is translated 
to the same extent in the liver of the knock-in mouse model as its wild-type counterpart. As 
predicted, no GSTP1 protein can be detected in Gstp1/2
-/- 
mice. This demonstrates that the 
antibody used is specific for GSTP1, as it shows no cross-reactivity with other GST classes. 
There was no evidence to suggest that deletion or catalytically inactivating GSTP1 resulted in 
upregulation of other GST classes as a compensatory mechanism, an observation which 
correlates with previous reports (Kitteringham et al., 2003).  
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Table 6. Organ to body weight ratios of transgenic mice. 
The organ to body weight ratios of male and female Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice (aged 10-14 weeks) 
are given in the table above. Data are provided as mean ± standard deviation (n=3). Differences in ratios 
between female and male mice are highlighted (*) when P < 0.05. 
 
 
 
 
 
Organ Organ:weight ratios 
 Male Female 
 Gstp1
WT
 Gstp1/2
-/-
 Gstp1
Y7F
 Gstp1
WT
 Gstp1/2
-/-
 Gstp1
Y7F
 
Bladder 0.09±0.024 0.12±0.004 0.12±0.05 0.06±0.03 0.09±0.004 0.11±0.07 
Brain 1.66±0.13 1.78±0.09* 1.77±0.1 2.07±0.08 2.21±0.27* 2.15±0.16 
Kidney 1.19±0.13 1.2±0.12 1.46±0.16 1.08±0.009 1.11±0.18 1.17±0.07 
Liver 5.4±1.01 5.36±0.31 4.95±1.01 5.44±0.19 4.52±0.69 4.52±1.05 
Lung 0.59±0.01 0.61±0.04 0.622±0.08 0.68±0.04 0.69±0.04 0.72±0.03 
Spleen 0.36±0.15 0.3±0.02 0.38±0.17 0.35±0.02 0.42±0.1 0.42±0.04 
Testes 0.64±0.07 0.8±0.19 0.58±0.12 n/a n/a n/a 
Thymus 0.25±0.08 0.2±0.07 0.18±0.04* 0.37±0.05 0.31±0.03 0.34±0.02* 
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3.5.2 PrdxVI 
Peroxiredoxins are a family of selenium-independent antioxidants involved in the reduction 
of hydroperoxides to alcohols (Wood et al., 2003). There are two main families of 
peroxiredoxins; those containing two conserved cysteine residues in their C-terminal domain 
(2-Cys) and those only containing one cysteine residue (1-Cys). The lack of an extra cysteine 
molecule for the 1-Cys family, or peroxiredoxin VI (PrdxVI), means that another molecule 
containing a thiol group is needed in order to reduce the oxidised Cys 47 molecule and to 
regenerate the active PrdxVI (Choi et al., 1998). It has been suggested that GSTP1 provides 
the thiol group required in a glutathionylation step by forming a heterodimer with PrdxVI 
(Manevich et al., 2004) and it has been demonstrated in vitro that a stable GSTP1:Cys1 
complex could be formed which restores active PrdxVI activity (Ralat et al., 2006). This 
example of GSTP1 mediated glutathionylation of cellular proteins is discussed further in 
Chapter 4. However, further data suggest interplay in the regulation of these two proteins, in 
that deletion of GSTP1 results in the upregulation of PrdxVI protein expression in mice bred 
on a C57x129 background (Kitteringham et al., 2003). In our studies, we could not detect any 
difference in PrdxVI expression in the livers of Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice 
generated on a C57Bl/6J background (Figure 3.5). This result may allude to differences in 
mouse strain, and perhaps is a result of different function of Ala
124
 and Asp
124
 polymorphic 
variants of PrdxVI, observed in C57Bl/6J and 129 mouse strains, respectively. 
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Figure 3.4. Protein expression profile of Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice. 
Hepatic cytosolic fractions (10µg) from male mice (n=3) were resolved on a SDS PAGE gel and proteins 
analysed by Western blot analysis. Blots demonstrate the presence of GSTP1 in Gstp1
WT 
and Gstp1
Y7F
 mice and 
its absence in Gstp1/2
-/- 
mice. The blots demonstrate that there is no apparent compensation in the expression of 
other GSTs. 
 
 
 
Figure 3.5. PrdxVI expression in the livers of Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice. 
Hepatic cytosolic fractions (10µg) from male mice (n=3) were resolved on a SDS PAGE gel and proteins 
analysed by Western blot analysis. Blots demonstrate that there is no change in the expression of PrdxVI protein 
levels in either Gstp1/2
-/-
 or Gstp1
Y7F 
mice. 
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3.5.3 Localisation 
Although widely distributed in a range of tissues, in mice GSTP1 is expressed largely in the 
liver and can be found in hepatocytes but not in Kupffer cells, bile duct cells and endothelial 
cells (Vaughn et al., 2011). Using an anti-GSTP1 antibody, immunohistochemical analysis 
shows that the expression of GSTP1 in wild-type mice appears to localise in hepatocytes 
predominantly within midzonal regions of the liver, although expression is observed in 
centrilobular regions (Figure 3.6). GSTP1 expression in Gstp1
Y7F
 mice localises to similar 
regions and cells within the liver, which suggests that not only is the non-catalytic protein 
expressed to the same extent as its wild-type counterpart, but that it is also localised to the 
same cellular compartments. Similarly to that observed in Figure 3.4, no GSTP1 protein can 
be detected in Gstp1/2
-/- 
liver sections, highlighting the specificity of the antibody for GSTP1. 
 
3.5.4 Catalytic activity of GSTP1 in mouse liver 
The catalytic activity of GSTP1 in mouse liver was determined spectrophotometrically using 
ethacrynic acid. Due to its cross reactivity with other GSTs, CDNB is unsuitable as a 
substrate due to the presence of GSTM and GSTA classes within cytosolic fractions (Figure 
3.4). Although it has been shown to cross react with other GST classes (Ploemen et al., 
1993), ethacrynic acid is a potent inhibitor of GSTP1 and is commonly used to determine the 
enzymatic activity of GSTP1. Figure 3.7 shows that only hepatic cytosolic fractions prepared 
from Gstp1
WT
 mice exhibits activity towards ethacrynic acid, demonstrating that GSTP1 
present in Gstp1
Y7F
 mouse liver is catalytically redundant.  
 
Incorporating both the protein expression and catalytic data, we can confidently assume that 
Gstp1
Y7F
 mice express a GSTP1 protein which is expressed and localised to the same extent 
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in the liver as its wild-type counterparts but is catalytically inactive. Therefore, any 
subsequent phenotype observed in these mice is a result of the catalytic function of GSTP1. 
However, we must acknowledge that these mice still retain the Gstp2 gene and, although 
transcriptionally and catalytically redundant, may have a non-catalytic role in cytoprotection. 
However, as both Gstp1
WT
 and Gstp1
Y7F
 mice carry the Gstp2 gene, it is unlikely to account 
for any difference in phenotype. It is also important to acknowledge that there may be some 
residual catalytic activity as a result of the Y7F mutation that has not been detected by the 
ethacrynic acid assay but is clearly evident from recombinant protein studies (Table 5).  
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Figure 3.6. Immunohistochemical staining of GSTP1 in mouse liver 
Localisation of GSTP1 was observed in formalin fixed tissue sections (5µm) from Gstp1
WT
, Gstp1/2
-/- 
and 
Gstp1
Y7F
 male mouse livers using an anti-GSTP1 antibody (1:500). Sections are representative of 3 separate 
animals. 
 
 
 
Figure 3.7. Assessing catalytic activity of GSTP1 in cytosolic mouse liver fractions. 
The enzymatic activity of hepatic cytosolic fractions prepared from Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 male 
mouse livers (=3) towards ethacrynic acid was measured spectrophotometrically at 270nm.  
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3.6 Acetaminophen (APAP) treatment of Gstp1WT, Gstp1/2-/- and Gstp1Y7Fmice 
Initially described on a 129xMF1 background, the ability of Gstp1/2
-/-
 mice to regulate their 
hepatic glutathione levels in response to acetaminophen treatment is a potential mechanism in 
which toxicity is mitigated, as pharmacokinetic studies show no or little difference in the way 
acetaminophen is metabolised between Gstp1
WT
 and Gstp1/2
-/-
 mice  (Henderson et al., 2000). 
The use of acetaminophen in this study was not to establish translational effects of 
acetaminophen hepatotoxicity in humans, as human liver contains little GSTP1, but to 
establish the function of mGSTP1 in response to hepatic stress using a well characterised 
model of hepatotoxicity. With the development of a catalytically inactive GSTP1 mouse 
model, we can now address whether resistance is only acquired in the absence of GSTP1, or 
whether the catalytic activity of GSTP1 is important in contributing to acetaminophen 
toxicity. Male Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F 
mice, aged between 8-16 weeks old were 
administered a single dose of acetaminophen (300mg/kg body weight, oral gavage) and left 
for 24 hours. Mice were starved for 16 hours prior to acetaminophen treatment to ensure 
complete absorption of acetaminophen across the gastrointestinal tract. Mice were age 
matched across groups. Alanine aminotransferase (ALT) is present within liver hepatocytes 
and catalyses the amino transfer from alanine to α-ketoglutarate. When the liver is damaged, 
ALT is leaked into the blood and can be used to assess the extent of hepatic damage after 
exposure to a given toxicant. Lactate dehydrogenase (LDH) release into the bloodstream can 
also be used as a measure of tissue damage, although results are less specific of liver damage 
than ALT. After 24 hours, mice were sacrificed and plasma ALT and LDH levels were 
determined to assess hepatotoxicity (Figure 3.8A and Figure 3.8B respectively). After 24 
hours, plasma ALT and LDH levels were significantly higher in acetaminophen treated wild-
type mice compared to saline (control) treated mice, indicating a large degree of hepatic 
damage as a result of acetaminophen treatment. Plasma bilirubin and creatinine levels 
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remained unchanged (data not shown). No increase in ALT or LDH plasma concentrations 
were detected in acetaminophen treated Gstp1/2
-/-
 mice which correlates with previous 
studies showing that Gstp1/2
-/-
 mice are resistant to the hepatotoxic effects of acetaminophen 
(Henderson et al., 2000, Vaughn et al., 2011). Similar to Gstp1/2
-/-
 mice, Gstp1
Y7F
 mice show 
no increase in ALT or LDH plasma concentrations 24 hours after acetaminophen treatment, 
suggesting that these mice are also resistant to the hepatotoxic effects of acetaminophen.  
 
The majority of publications involving Gstp1/2
-/-
 mice have been using mice bred from an 
outbred (129xMF1) background. It is well documented that differences in mouse strain may 
account for differences in susceptibility to a given toxicant or mutational status, with some 
inbred strains showing differences in response to acetaminophen treatment (Harrill et al., 
2009b, Turk et al., 2004, Silva et al., 1997). Not only are the data presented here agreeable 
with previous publications on Gstp1/2
-/-
 resistance to acetaminophen, but they also show a 
common phenotype of Gstp1/2
-/-
 mice across two different mouse strains, 129xMF1 and 
C57Bl/6J. This suggests that original observations made by Henderson et al, were not 
influenced by mouse strain selection and that the catalytic function of GSTP1 appears to be 
the main factor behind acetaminophen toxicity in this study. 
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Figure 3.8. Plasma ALT and LDH levels in mice treated with acetaminophen. 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage, n=3) and sacrificed after 24 hours. The blood was removed, heparinised and ALT and 
LDH levels were determined. Data show mean ± standard deviation values for ATL (A) and LDH (B). ** 
Statistical difference between saline and acetaminophen treated mice, P < 0.01. 
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The extent of liver damage in acetaminophen treated mice was determined by histochemical 
examination of liver tissue (Figure 3.9). Immunohistochemical staining of mouse liver 
sections following acetaminophen treatment shows extensive centrilobular necrosis as a result 
of acetaminophen treatment in Gstp1
WT
 mice (Figure 3.9) which correlates with increased 
plasma ALT and LDH levels. The level of oxidative stress was also assessed from these 
sections. Haem oxygenase-1 (HO-1) catalyses the cleavage of haem into iron, carbon 
monoxide and biliverdin and can be induced to a diverse set of stimuli including UV 
radiation, oxidative stress nitrosative stress, ethanol, inflammation and heavy metals. Activity 
of HO-1 reduces the levels of oxidative stress in the cell, primarily through the removal of 
haem, but also through the activity and properties of the by-products of haem degradation. In 
our studies, 24 hours after acetaminophen treatment showed that surrounding regions of 
hepatic necrosis exhibited increased expression of HO-1, indicative of increased stress 
response to acetaminophen treatment. No liver damage could be detected in Gstp1/2
-/-
 or 
Gstp1
Y7F
 mice after 24 hours of a single dose of acetaminophen. However, HO-1 expression 
was evident around the centrilobular regions of acetaminophen treated livers in these mice, 
suggesting that although resistant to the hepatotoxicity of acetaminophen, a stress response is 
still apparent in the livers of these mice. This indicates that in the absence of a catalytically 
functioning GSTP1, acetaminophen-induced oxidative stress is nullified to a greater extent 
resulting in attenuation of hepatotoxicity.  
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Figure 3.9. Liver immunohistochemistry of haem oxygenase-1 in acetaminophen treated 
mice. 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage) and sacrificed after 24 hours. Livers were removed, fixed and cut into 5µm sections 
before stained for haem oxygenase-1 expression (HO-1, 1:100). Sections are representative of 3 separate 
animals. 
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3.7 Hepatic glutathione levels following acetaminophen treatment 
A possible mechanism explaining the resistance of Gstp1/2
-/-
 and Gstp1
Y7F
 mice against 
acetaminophen toxicity could be in the regeneration of hepatic glutathione levels, as 
glutathione is rapidly depleted from the liver following acetaminophen treatment. Male 
Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F 
mice aged 10-16 weeks were administered a single dose of 
acetaminophen (300mg/kg, oral gavage) after an initial 16hr starvation period. The mice were 
then sacrificed at 20, 40, 90 and 240 minutes and the liver and blood removed. To ensure 
accuracy of analysis across all samples taken, lobe 2 of the liver was used for glutathione 
analysis. Resting levels of both total and disulphide glutathione (GSSG) did not vary greatly 
between genotypes as shown in Figure 3.10A and Figure 3.10B respectively. Rapid depletion 
of glutathione was evident upon acetaminophen treatment, with maximum hepatic 
glutathione depletion occurring at 90 minutes for all genotypes (Figure 3.10A). However, the 
rate of glutathione depletion was more dramatic in Gstp1
WT
 livers where maximum depletion 
occurred after 40 minutes. In Gstp1
WT
 mice hepatic glutathione levels remained depleted by 
240 minutes, whereas hepatic glutathione was fully regenerated by this time point in Gstp1/2
-
/-
 mice. Gstp1
Y7F
 mice only achieved partial recovery of hepatic glutathione levels (41.6%) by 
240 minutes. The ability of Gstp1
Y7F
 mice to only partially regenerate hepatic glutathione 
levels appears sufficient to avoid the hepatotoxic effects of acetaminophen and is in line with 
other studies showing that covalent binding of proteins adducts and, as a result of which, 
subsequent necrosis only occurs at maximal (80-90%) glutathione depletion in hepatocytes 
(Jollow et al., 1974, Green et al., 1984). However, hepatic glutathione concentrations reached 
similar levels of depletion in each genotype suggesting that a mechanism downstream of 
glutathione depletion is responsible for the toxicity and not the initial depletion itself. 
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Figure 3.10. Hepatic glutathione levels in mice following acetaminophen treatment 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage, n=3) and sacrificed at the time points shown. Livers were removed and analysed for A) 
total levels of glutathione and B) disulphide levels of glutathione. Data are presented as mean ± standard 
deviation. Statistical difference is shown between wild-type mice and Gstp1/2
-/-
/Gstp1
Y7F
mice where *** P 
<0.001. Statistical difference between Gstp1/2
-/- 
and Gstp1
Y7F
mice is shown where $, P <0.01 
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In this study, maximal depletion of glutathione in Gstp1
WT
 mice occurs after 40 minutes of 
acetaminophen treatment and corresponds with a significant increase in the proportion of 
GSSG (Figure 3.10B). As maximal depletion of glutathione occurs after 90 minutes in 
Gstp1/2
-/-
 and Gstp1
Y7F
 mice, we observe a delayed response in the oxidation of glutathione 
in absence of a catalytically functioning GSTP1. However, at this time point, there is no 
difference in levels of GSSG across the genotypes. It is also interesting to note that despite 
the differences in total glutathione after 240 minutes, there is no statistical difference in the 
proportion of GSSG across the genotypes, suggesting that oxidative stress is not a mechanism 
by which hepatotoxicity is potentiated in Gstp1
WT
 mice. This observation is strengthened 
further when examining HO-1 expression from liver samples taken from Gstp1
WT
, Gstp1/2
-/-
 
and Gstp1
Y7F
 mice (Figure 3.11). Western blot analysis of whole cell lysates demonstrates 
increased HO-1 expression after 240 minutes across all genotypes, implying that although 
oxidative stress response is evident in the livers of these mice, it is not indicative of the 
severity of the toxicity. This correlates well with our previous observations examining HO-1 
localisation in mouse liver 24 hours post acetaminophen treatment (Figure 3.9).  
 
3.8 Activation of MAP Kinase signalling 
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine-specific protein 
kinases that, in response to a diverse set of stimuli, regulate a number of pathological 
pathways, such as differentiation, inflammation, stress response and apoptosis, through a 
series of phosphorylation cascades. The MAPKs are composed of 3 major subfamilies, the 
extracellular signal regulated kinases (ERK), c-Jun N-terminal kinases (JNK) and the p38 
MAPKs. Activation of MAPKs occurs through a three tiered cascade whereby a given 
stimulus activates a MAPK kinase kinase (MKKK/MEKK), which in turn phosphorylates a 
MAPK kinase (MAPKK) upstream of MAPK. MAPKs have been shown to have overlapping 
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substrate specificities as well as demonstrating interactions between signalling cascades 
(Staples et al., 2010). Where ERK activation is predominantly regulated by hormones and 
growth factors, the JNK and p38 family of MAPKs are activated in response to a variety of 
stressors such as inflammation, environmental stress, oxidative stress and DNA damage. 
Regulation of these pathways is mediated through MAPK phosphatases (MKPs) which 
negatively regulate the activation of these cascades through dephosphorylation of MAPKs 
(Owens and Keyse, 2007), although there is evidence to suggest that ubiquitylation of 
upstream MEKKs may feature in the negative regulation of some MAPKs (Witowsky and 
Johnson, 2003). 
 
Regulation of JNK and ERK pathways has been shown to be an important factor in 
hepatocellular processes such as hepatocyte apoptosis and steatohepatitis induced by non-
alcoholic fatty liver disease (NAFLD) (Qiao et al., 2003, Schattenberg et al., 2006). In 
response to stress, JNK phosphorylation results in the activation and stabilisation of a number 
of its transcription targets such as c-Jun, JunB, p53 and ATF-2 which in turn activate a 
number of cellular processes. The activation of JNK in response to acetaminophen treatment 
has been demonstrated as a potential mechanism by which toxicity may be propagated. 
Blocking JNK phosphorylation using a small molecule inhibitor protects mice against 
acetaminophen induced hepatotoxicity (Gunawan et al., 2006), while a lack of JNK 
phosphorylation in SOD1
-/-
 mice has been attributed to a decrease in sensitivity to 
acetaminophen (Zhu et al., 2006). In contrast, the use of JNK knockout mice in determining 
the role of JNK in response to acetaminophen has been contradictory. The JNK family is 
encoded by 3 distinct genes, Jnk1, Jnk2 and Jnk3. Jnk1 and Jnk2 are ubiquitously expressed, 
whereas Jnk3 is mainly localised to the nervous system. Deletion of both Jnk1 and Jnk2 is 
embryonically lethal. Deletion of individual isoforms of JNK has demonstrated inconsistent 
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changes in sensitivity to acetaminophen, with reports differing on the sensitivity of these 
mice, or demonstrating no sensitivity whatsoever (Gunawan et al., 2006, Bourdi et al., 2008). 
However, a recent study by Wancket et al may shed light on the mechanism by which JNK 
activation causes hepatotoxicity. In mice nulled for Mkp-1, which negatively regulates JNK 
through dephosphorylation, acetaminophen treatment induces gross hepatotoxicity compared 
to wild-type mice (Wancket et al., 2012), suggesting that the regulation of JNK 
phosphorylation, and not necessarily its activation, is important in the propagation of 
hepatotoxicity.   
 
In response to a single dose of acetaminophen (300mg/kg, oral gavage), Western blot 
analysis demonstrates increased phosphorylation of both JNK1 and JNK2 isoforms in 
Gstp1
WT
 mice at 90 and 240 minutes post acetaminophen dosing (Figure 3.11). 
Phosphorylation of MAP kinase pathways does not appear exclusive to JNK1/2 as ERK1/2 
activation is also apparent in these mice. Interestingly, phosphorylation of ERK1/2 appears to 
occur earlier than phosphorylation of JNK1/2. In Gstp1
WT
 mice, kinase phosphorylation is 
sustained for up to 240 minutes when glutathione depletion is maximal. In contrast, Gstp1/2
-/-
 
mice have increased JNK1/2 and ERK1/2 phosphorylation at 90 minutes, but MAPK 
phosphorylation is lost at 240 minutes when a full recovery of hepatic glutathione levels is 
observed. Gstp1
Y7F
 mice display a similar profile to that of their wild-type counterparts, 
showing sustained JNK1/2 phosphorylation at 90 and 240 minutes post acetaminophen 
dosing. Although ERK1/2 phosphorylation is also evident, it appears markedly reduced 
compared to Gstp1
WT
 mice, correlating well with a partial recovery of hepatic glutathione 
levels. Phosphorylation of ERK1/2 is also evident from immunohistochemical analysis of 
liver sections from these mice (Figure 3.12). 
Results Chapter 3 
 
88 
 
 
 
Figure 3.11. Expression of markers of MAP Kinase signalling in response to 
acetaminophen treatment. 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage, n=3) and sacrificed at the time points shown. Livers were removed and whole cell 
lysates were prepared. Pooled lysates from 3 animals (10µg) were resolved on a SDS PAGE gel and proteins 
analysed by Western blotting.  
 
Figure 3.12 demonstrates phosphorylation of ERK1/2 around centrilobular regions of the 
liver in Gstp1
WT
 and Gstp1
Y7F
 mice in response to acetaminophen, but is largely attenuated in 
Gstp1/2
-/-
 mice. These data demonstrate a positive correlation between activation of MAP 
kinase pathways and hepatic glutathione levels, suggesting that acetaminophen-induced 
hepatotoxicity is associated with the activation of MAP kinase activation as a result of 
glutathione depletion. These studies show a potential mechanism by which Gstp1/2
-/-
 mice 
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appear resistant to the toxicity of acetaminophen. However, due to the resistance of Gstp1
Y7F
 
mice to acetaminophen, it is unlikely that the lack of MAPK activity in Gstp1/2
-/-
 mice is 
solely responsible for resistance against acetaminophen. 
 
3.9 Mitochondrial localisation and function of GSTP1 
It is well documented that mitochondrial damage as a result of acetaminophen treatment can 
contribute to hepatocellular necrosis. In particular, changes to mitochondrial membrane 
permeability in response to a number of stressors, such as calcium ion increase and oxidative 
stress can lead to depolarisation of the mitochondrial membrane, uncoupling of respiratory 
chains and mitochondrial leakage (Ray et al., 1993, Burcham and Harman, 1991, Weis et al., 
1992).  Blockage of the mitochondrial permeability transition pore (MPTP) by Cyclosporine 
A and its analogues leads to a reduction in acetaminophen induced toxicity in hepatocytes 
(Kon et al., 2004). Increased levels of peroxide formation in mitochondria have been reported 
in response to acetaminophen treatment (Cover et al., 2005) while recent evidence suggests 
that the activity of manganese superoxide dismutase (MnSOD) localised within the 
mitochondria is significantly reduced due to nitrosylation of the enzyme in the presence of 
NAPQI (Agarwal et al., 2011).  
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Figure 3.12. Liver immunohistochemistry of phosphorylated ERK in acetaminophen 
treated mice. 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage) and sacrificed at the time points shown (n=3). Livers were removed, fixed and cut into 
5µm sections before stained for p-ERK expression (1:100). Sections are representative of 3 separate animals. 
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There are a number of recent studies which suggests that GSTP1 is present within 
mammalian mitochondria although its function is still largely unknown (Sun et al., 2012, 
Gallagher et al., 2006). Goto et al demonstrated that GSTP1 is present in the mitochondria of 
a number of cancer cell lines and, through site-directed mutagenesis, determined that its 
localisation is dependent on a series of positively charged residues in its N-terminal region 
(Goto et al., 2009). In our studies, we are interested in whether mGSTP1 localisation and 
function within the mitochondria can lead to differences in acetaminophen sensitivity. Using 
immunogold labelling of a GSTP1 antibody, we aimed to identify whether GSTP1 can 
localise to the mitochondria in mouse liver, and if its expression changes in response to 
acetaminophen treatment. In line with previous reports, at resting levels we can identify 
GSTP1 within hepatocytes and determine that its expression within the mitochondria is much 
lower compared to its expression in the cytoplasm (Figure 3.13A). We also observe that the 
Y7F mutation does not affect the localisation of GSTP1 within the mitochondria (Figure 
3.13A). In response to a single oral dose of acetaminophen (300mg/kg), GSTP1 does not 
appear to increase its mitochondrial or cytoplasmic expression in Gstp1
WT
 mice (Figure 
3.13B). The expression of GSTP1 in these mice appears reduced 24 hours after 
acetaminophen treatment; however the apparent hepatic necrosis associated with 
acetaminophen treatment at this time point may account for this observation. GSTP1 
expression is evident in Gstp1
Y7F 
mice prior to and after acetaminophen treatment although no 
apparent change in subcellular localisation is evident after acetaminophen treatment. As 
negative controls, no GSTP1 protein could be detected in Gstp1/2
-/-
 mice or in the absence of 
the primary antibody. 
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Figure 3.13. Mitochondrial localisation of GSTP1 in response to acetaminophen 
treatment. 
Male Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice were administered a single dose of saline or acetaminophen 
(300mg/kg, oral gavage) and sacrificed after 24 hours (n=1). Livers were removed and fixed before intracellular 
localisation of GSTP1 was evaluated using immunogold labelling of a GSTP1 antibody (black arrows) and 
analysed by electron microscopy (B). The basal expression of GSTP1 within the mitochondria was also 
evaluated (A). All images are at a magnification of 25,000x. 
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To assess whether GSTP1 has an active function within the mitochondria, mouse embryonic 
fibroblasts (MEFs) were isolated from Gstp1
WT
, Gstp1/2
-/- 
and Gstp1
Y7F
 mice and incubated 
with rotenone, which inhibits complex I of the mitochondrial respiratory chain and thereby 
inhibiting mitochondrial respiration. Paradoxically, after 72 hours of rotenone treatment, 
there is a slight increase in resistance to rotenone in Gstp1/2
-/-
 MEFs compared with Gstp1
WT
 
or Gstp1
Y7F
 MEFs (Figure 3.14). Although not statistically significant, the results may 
indicate a potential and novel function of GSTP1 within the mitochondria in response to 
stress.  
 
 
Figure 3.14. Cytotoxic effect of rotenone in Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 MEFs. 
Mouse embryonic fibroblasts (MEFs) isolated from Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice were incubated with 
rotenone over 72 hours (n=3). The data show mean ± standard deviation. 
 
To further examine the role of GSTP1 within the mitochondria, levels of oxygen 
consumption and glycolysis were determined in response to mitochondrial stress using the 
XF24 Analyser (Seahorse Biosciences). Cells were plated at 20,000 cells per well and basal 
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oxygen consumption and glycolytic rates were measured before incubating cells with 100µM 
of 2,4-dinitrophenol (DNP), which uncouples respiration from ATP synthesis and thereby 
increasing both mitochondrial oxygen consumption and glycolysis. In 2007, Wu et al 
demonstrated the specificity of the XF Analyser in measuring glycolytic and respiratory rates 
using a number of compounds which act differentially on mitochondrial function (Wu et al., 
2007). At resting levels, we observe marked differences in oxygen consumption between 
genotypes, with Gstp1/2
-/-
 MEFs possessing a much lower oxygen consumption rate (OCR) 
than Gstp1
WT
 or Gstp1
Y7F
 MEFs (Figure 3.15A). In response to DNP treatment, there is a 
significant increase in OCR across all genotypes observing 2.6 and 3.2 fold increases in OCR 
in Gstp1
WT
 and Gstp1
Y7F
 MEFs, respectively. Despite a lower rate of OCR in response to 
DNP the fold difference increases dramatically to 4.9 in Gstp1/2
-/-
 MEFs indicating that, 
while basal oxygen consumption is lower, mitochondria lacking GSTP1 are respiring at a 
larger rate in response to stress. This may in part explain why the effects of rotenone, which 
inhibits mitochondrial respiration, are attenuated in Gstp1/2
-/-
 MEFs.  
 
It is interesting to note that there is no difference in basal glycolytic rates (ECAR) across 
genotypes (Figure 3.15B). When exposed to DNP however, ECAR dramatically increases in 
Gstp1
WT
 and Gstp1
Y7F
 MEFs due to increased lactic acid formation, yet only mildly increases 
in Gstp1/2
-/-
 MEFs. Firstly, this demonstrates that the presence of GSTP1 and not its catalytic 
function is responsible for this increase, highlighting potential non-catalytic functions of 
GSTP1 within the mitochondria. Secondly, the observation that glycolytic rate in Gstp1/2
-/-
 
MEFs was much lower than other genotypes, while the fold difference in OCR was much 
higher suggests that perhaps mitochondria favour oxidative phosphorylation over glycolysis 
in response to stress in the absence of GSTP1. 
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Figure 3.15. Mitochondrial respiratory function of GSTP1 in response to 2,4-
dintrophenol (DNP). 
Oxygen consumption rates (A) and levels of glycolysis (B) were analysed in mouse embryonic fibroblasts 
(MEFs) isolated from Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice using the XF24 Analyser (n=3). Cells were 
incubated in unbuffered media for 1 hour prior to analysis. After 5 initial readings, cells were treated with DNP 
(100µM). Data show mean ± standard deviation. 
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In summary, a Y7F substitution results in a GSTP1 protein which is catalytically inactive in 
vivo. Initial studies suggest that the catalytic function of GSTP1 is not essential for murine 
development but contributes to the hepatotoxicity associated with APAP. Gstp1/2
-/-
 and 
Gstp1
Y7F 
mice do not develop hepatic necrosis after APAP treatment and are able, in part, to 
regenerate hepatic GSH levels in response to APAP. This phenotype does not appear to be 
related to oxidative stress but relies on the activation of particular MAP Kinase pathways. 
Further studies are required to determine if the mitochondrial function of GSTP1 may play a 
role in propagating this effect, although preliminary data suggest that GSTP1 may act non-
catalytically in mediating mitochondrial regulation. 
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4. Chapter 4: GSTP1-mediated protein S-glutathionylation of 
cellular proteins 
 
Introduction  
Chapter 3 largely examined the in vivo function of GSTP1 in relation to a hepatotoxic 
compound; the exact mechanism by which GSTP1 contributes to this phenotype is still not 
fully understood. Specific GSTP1-mediated cell regulation has been difficult to ascertain in 
vivo due to the complexity of stress response pathways and upregulation of compensation 
mechanisms as a result of loss of function. Therefore examining GSTP1 function in a simpler 
in vitro system may lead to the identification and detailing of novel mechanistic pathways. To 
date, in vitro studies have yielded a diverse set of possible mechanisms by which GSTP1 may 
regulate cell function. However, the majority of these are either not translatable to all 
environments or have not been studied in great detail. This chapter intends to examine cell 
specific regulation of GSTP1 in an in vitro system to uncover novel pathways and processes 
GSTP1 may be involved in. In particular, this chapter will examine the role of GSTP1 in 
catalysing a novel posttranslational modification known as protein S-glutathionylation. 
 
4.1 Thiol modification 
Modulation of protein thiols is recognised as an important component of protein regulation 
and sulfhydryl homeostasis. The human proteome codes for around 214,000 cysteine 
residues, and is relatively underrepresented in most organisms, with the percentage of 
cysteine residues increasing with the complexity of the organism (Miseta and Csutora, 2000). 
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Cysteine residues can undergo a number of modifications which may lead to diverse changes 
in protein function, signalling, folding and localisation, particularly in environments of 
oxidative stress. This is because thiols have great reducing potential and are strong 
nucleophiles. In the presence of ROS or RNS, reactive thiols are more likely to donate 
electrons to radical species, resulting in disulphide modification of thiyl radicals. Thiol 
groups can undergo a number of modifications, the reactivity of which is dependent on the 
pKa of the cysteine. Cysteine residues typically have a pKa value of around 8.5 in reducing 
conditions, such as the cytoplasm, and are unlikely to undergo any modification. Lowering of 
the pKa value enhances the reactivity of cysteine groups and is influenced by the charge of 
neighbouring amino acids (Rhee et al., 2000). Electrostatic interactions with basic (positively 
charged) residues results in a lowering of the pKa and increases the activity of the cysteine 
group, rendering them more susceptible to posttranslational modifications. Metal binding of 
cysteine groups, such as zinc, increases the reactivity and susceptibility to oxidation of thiols, 
an important feature in the regulation of transcription factors (Chen et al., 2004, Zdanowski et 
al., 2006).  
 
Protection of protein thiols is critical in preventing irreversible oxidation of cysteine residues 
and loss of protein function. Reaction of thiols with ROS or RNS can lead to a number of 
intra- and inter-molecular adaptations but commonly leads to the formation of protein-
sulfenic acids. Sulfenic acids are unstable and transient in nature (Saurin et al., 2004), often 
oxidised to sulfinic or sulfonic acids, which are relatively stable and generally irreversible. 
Alternatively, sulfenic acids can interact with other thiol groups forming intra- and inter- 
molecular disulphide bridges and can act as intermediates to other thiol modification such as 
modulation by GSH to form S-glutathionylated proteins (Barrett et al., 1999) which 
subsequently restores the thiolate anion and acts as a reversible form of thiol protection 
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against oxidative stress. Although regulation of thiol groups is controlled extensively by a 
range of posttranslational modifications such as that by the gasotransmitters nitric oxide (van 
der Vliet et al., 1998) and hydrogen sulphide (Peshenko and Shichi, 2001), this chapter will 
predominantly focus on the regulation of thiol groups by S-glutathionylation. 
 
4.2 Glutathione  
4.2.1 Synthesis and degradation 
In its reduced form, the tripeptide glutathione (L-γ-glutamyl-L-cysteinyl-glycine, GSH) is 
one of the most ubiquitously abundant antioxidants in the cell. Composed of glutamate, 
cysteine and glycine, GSH is maintained at stable and often high concentrations due to the 
presence of a γ-carboxyl group linking cysteine and N-terminal glutamate that protects GSH 
from protease degradation, which typically digest α-carboxyl groups of amino acids (Figure 
4.1A). GSH is synthesised de novo and is dependent on the availability of cysteine and the 
activity of key catalysing enzymes. Initially, γ-glutamylcysteine is formed from glutamate 
and cysteine, catalysed by glutamate-cysteine ligase (GCL), the rate-limiting step in 
glutathione synthesis. GCL is composed of two subunits, a ‘heavy’ C unit (73kDa) and a 
‘light’ M unit (28kDa) which are upregulated during oxidative stress through binding of Nrf2 
to an antioxidant response element (ARE) in the promoter regions of GCLC and GCLM 
(Zhang et al., 2007, Erickson et al., 2002, Wild et al., 1999). The C subunit possesses the 
catalytic activity for GCL while the M subunit is thought to enhance the efficiency of the 
enzyme and reduce the sensitivity to feedback inhibition (Tu and Anders, 1998, Choi et al., 
2000). Glutathione synthetase (GS) adds glycine to the γ-glutamylcysteine unit to form GSH. 
GSH synthesis from cysteine can also be produced from the catabolism of methionine via the 
transsulfuration pathway but is only specific to hepatocytes (Finkelstein, 1990).  
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GSH is specifically hydrolysed by the ectoenzyme γ-glutamyltranspeptidase (GGT) upon its 
transport from the cell. GSH can be exported in its reduced or disulphide form and as a 
conjugate. Extracellular GSH is hydrolysed in an ATP dependent manner at the gamma 
linkage between glutamate and cysteine releasing cysteinylglycine and glutamate, which in 
turn is transferred to another amino acid, often cystine. Cysteinylglycine is cleaved by 
dipeptidase into cysteine and glycine which are then transported back into the cell. Glutamyl 
conjugates are also transported into the cell where the glutamyl residue forms 5-oxoproline 
and then glutamate, through the action of 5-oxoprolinase. Cystine can also be transported into 
the cell or via conjugation with glutamyl where it is reduced to cysteine. In this regard, GSH 
acts as a reservoir for cysteine storage, as cysteine is unstable extracellularly as it is often 
oxidised to cystine. Control of cysteine/cystine redox potential in extracellular compartments 
is important in maintaining redox homeostasis, changes in which can lead to activation of 
intracellular free radicals and upregulation of glutamate receptors (Zhu et al., 2012). Effective 
uptake of cysteine/cystine has been shown to be important in cancer cell survival. In a recent 
study by Zhang et al, bone marrow stromal cells were found to enhance the survival of 
chronic lymphocytic leukaemia (CLL) cells through interactions of the cysteine/cystine 
transport system, despite inefficient uptake of cystine by CLL cells due to low expression of 
the cystine transporter Xc
-
 (Zhang et al., 2012). It was hypothesised that stromal cells import 
cystine and convert it to cysteine which is released into the microenvironment and 
subsequently taken up by CLL cells. Inhibition of cystine uptake by stromal cells 
significantly decreased GSH levels in CLL cells and leads to cell death demonstrating a role 
of GSH in cancer cell survival. 
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In most cellular organelles, particular the cytoplasm and mitochondria, about 90-99% of GSH 
is present in its reduced form to maintain cellular function and redox homeostasis. However, 
in the endoplasmic reticulum, the ratio of reduced and disulphide glutathione is more 
balanced as disulphide bonding is necessary for the proper folding of proteins during 
synthesis. GSH is synthesised only in the cytoplasm, where it is then transported to other 
organelles. Typically, around 10% of GSH is localised in the mitochondria. Interestingly, 
mitochondria do not appear to efflux oxidised glutathione and reduction of disulphide to 
reduced glutathione is mediated predominantly by glutathione reductase (Olafsdottir and 
Reed, 1988). As mitochondria contain little volume, the concentration of GSH relative to the 
cytoplasm is greater and therefore has a lower reduction potential (Go and Jones, 2008). To 
overcome this gradient, two mitochondrial transporters, the 2-oxoglutarate and dicarboxylate 
carriers aid in GSH transport and account for around 80% of total GSH transport into the 
mitochondria (Lash et al., 2002, Chen et al., 2000b). The mitochondrial glutathione reduction 
potential is of great importance in relation to protection against free radicals, as it is estimated 
that the majority of cellular ROS are associated with the mitochondria (Balaban et al., 2005). 
 
4.2.2 Role as an antioxidant  
Radical intermediates formed from oxidative reactions such as superoxide (O2
·-
), nitric oxide 
(
·
NO) and hydrogen peroxide (H2O2) contribute to cell injury through direct oxidation of 
proteins, DNA and lipids or by inducing apoptotic and necrotic pathways. GSH serves as a 
reducing agent within the cell and has a central role in maintaining redox homeostasis 
through a diverse set of mechanisms such as conjugating reactive metabolites, maintaining 
the thiol redox status of proteins, iron transfer and modulating cellular processes. Antioxidant 
reactions involving GSH are mediated through a reactive sulfhydryl present on the cysteine 
residue where it conjugates electrophiles spontaneously or is catalysed enzymatically via 
Results Chapter 4 
 
102 
 
glutathione S-transferases. GSH can also mediate the reduction of peroxides, acting as a co-
substrate for glutathione peroxidase in the degradation of hydrogen peroxide. In addition, 
many endogenous compounds such as prostaglandins and leukotrienes and endogenously 
produced toxicants such as 2-oxopropanal and lipid peroxidation metabolites, are detoxified 
by GSH, either directly or acting as a cofactor (Heasley and Brunton, 1985, Rouzer et al., 
1981, Inagi et al., 2010). GSH also mediates the cellular export of a number of xenobiotic 
compounds via the multidrug-resistance-associated protein (MRP) and there have been 
numerous studies detailing high concentrations of GSH have been associated with resistance 
to anticancer compounds and cell survival (Zaman et al., 1995, Mulcahy et al., 1994). 
Reaction of GSH with radical species leads to the production of thiyl radicals (GS
·
) which in 
turn can form disulphide bonds with other molecules or dismutate with other glutathionyl 
anions resulting in glutathione disulphide (also known as oxidised glutathione, GSSG, Figure 
4.1B). Perturbations in cellular redox levels as a result of oxidative stress and increased ROS 
production leads to increased levels of glutathione disulphide formation (Jones, 2006). Once 
formed, GSSG can be exported from the cell or reduced back to GSH by glutathione 
reductase at the expense of NADPH.  
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Figure 4.1. Molecular structures of glutathione in its A) reduced form and B) disulphide 
form. 
 
4.3 Protein S-glutathionylation 
The function of glutathione extends well beyond its role as an antioxidant, possessing many 
properties related to cell signalling. One mechanism by which GSH is thought to regulate cell 
function is through conjugation with protein thiols. Protein S-glutathionylation is a reversible 
posttranslational modification involved in sulfhydryl homeostasis, believed to protect protein 
thiols against irreversible oxidation. In S-glutathionylation, the glutathione anion (GS
·
) forms 
a disulphide bond with reactive protein thiols preventing oxidation of cysteine residues from 
ROS/RNS and oxidative metabolites derived from carbohydrate and lipid modification 
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(Refsgaard et al., 2000). Protein S-glutathionylation can be induced globally (Eaton et al., 
2002) or selectively (Adachi et al., 2004) depending on the origin of oxidative stress but can 
also be found at resting levels (Wang et al., 2001a), suggesting that S-glutathionylation may 
play a functional role in protein regulation as well as thiol protection. Conversely, protein S-
glutathionylation may also function in preventing the export of GSH from the cell in the form 
of GSSG, concentrations of which are increased and exported from the cell under oxidative 
stress. The function of protein S-glutathionylation in vivo is still not fully understood, 
induction of which is prevalent in the aetiology of certain diseases related to oxidative stress 
such as diabetes (Sampathkumar et al., 2005), cardiovascular disease (Eaton et al., 2002), 
Parkinson’s (Naoi et al., 2008) and Alzheimer’s (Di Domenico et al., 2009). Whether protein 
S-glutathionylation confers a difference in protein function contributing to a particular 
disease or is a direct consequence of oxidative stress (and therefore has potential as a 
therapeutic biomarker) is still to be fully addressed.  
 
4.3.1 Mechanisms of protein S-glutathionylation 
Proteins can become S-glutathionylated through a diverse set of pathways. Common 
mechanisms resulting in protein S-glutathionylation often involve the production of a reactive 
intermediate of cysteine modification such as sulfenic acids (Barrett et al., 1999), thiyl 
radicals (Starke et al., 2003) or thiosulfinate intermediates (Li et al., 2001), all of which are 
relatively unstable and are highly reactive with thiol groups. Nitric oxide (NO) mediated S-
nitrosylation of glutathione (S-nitrosoglutathione, GSNO) and proteins (S-nitrosothiols, 
PSNO), although stable, may also act as an intermediate to protein S-glutathionylation. 
GSNO can induce the S-glutathionylation of a number of proteins in vitro (Giustarini et al., 
2005, Mohr et al., 1999). However, due to the stability of GSNO it is unclear what conditions 
favour protein S-glutathionylation over PSNO in vivo although it is hypothesised that 
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neighbouring amino acid groups may influence the outcome of a cysteine becoming S-
nitrosylated or S-glutathionylated (Giustarini et al., 2005). Although reactive intermediates 
from cysteine modifications appears to be a more likely mechanism for protein S-
glutathionylation in vitro, there is still very little evidence that the kinetic and thermodynamic 
biochemistry of these reactions are upheld in vivo.   
 
One of the more hypothetical mechanisms of protein S-glutathionylation is through 
disulphide-exchange of the protein thiols. GSH is largely reduced in the cell but under 
oxidative conditions, dismutates to form GSSG. Hypothetically, GSSG accumulation could 
induce protein S-glutathionylation through a thiol-disulphide exchange between a protein 
thiol and GSSG as a means of regulating cellular redox levels and acting as a form of GSH 
storage within the cell. However, many observers have deemed this route improbable in vivo 
predominantly because the ratio of GSH to GSSG would have to drop dramatically to shift 
the disulphide equilibrium towards protein thiolation (Gilbert, 1995), while some have 
questioned the accessibility of GSSG to sulfhydryl groups due to its increased mass and 
charge (Hu et al., 2010). However, there is evidence to suggest that some proteins which have 
atypical redox potentials such as c-Jun may be susceptible to S-glutathionylation through 
disulphide exchange at high GSH:GSSG concentrations (Klatt et al., 1999). 
 
4.3.2 Glutaredoxins 
Protein S-glutathionylation can be reversed through the action of glutaredoxin, which 
possesses high specificity for S-glutathionylated thiols over other disulphide modifications. 
Two isoforms largely account for the majority of deglutathionylation reactions; Grx1 which 
is localised to the cytosol, and Grx2 which is localised in the mitochondrial matrix. Grx1 
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contains a CPYC motif which contains an exposed Cys11 residue (Bushweller et al., 1992), 
while Grx2 contains a CSYC within its active site and a Cys70 residue which is involved in 
deglutathionylation (Gladyshev et al., 2001). GSH is transferred from the protein to the Cys 
residue which can then react with another GSH molecule to yield GSSG. Recent in vivo 
studies have highlighted the importance of Grx1 in mediating deglutathionylation of cellular 
proteins. Hoffman et al demonstrated that Grx1
-/-
 mice have an attenuated airway hyper-
responsiveness to ovalbumin which correlates with an increase in protein S-glutathionylation 
as well as a decrease in other inflammatory mediators (Hoffman et al., 2012), while Wu et al 
showed Grx2
-/-
 mice to have increased sensitivity to oxidative stress and increased protein S-
glutathionylation (Wu et al., 2011). Sulforedoxin, an oxidoreductase, has also been suggested 
as an enzyme involved in the deglutathionylation of cellular proteins, however it is more 
likely that it reduces the intermediates formed prior to protein S-glutathionylation than S-
glutathionylated proteins themselves. 
 
4.3.3 Identification and function of S-glutathionylated proteins in biology 
Due to the influence of the local protein micro-environment on cysteine reactivity, there does 
not appear to be a canonical sequence motif for reactive cysteine residues within proteins 
which makes identification and characterisation of susceptible proteins to posttranslational 
modification difficult. Weerapana et al attempted to characterise cysteine functionality using 
a large scale quantitative proteomic approach encompassing LC-MS/MS analysis of cysteine 
residues labelled with an alkynylated iodoacetamide (IAM) probe (Weerapana et al., 2010).  
This approach quantitated the reactivity of IAM labelled cysteines, and therefore identifies 
cysteine residues susceptible to general posttranslational modification. In relation to S-
glutathionylation, a number of proteins have been identified as S-glutathionylated using an 
array of biochemical methods (Table 7). The impact of S-glutathionylation on cellular 
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proteins is somewhat contradictory. There is a large body of evidence that demonstrates in 
times of oxidative stress, S-glutathionylation appears to inhibit protein function. For example, 
S-glutathionylation of p53 reduces its ability to bind to DNA (Velu et al., 2007) while S-
glutathionylation of actin reduces its affinity for tropomyosin and therefore reduces its ability 
to polymerise (Chen and Ogut, 2006). In contrast, ROS induction following Angiotensin II 
treatment of smooth muscle cells causes S-glutathionylation of Ras which subsequently leads 
to increased p38 and Akt phosphorylation (Adachi et al., 2004). It is interesting to note that 
GSTP can also be S-glutathionylated at 2 cysteine residues, Cys47 and Cys101 which affect 
its apparent binding to target proteins (Townsend et al., 2008a, Tew et al., 2011). This is 
particularly interesting with regards to a potential role of GSTP in the catalysis of protein S-
glutathionylation. 
 
 
 
 
 
 
 
 
 
 
Results Chapter 4 
 
108 
 
Protein class Impact of 
glutathionylation 
Notable proteins of interest 
Proteins with 
thiol active 
centres 
In general, S-
glutathionylation results in 
function inhibition. S-
glutathionylation of PrdxVI 
results in reactivation of 
enzyme. 
Carbonic anhydrase III, Tyrosine 
hydrolase, α-ketoglutarate dehydrogenase, 
aldose reductase, creatine kinase, 
GAPDH, HIV-1 protease, PrdxI, PrdxVI, 
Inosine 5’-monophosphate dehydrogenase 
2, protein disulphide isomerase, elonase 
1α, phosphoglycerate kinase, aldolase, 
phosphorylase kinase, 6-
Phosphogluconolactonase, 
Triosephosphate isomerase, Adenylate 
kinase 2, dUTP pyrophosphatase, 
Peptidylprolyl isomerase (cyclophilin A), 
Cytochrome c oxidase, Ubiquitin-
conjugating enzyme E2N, Thioredoxin 1 
Glutathione S-transferase P1, Endothelial 
nitric oxide synthase 
Cytoskeletal 
proteins 
S-glutathionylation results 
in function inhibition or 
inhibition of 
polymerisation/filament 
formation. 
Vimentin, G-Actin Tropomyosin, 
Transgelin, SM22 homolog calponin-like, 
Cofilin, Myosin, Profilin, Βeta-Tubulin, 
Annexin II, Spectrin 
Signalling 
proteins 
In general, S-
glutathionylation results in 
function inhibition. S-
glutathionylation of T cell 
p59
fyn
 kinase and p21 ras 
results in function 
activation. 
Protein kinase A, Protein kinase C, ERK, 
T cell p59
fyn
 kinase, PTP1B, MEKK1, 
PTEN, Protein kinase G, c-Abl, Caspase 
3, p21 ras 
Transcription 
factors 
S-glutathionylation results 
in function inhibition. 
c-Jun, NF-κB subunits 65 and 50, IKK β-
subunit, Pax-8, OxyR, p53 
Heat shock S-glutathionylation results HSP60, HSP70 
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proteins in function inhibition. 
Ion channels, 
transport pumps 
In general, S-
glutathionylation results in 
function activation. S-
glutathionylation of CFTR 
results in function 
inhibition. 
RyR1, CFTR, SERCA, S100 A1, S100 
A4, S100 B 
Energy 
metabolism/glyco
lysis 
S-glutathionylation results 
in function inhibition. 
Complex I, NADP+-dependent isocitrate 
dehydrogenase, Cytochrome oxidase, 
ATPase, NADH ubiquinone reductase, 
Carbonic anhydrase III, Catechol-O-
methyltransferase, Pyruvate 
dehydrogenase 
 
Table 7. Overview of S-glutathionylation on protein class and function. 
The table highlights a brief overview on the number of proteins which are thought to be S-glutathionylated and 
the biological impact of S-glutathionylation on protein function. Adapted from Tew et al 2011. 
 
4.3.4 GSTP1 as a catalyst of protein S-glutathionylation 
S-glutathionylation is often regarded as a transient reaction in response to oxidative stress. 
However, some groups have recently argued that the reaction may be catalysed by GSTP1. 
Peroxiredoxins (Prdxs) reduce hydroperoxides to alcohols via active cysteine residues. There 
are two main families of peroxiredoxins; those containing two conserved cysteine residues in 
their C-terminal domain (2-Cys) and those only containing one cysteine residue (1-Cys). The 
lack of an extra cysteine molecule for the 1-Cys family, or peroxiredoxin VI (PrdxVI), means 
that another molecule containing a thiol group is needed in order to reduce the oxidised Cys 
47 residue and to regenerate the active PrdxVI (Choi et al., 1998). It has been suggested that 
GSTP1 provides the thiol group required in a glutathionylation step by forming a heterodimer 
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with PrdxVI (Manevich et al., 2004) and it has been demonstrated in vitro that a stable 
GSTP1:Cys1 complex could be formed which restores active PrdxVI activity (Ralat et al., 
2006). However, due to the large number of inter-disulphide interchange reactions, the 
kinetic competence of this mechanism has been questioned (Gallogly and Mieyal, 2007).  
 
Further evidence for GSTP1-mediated S-glutathionylation has been proposed from the 
laboratory of Professor Kenneth Tew. Townsend et al neatly demonstrated that the nitric 
oxide releasing prodrug PABA/NO results in apoptosis and protein kinase activation 
correlating with increased protein S-glutathionylation and the presence of GSTP1 (Townsend 
et al., 2006). The group later demonstrated that global protein S-glutathionylation was 
potentiated by GSTP1 in response to nitrosative and oxidative stress (Townsend et al., 
2008a). Whether this is due to the specificity of GSTP1 for PABA/NO or the increased 
cytotoxic effect of PABA/NO on GSTP1 expressing cells is yet to be determined. It appears 
contradictory that GSTP1 can catalyse protein S-glutathionylation in times of oxidative and 
nitrosative stress, when itself is S-glutathionylated leading to reduced activity. The same 
group has recently collaborated on a number of publications demonstrating that GSTP1 may 
potentiate the S-glutathionylation of the death receptor Fas (Anathy et al., 2012) while 
showing a potential role of GSTP1 in controlling cocaine induced protein S-glutathionylation 
(Uys et al., 2011).   
 
The role of GSTP1 in mediating protein S-glutathionylation is still not fully understood. 
Nonetheless, the ability of GSTP1 to conjugate GSH to many xenobiotic substrates makes it a 
potential candidate in catalysing GSH conjugation to proteins. The focus of this chapter will 
be to examine the extent of protein S-glutathionylation mediated by GSTP1 in vitro. 
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Results 
4.4 Transient silencing of GSTP1 in HCT116 cells 
The human colon carcinoma cell line, HCT116, was used in this study as they are near 
diploid, stable in cell culture and, have been shown to require GSTP1 expression for 
proliferation, demonstrating a potential role for GSTP1 in mediating cellular function 
independent of drug metabolism (Dang et al., 2005). GSTP1 was transiently silenced in 
HCT116 cells using siRNA targeted against GSTP1 or a control siRNA to account for off 
target effects. Cells were also mock transfected with nuclease free water to account for off 
target effects associated with siRNA transfection. The concentration of siRNA to be used was 
optimised by transfecting increasing concentrations of siRNA (from 1nM to 50nM) into 
HCT116 cells and determining GSTP1 expression from 24 to 72 hours post transfection. The 
minimal concentration of siRNA which resulted in maximal depletion of GSTP1 protein was 
found to be 10nM after 72 hours, as determined by Western blot analysis (data not shown).  
 
Figure 4.2 demonstrates that transient knockdown of GSTP1 in HCT116 cells does not 
induce compensatory changes in other GSTs or antioxidant response genes, as shown by 
Western blotting of GSTM1 and NAD(P)H: quinone oxidoreductase 1 (NQO1) expression. 
NQO1 catalyses the detoxification of quinones and is induced in response to a number of 
carcinogenic and pro-oxidant compounds. The lack of NQO1 induction as a result of GSTP1 
silencing suggests that the cellular redox state does not appear to be intrinsically regulated by 
GSTP1 in HCT116 cells.  
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Figure 4.2. Transient silencing of GSTP1 in HCT116 cells. 
HCT116 cells were transiently transfected with nuclease free water (mock), 10nM siRNA targeted against 
GSTP1 or control siRNA. After 72 hours, cells were harvested and lysates (10µg) resolved on a SDS-PAGE gel 
before analysed by Western blotting. Blots are representative of 3 independent experiments. 
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This observation is strengthened further through examination of the cellular morphology. 
Silencing of GSTP1 does not appear to induce any significant change in cellular morphology 
and the cells show no apparent signs of stress or apoptosis as a result of GSTP1 silencing 
(Figure 4.3). The only noticeable difference is the apparent protruding outer membranes of a 
number of cells silenced for GSTP1. This phenotype may be related to changes in 
cytoskeletal expression which are discussed later in Chapter 5. It is important to address that 
while the lack of noticeable changes in morphology and NQO1 induction may imply that 
redox and other cellular changes have not occurred, upregulation of other compensatory 
pathways that have not yet been accounted for may be implicit in maintaining cellular 
homeostasis. 
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Figure 4.3. Examination of the cellular morphology of GSTP1 silenced HCT116 cells. 
HCT116 cells were transiently transfected with nuclease free water (mock), 10nM siRNA targeted against 
GSTP1 or control siRNA. The morphology of the cells was examined 72 hours post transfection. Pictures are 
representative of 3 independent experiments. 
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4.5 Role of GSTP1 in proliferation of HCT116 cells 
In the initial characterisation of HCT116 cells, the extent to which GSTP1 can affect cell 
cycle and survival was examined through cell cycle profiling of HCT116 cells. Cells were 
transfected with GSTP1 siRNA, stained with propidium iodide (PI) and analysed by flow 
cytometry. HCT116 cells were transfected with 10nM of control siRNA or siRNA targeted 
against GSTP1 and stained with PI 72 hours post transfection as described under ‘Materials 
and Methods’. In line with morphological observations, examination of the cell cycle profile 
of HCT116 cells silenced for GSTP1 staining demonstrates little change in apoptosis or arrest 
as shown by low levels of G1/G0 (subG1) (Figure 4.4A). Detailed analysis of apoptotic 
pathways using the Intellicyt Multimetric Apoptosis Screening kit demonstrated no change in 
caspase activation, annexin V, mitochondrial integrity or cell viability (Figure 4.4B). 
Silencing of GSTP1 increases the proportion of cells in G1, suggesting that they are spending 
more time in the ‘growth phase’ of the cell cycle and are slower at progressing through into 
mitosis, indicative of the lower S and G2/M phases also shown. This observation correlates 
neatly with an increase in doubling time of HCT116 cells silenced for GSTP1. Although not 
always statistically significant, a trend in cells silenced for GSTP1 demonstrates a longer 
doubling time than their wild-type or control treated counterparts when seeded at different 
densities (Table 8). As GSTP1 silenced cells are remaining in G1 for longer periods, this 
decreases the number of cells undergoing mitosis and therefore leads to a reduction in cell 
proliferation. Although GSTP1 is not essential for the prevention of cell cycle arrest, the 
results demonstrates that GSTP1 is important for the proliferation of HCT116 cells in culture. 
The precise mechanism by which this occurs is not fully understood, however differences in 
cytoskeleton remodelling as a result of GSTP1 knockdown may contribute to the reduction in 
cell proliferation and is demonstrated and discussed in Chapter 5. 
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Figure 4.4. Cell cycle profile of GSTP1 silenced HCT116 cells. 
HCT116 cells were transiently transfected with nuclease free water (mock), 10nM siRNA targeted against 
GSTP1 or control siRNA (n=3). (A) After 72 hours, cells were washed and fixed in 70% ethanol before stained 
with propidium iodide. Cell cycle profiles were analysed by flow cytometry. (B) After 72 hours, cells were 
washed and stained for a number of apoptotic pathways using the Intellicyt Multimetric Apoptosis Screening 
kit. Apoptotic parameters were measured simultaneously using a Becton Dickinson LSRFortessa. Values are 
represented as mean ± standard deviation. 
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Table 8. Doubling time (hrs) of GSTP1 silenced HCT116 cells. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA. Post 
transfection (24 hours), cells were trypsinised and seeded onto a 96 well plate at the seeding densities described 
in the table. The doubling time was assessed 72 hours after seeding using the ATP assay. To establish that ATP 
levels correlate with cell number and not differences in metabolic pathways, preliminary studies determined cell 
number using trypan blue staining and the number of cells was found to strongly correlate with ATP levels. 
Values are represented as mean ± standard deviation, where * GSTP1 vs Untreated P < 0.05, $ GSTP1 vs 
control siRNA P < 0.05.   
 
4.6 GSTP1 mediated cell regulation of JNK inhibition 
As described in Chapter 3, one of the proposed mechanisms by which GSTP1 is thought to 
mediate cell signalling is through inhibition of JNK activity. Under certain stresses, GSTP1 
inhibition of JNK prevents the downstream phosphorylation of its transcription factor c-Jun 
and subsequent transcription of stress response genes (Adler et al., 1999). This model 
suggests that in the absence of GSTP1, JNK activity is propagated under basal and stress 
conditions, leading to increased stress response. In order to examine this hypothesis, HCT116 
cells were silenced for GSTP1 using siRNA as described previously before exposed to 
 Doubling time of HCT116 cells after siRNA treatment (hrs) 
Number cells seeded 
per well 
Untreated Control siRNA GSTP1 siRNA 
2000 17.32±3.35 20.53±0.88 25.69±1.49 
1000 17.42±0.95 23.51±2.93 23.36±1.75 
500 19.41±3.22 21.88±1.54 29.73±3.00*
$
 
250 18.78±3.91 20.28±1.05 26.08±7.35 
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different doses of UV radiation. Cells were incubated for 1 hour at 37°C in culture media 
after UV exposure before lysates were prepared and resolved on a SDS-PAGE gel. Figure 4.5 
demonstrates that exposing HCT116 cells to increasing levels of UV increases the level of 
JNK phosphorylation and phosphorylation of its downstream target, c-Jun. However, this 
figure clearly demonstrates that there is no difference in the level of JNK phosphorylation in 
the presence or absence of GSTP1, highlighting that in HCT116 cells, GSTP1 must have 
other cellular functions besides regulation of JNK activity. 
 
 
Figure 4.5. UV induction of JNK phosphorylation is not attenuated in the presence of 
GSTP1 in HCT116 cells. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. HCT116 cells were exposed to increasing doses of UV radiation and incubated in media for 
1 hour at 37°C. Cells were harvested and lysates (10µg) were resolved on a SDS-PAGE gel and analysed by 
Western blotting. Blots are representative of 3 independent experiments. 
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4.7 Oxidation state of HCT116 cells silenced for GSTP1 
GSTP has previously been shown to be an important mediator in redox control (Townsend et 
al., 2006). To determine the amount of reactive oxygen species produced as a result of 
silencing GSTP1, HCT116 cells were incubated with dichlorodihydrofluorescein diacetate 
(H2DCFDA), a reduced fluorescein which is readily converted to a green-fluorescent form in 
the presence of oxidation. Silencing of GSTP1 does not appear to induce the level of ROS 
within HCT116 cells as we cannot detect any shift in H2DCFDA intensity as determined by 
flow cytometry (Figure 4.6). Therefore at resting levels within HCT116 cells, the production 
of reactive intermediates is not dependent on the function of GSTP1. However, that may be 
dependent on increases in other redox mechanisms compensating for the scavenging of 
excess ROS intermediates as a result of silencing GSTP1. 
 
One of the most abundant radical scavengers in the cell is the tripeptide glutathione. 
Examination of total and disulphide glutathione levels may indicate whether silencing of 
GSTP1 induces changes in the redox status of HCT116 cells. The levels of total and oxidised 
glutathione were analysed in HCT116 cells 72 hours following transient knockdown of 
GSTP1 using siRNA. As Figure 4.7 demonstrates, transient silencing of GSTP1 increases the 
total concentration of glutathione within the cell (Figure 4.7A) and increases the proportion 
of glutathione which is oxidised (Figure 4.7B), suggesting an elevation in ROS/oxidative 
stress formation in HCT116 cells after silencing GSTP1. 
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Figure 4.6. Dichlorodihydrofluorescein diacetate (H2DCFDA) staining of GSTP1 
silenced HCT116 cells. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=3). 
After 72 hours, cells were incubated with 10µM H2DCFDA in PBS for 30 minutes. Cells were trypsinised, 
washed in PBS and analysed by flow cytometry. A) Histogram plot of HCT116 cells treated with H2DCFDA. 
The left hand peak is cells treated with PBS only and used as a negative control against H2DCFDA staining. M1 
denotes area of shift from PBS control samples. B) The bar chart represents the area under each histogram plot. 
Fluorescence is shown as a percentage of untreated HCT116 cells. Values are represented as mean ± standard 
deviation. 
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Figure 4.7. Glutathione levels in GSTP1 silenced HCT116 cells. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=3). 
Levels of total (A) and oxidised (B) glutathione were analysed 72 hours after siRNA transfection. Values are 
represented as mean ± standard deviation, where ** P <0.01 compared to untreated and control siRNA values. 
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4.8 Role of GSTP1 in the protein S-glutathionylation of HCT116 cells 
The function of glutathione within the cell has broadened from that of a metabolite 
scavenger. Protein S-glutathionylation is a reversible post-translational modification in which 
proteins are conjugated to glutathione in what is thought to be a protective function against 
irreversible oxidative stress. It has been proposed that GSTP1 can potentiate the S-
glutathionylation of a number of proteins following oxidative and nitrosative stress 
(Townsend et al., 2008a), although studies have yet to determine whether this is a global 
event or particular to only a subset of proteins. After observing differences in the levels of 
total and oxidised glutathione after silencing of GSTP1, the level of protein S-
glutathionylation was determined in HCT116 cells using a biotinylated form of glutathione 
known as biotinylated glutathione ethyl ester (BioGEE). BioGEE is a cell-permeable 
glutathione analogue which is transiently incorporated into proteins under conditions of 
oxidative stress and can therefore be used as marker of protein S-glutathionylation. Although 
other in vitro methods have been described, many common procedures rely on the biotin-
switch method in which Grx reduction of the S-glutathionylated protein is labelled with 
another molecule, such as biotin-HPDP. Whilst many proteins have been identified using this 
method, the false positive rate is relatively high due to the number of procedure steps 
involved (increasing the chance of oxidative stress not associated with cell culture treatment) 
and the sensitivity of exposed thiol groups to light. BioGEE also avoids many of the false 
positives associated with using anti-glutathione antibodies and provides in situ labelling of S-
glutathionyated proteins without introducing further oxidative stress. The initial hypothesis 
assumes that if GSTP1 is active in the catalysis of protein S-glutathionylation, HCT116 cells 
silenced for GSTP1 would show a marked reduction of biotin incorporation when treated 
with BioGEE. 
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GSTP1 was transiently silenced in HCT116 cells as described previously. HCT116 cells were 
treated with BioGEE (0.4mM) for 1 hour, 72 hours post siRNA transfection. Cells were lysed 
in RIPA buffer supplemented with 25mM N-ethylmaleimide to prevent further modification 
of thiol groups and lysates were resolved on a non-reducing SDS-PAGE gel and analysed by 
Western blotting. A streptavidin antibody conjugated to horseradish peroxidase (HRP) was 
used for the detection of biotinylated proteins. Figure 4.8 demonstrates that BioGEE was 
incorporated into HCT116 cells and results in the labelling of a number of proteins. There is 
no difference in the level of streptavidin binding between untreated HCT116 cells and cells 
transfected with a control siRNA, suggesting that BioGEE was incorporated equally in 
control cells. However, in GSTP1 silenced cells, streptavidin expression is greatly increased, 
suggesting more incorporation of BioGEE and therefore higher levels of protein S-
glutathionylation when expression of GSTP1 is silenced. HCT116 cells were incubated with 
BioGEE for 1 hour although other time points have been tested with similar results. Longer 
time courses do not necessarily result in greater incorporation of the biotin signal, while 
similar (although slightly weaker) signals can be detected after 30 minutes incubation (data 
not shown). In contrast to our initial hypothesis, the data imply that GSTP1 is not required for 
the S-glutathionylation of cellular proteins and silencing GSTP1 in HCT116 cells 
significantly increases the level of protein S-glutathionylation. Initial results suggest that 
there is no difference in the number of proteins which are S-glutathionylated, but that these 
proteins are more susceptible to the labelling of BioGEE.  
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Figure 4.8. Protein S-glutathionylation of HCT116 cells silenced for GSTP1. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=3). 
Cells were incubated with BioGEE (0.4mM)  for 1 hour, 72 hours post siRNA transfection. Cells were harvested 
and lysates (10µg) resolved on a SDS-PAGE gel in non-reducing conditions and analysed by Western blotting. 
The Western blot shows the presence of biotinylated proteins as determined by streptavidin-HRP (1:1000), 
while the coomassie-stained gel demonstrates equal loading of lysates. Blots are representative of 3 independent 
experiments. 
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The predominant function of protein S-glutathionylation is to protect reactive cysteine groups 
from irreversible oxidation. In order to examine whether there is a functional consequence of 
increased protein S-glutathionylation in GSTP1-silenced HCT116 cells, cells were incubated 
with the alkylating agent, N-ethylmaleimide (NEM) over a 72 hour cytotoxic screen. If 
protein S-glutathionylation contributes to the protection of cysteine groups, then GSTP1 
silenced cells should be more resistant to the thiol blocking effects of NEM. Indeed, GSTP1-
silenced cells treated with NEM show increased resistance towards NEM as demonstrated in 
Figure 4.9, highlighting a potential functional response of increased protein S-
glutathionylation as a consequence of silencing GSTP1. Although from these data we cannot 
determine if resistance is mediated specifically through increased thiol S-glutathionylation as 
other thiol modifications may also occur, the data show strong correlation between increased 
protein S-glutathionylation in GSTP1-silenced cells and resistance to NEM.  
 
4.9 Protein S-glutathionylation in response to endogenous glutathione depletion 
It is important to acknowledge that, so far, differences in protein S-glutathionylation may be 
masked by the activity of endogenous glutathione, especially when differences in these levels 
can be observed upon silencing of GSTP1 (Figure 4.7). It is also difficult to assess whether 
the increase in BioGEE incorporation is due a stress response and is a true reflection of 
increased protein S- glutathionylation in GSTP1 silenced cells, or the fact that more reactive 
thiol groups are available in GSTP1 silenced cells for BioGEE to bind. If the latter was true, 
it would be difficult to assess whether or not protein S-glutathionylation was increased or 
decreased. To circumvent this potential problem, endogenous glutathione levels were 
depleted using buthionine sulfoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase 
(γ-GCS), the rate-limiting step in glutathione synthesis.  
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Depletion of glutathione was carried out as described by Higgins et al 2009, with 
modifications (Higgins et al., 2009). HCT116 cells were silenced for GSTP1 as described 
previously. Cells were grown for 48 hours before incubated with BSO (50µM) for 6 hours. 
Cell culture media was then replaced with fresh media containing BSO (50µM) and 
incubated for a further 12 hours. 
 
 
 
Figure 4.9. IC50 curve of N-ethylmaleimide treated HCT116 cells silenced for GSTP1. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=4). 
Cells were trypinised and seeded into a 96 well plate 72 hours post transfection and incubated with different 
concentrations of N-ethylmaleimide (NEM). Cell viability was determined using the ATP assay 72 hours after 
NEM treatment. The IC50 values are shown in the table above. Values are represented as mean ± standard 
deviation. 
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Cells were treated with BioGEE (0.4mM) for 1 hour and lysates were prepared and resolved 
on a non-reducing SDS-PAGE gel. Western blot analysis using a streptavidin-HRP antibody 
demonstrates that depletion of endogenous glutathione levels enhances the sensitivity of 
BioGEE labelling, as increased protein labelling can be detected in control siRNA and 
GSTP1 siRNA treated cells after incubation with BSO (Figure 4.10A). BSO (50µM) 
treatment reduced glutathione levels to 18% and 22% in control and GSTP1 siRNA treated 
HCT116 cells respectively (data not shown). In the absence of BSO, BioGEE is only able to 
accurately label high molecular weight proteins as smaller proteins are already saturated by 
endogenous glutathione. After endogenous glutathione depletion, BioGEE is more readily 
incorporated into smaller molecular weight proteins and therefore increases the resolution of 
proteins S-glutathionylated. BioGEE labelling is greatly enhanced in GSTP1-silenced cells, 
demonstrating increased protein S-glutathionylation after endogenous glutathione depletion 
when compared to control cells. This may be due to an increase in the reactivity of the 
cysteine groups after silencing of GSTP1, evident from the observation that levels of ROS 
increases after BSO treatment in GSTP1-silenced HCT116 cells as determined by H2DCFDA 
staining (Figure 4.11). However, a lack of HO-1 induction suggests that the level of oxidation 
in the cell does not warrant induction of other stress response pathways. These data 
demonstrate that GSTP1 is not required for the S-glutathionylation of cellular proteins in 
HCT116 cells as proteins are more readily S-glutathionylated in the absence of GSTP1. 
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Figure 4.10. Increased protein S-glutathionylation in GSTP1-silenced HCT116 cells 
after endogenous glutathione depletion. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=3). 
Cells were grown for 48 hours before incubated with BSO (50µM) for 6 hours. Cell culture media was then 
replaced with fresh media containing BSO (50µM) and incubated for a further 12 hours before treated with 
BioGEE (0.4mM) for 1 hour. Cells were harvested and lysates (10µg) were resolved on a non-reducing SDS-
PAGE gel and analysed by Western blotting using a streptavidin-HRP antibody (1:1000).  
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Figure 4.11. ROS activity after depletion of endogenous glutathione levels. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA (n=3). 
Cells were grown for 48 hours before incubated with BSO (50µM) for 6 hours. Cell culture media was then 
replaced with fresh media containing BSO (50µM) and left for 12 hours. Cells were incubated with H2DCFDA 
(10µM) in PBS for 30 minutes before trypsinised, washed in PBS and analysed by flow cytometry. A) 
Histogram plot of HCT116 cells treated with H2DCFDA. The left hand peak is cells treated with PBS only and 
used as a negative control against H2DCFDA staining. B) The bar chart represents the area under each 
histogram plot. Fluorescence is shown as a percentage of untreated HCT116 cells. Values are represented as 
mean ± standard deviation, where *** P < 0.001. 
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4.10 Effect of NOS signalling on protein S-glutathionylation 
As discussed previously, there are a number of ways in which proteins can become S-
glutathionylated. In the context of silencing GSTP1 in HCT116 cells, a rise in glutathione 
disulphide content (Figure 4.7B) as a result of increased disulphide exchange could account 
for the increase in protein S-glutathionylation observed in GSTP1 silenced HCT116 cells 
(Figure 4.8). However, it could also be hypothesised that an increase in protein nitrosylation 
or formation of nitrosyl- intermediates may act as a precursor to protein S-glutathionylation. 
In order to examine this hypothesis, HCT116 cells silenced for GSTP1 were incubated with 
N-Nitro-L-arginine methyl ester hydrochloride (L-NAME), an analogue of arginine that 
inhibits nitric oxide (NO) production. Cells were silenced for GSTP1 using siRNA as 
previously described and then incubated with 5, 50 or 500µM L-NAME for 7 hours. BioGEE 
(0.4mM) was added for 1 hour after L-NAME treatment and the level of protein S-
glutathionylation determined from Western blot analysis. 
 
Pre-treatment of HCT116 cells with L-NAME does not appear to greatly reduce the 
expression of protein S-glutathionylation in HCT116 cells, even at high concentrations of L-
NAME (Figure 4.12). The data presents a crude analysis of NO contribution to protein S-
glutathionylation. However, in principle it suggests that NO production does not contribute 
greatly to increased protein S-glutathionylation in GSTP1 silenced HCT116 cells. Our data 
therefore suggest that increased disulphide exchange between reduced and oxidised 
glutathione may account for the increased protein S-glutathionylation. However, if this 
mechanism is due to slight variations in the oxidation state of the cell upon silencing GSTP1, 
it is difficult to conceive why an increase in the oxidation of glutathione does not correlate 
with increases in other redox mechanisms such as nitrosylation. Therefore, although the 
current data imply increased disulphide exchange as a mechanism of increased protein S-
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glutathionylation in GSTP1 silenced HCT116 cells, other cellular processes cannot be fully 
excluded. 
 
 
Figure 4.12. Inhibition of NOS signalling on the activity of protein S-glutathionylation. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. Cells were treated with different concentrations of the nitric oxide synthase inhibitor, L-
NAME, for 7 hours before incubated with BioGEE (0.4mM) for 1 hour. Cells were harvested and lysates (10µg) 
were resolved on a non-reducing SDS-PAGE gel and analysed by Western blotting using a streptavidin-HRP 
antibody (1:1000). Blots are representative of 3 independent experiments. 
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4.11 Increase in the protein S-glutathionylation of mitochondrial proteins 
So far the data have examined the expression of global protein S-glutathionylation from 
whole cell lysate. To enhance the identification and localisation of proteins which are S-
glutathionylated, fractionation of subcellular compartments was performed in GSTP1 
silenced HCT116 cells after 1 hour incubation with BioGEE (0.4mM) by centrifugal 
differentiation. Cytosolic and mitochondrial lysates (10µg) were resolved on a non-reducing 
SDS-PAGE gel and analysed by Western blotting (Figure 4.14). Lactate dehydrogenase 
(LDH) is localised within the cytosol and its expression in Figure 4.14 shows that there is 
little contamination of mitochondrial preparations from cytosolic fractions. Manganese 
superoxide dismutase (MnSOD) is predominantly localised to the mitochondria and in this 
study, demonstrates neat quantification of mitochondria extracted from HCT116 cells. From 
Western blot analysis, we can clearly identify a number of mitochondrial proteins which are 
S-glutathionylated and can observe an increase in protein S-glutathionylation in HCT116 
cells silenced for GSTP1. However, we do not observe a large proportion of protein S-
glutathionylation from cytosolic preparations, which is of some concern as the majority of S-
glutathionylated proteins to date have predominantly localised in the cytosol. The nature of 
the subcellular fractionation procedure, which results in heavily diluted cytosolic fractions, 
may account for this observation. The apparent increased protein S-glutathionylation within 
the mitochondria is of great interest in relation to GSTP1-mediated cytoprotection, where the 
localisation and function of GSTP1 within the mitochondria was previously discussed and 
analysed in Results Chapter 3. As mentioned previously, mitochondria cannot export 
oxidised glutathione. In times of oxidative stress, S-glutathionylation of mitochondrial 
proteins reduces the level of oxidised glutathione in the mitochondria in order to reduce 
mitochondrial damage as a result of increased ROS. Silencing of GSTP1 in HCT116 cells 
does not appear to be detrimental to the integrity of the mitochondria as was evident 
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examining various apoptotic parameters by flow cytometry in Figure 4.4B. Transmission 
electron microscopy (TEM) of mitochondria in HCT116 cells silenced for GSTP1 supports 
this observation, as very few changes can be identified in the mitochondrial structure upon 
silencing of GSTP1 (Figure 4.13). A possible mechanism is that in the absence of GSTP1, 
mitochondrial oxidative stress increases, which increases protein S-glutathionylation as a way 
of attempting to maintain redox homeostasis by reducing the concentration of GSSG. The 
results demonstrate a novel potential function of GSTP1 in relation to mitochondrial 
regulation. The role in GSTP1-mediated cytoprotection of the mitochondria is analysed and 
discussed later in the chapter in relation to protein-specific regulation. 
 
 
 
Figure 4.13. Analysis of mitochondria in GSTP1 silenced HCT116 cells using 
transmission electron microscopy. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. Cells were fixed in2% PFA in 0.1M Cacodylate buffer and post fixed in 1% aqueous 
osmium. Cells were dehydrated in graded alcohols and incubated in propylene oxide before placed in neat resin 
and analysed by transmission electron microscopy. Pictures are representative of 3 independent experiments. All 
images are at a magnification of 10,000x. 
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Figure 4.14. Analysis of protein S-glutathionylation of cytosolic and mitochondrial 
fractions in GSTP1 silenced HCT116 cells. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. Cells were incubated with BioGEE (0.4mM) for 1 hour before cytosolic and mitochondrial 
fractions were prepared by differential centrifugation as described in ‘Materials and Methods’. Lysates (10µg) 
were resolved on a non-reducing SDS-PAGE gel and analysed by Western blotting using antibodies against 
LDH (cytosolic marker, 1:1000), MnSOD (mitochondrial marker, 1:1000), GSTP1 (1:2000) and a streptavidin-
HRP antibody (1:1000). Blots are representative of 3 independent experiments. 
 
 
Results Chapter 4 
 
135 
 
4.12 Two-dimensional gel electrophoresis analysis of protein S-glutathionylation in 
GSTP1 silenced HCT116 cells 
Further to analysing protein S-glutathionylation through subcellular fractionation, individual 
S-glutathionylated proteins were separated and analysed by two-dimensional gel 
electrophoresis (2DE). GSTP1 was transiently silenced in HCT116 cells as described 
previously. Cells were incubated with BioGEE (0.4mM) for 1 hour and harvested in a non-
reducing lysis buffer. Proteins (100µg) were acetonitrile precipitated and resuspended in 
isoelectric focusing (IEF) buffer (100µl). Proteins were subsequently separated on 
Immobilised pH Gradient (IPG) ReadyStrips
™
 pH3-10 NL using a Protean IEF Cell (BioRad) 
as described in ‘Materials and Methods’. Western blot analysis of biotinylated proteins was 
performed using a streptavidin-HRP antibody, while silver staining of 2DE gels was 
performed to analyse sample loading accuracy. Analysis of the protein expression profiles 
highlights a number of individual proteins which appear to be S-glutathionylated (Figure 
4.15). Similarly to 1 dimensional gel electrophoresis, the majority of proteins identified in 
GSTP1 silenced HCT116 cells show increased S-glutathionylation compared to control 
siRNA treated cells. However, there does appear to be a cohort of proteins in which the 
biotinylation signal is markedly reduced or absent, highlighted in blue, implying that there 
may be a subset of proteins in which their ability to become S-glutathionylated is actively 
catalysed by GSTP1. Initial 2DE experiments have proven difficult to accurately identify 
individual proteins using mass spectrometric analysis from a crude lysate due to the 
cleanliness of the streptavidin-HRP antibody and an optimised approach for the identification 
of S-glutathionylated proteins is detailed in the ‘Discussion’ Chapter. 
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Figure 4.15. Analysis of protein S-glutathionylation in GSTP1 silenced HCT116 cells by 
two-dimensional gel electrophoresis. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. Cells were incubated with BioGEE (0.4mM) for 1 hour and harvested in non-reducing lysis 
buffer. Proteins were acetonitrile precipitated (100µg) and resuspended in 100µl of isoelectric focusing (IEF) 
buffer. Proteins were separated using two-dimensional gel electrophoresis and protein S-glutathionylation was 
analysed by Western blot analysis using streptavidin-HRP while equal loading was determined by silver stain 
(70µg protein for Western blot, 20µg protein for silver stain). The red arrow highlights a potential group of 
proteins which may be deglutathionylated upon silencing of GSTP1. Blots are representative of 3 independent 
experiments. 
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4.13 Stable knockdown of GSTP1 in HCT116 cells using shRNA 
The study has utilised siRNA to target GSTP1 knockdown in HCT116 cells, but this 
approach becomes limited when examining the long term effects of silencing GSTP1. 
Therefore, by creating a stably silenced GSTP1 HCT116 cell line, the accurate nature of 
protein S-glutathionylation mediated by GSTP1 can be determined. GSTP1 was stably 
silenced in HCT116 cells using lentiviral transduction of plasmids expressing short hairpin 
RNA (shRNA) constructs targeted against GSTP1 or expressing no shRNA (plasmid/negative 
control). Several shRNA constructs targeted against different regions of GSTP1 mRNA 
transcript were examined in HCT116 cells, of which only one shRNA construct produced a 
knockdown of over 60% as determined by rtPCR (Taqman) (data not shown) and was 
subsequently used for stable knockdown of GSTP1. After lentiviral transduction, positive 
clones were identified under puromycin selection. After colony selection and clonal 
expansion, cells were examined for GSTP1 protein expression by western blot analysis and 
transcript analysis using rtPCR. shRNA expression targeting GSTP transcript was driven 
from a pol III U6 promoter cloned into the pLKO.1 vector. Expression of shRNA from this 
promoter results in stable knockdown of GSTP1 in HCT116 cells as is evident from both 
protein expression analysis (Figure 4.16A) and transcript analysis (Figure 4.16B). Expression 
of the plasmid only, used as a negative control, has little effect on GSTP1 protein levels, 
whilst some clones showed slight differences in GSTP1 mRNA expression. The same clones 
were used for all ensuing studies but where more than one clone is used, this is highlighted in 
the text and figures. 
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Figure 4.16. Analysis of GSTP1 expression after lentiviral transduction of shRNA 
targeting GSTP1 in HCT116 cells. 
HCT116 cells were lentivirally transduced with shRNA plasmids targeting GSTP1 or an empty plasmid 
(control). After colony selection and clonal expansion, cells were examined for GSTP1 protein expression by 
western blot analysis (A) and transcript analysis using rtPCR (Taqman) (B). For Western blot analysis, cell 
lysates (10µg) were resolved on a SDS-PAGE gel and analysed using antibodies targeting GSTP1 (1:2000) 
whilst sample loading was analysed using an antibody targeting GAPDH (1:5000). For rtPCR, 1µg RNA was 
synthesised to cDNA, diluted 1:80 and used in a duplex Taqman reaction using probes targeting GSTP1 and 18S 
as an endogenous loading control. ∆∆Ct values were determined from the analysis and are displayed as 
percentage of expression in comparison to untreated HCT116 cells. 
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4.14 Effect of stable knockdown of GSTP1 on the proliferation of HCT116 cells 
Transient silencing of GSTP1 in HCT116 cells results in reduced proliferation of HCT116 
cells, possibly due to reduced progression through mitosis as is evident from changes in cell 
cycle profiles (Figure 4.4A). Similarly to transient silencing of GSTP1, stable knockdown of 
GSTP1 cells significantly increases the doubling time of a number of GSTP1 knockdown 
HCT116 clones (HCT116
shGSTP
) over a 72 hour period (Table 9). Therefore, GSTP1 appears 
to have an intrinsic function in the proliferation of HCT116 cells. This is in line with previous 
studies demonstrating deletion of GSTP1 in HCT116 cells results in reduced cell growth 
(Dang et al., 2005).  In order to determine whether this was a result of changes in cell cycle 
parameters, the cell cycle profile of individual HCT116
shGSTP1
 clones were analysed by flow 
cytometry (Figure 4.17). Unlike transient silencing of GSTP1 using siRNA, stable 
knockdown does not induce changes of cell cycle parameters in HCT116 cells, indicating that 
another mechanism may account for the reduced proliferation and not necessarily slower 
progression though mitosis.  
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Table 9. Doubling time (hrs) of HCT116 cells after stable knockdown of GSTP1. 
HCT116 cells were transduced with lentiviral plasmids expression shRNA targeting GSTP1 (HCT116shGSTP1) or 
no shRNA (HCT116
shcontrol
). Several individual clones isolated from the initial puromycin selection screen were 
used in this experiment (untreated HCT116 cells, n=3; control shRNA , n=4; GSTP1 shRNA, n=6). Cells were 
seeded onto a 96 well plate at 1500 cells per well and the doubling time was assessed 72 hours later using the 
ATP assay. Values are represented as mean ± standard deviation, where * GSTP1 vs control shRNA P < 0.05. 
 
 
Figure 4.17. Cell cycle profile analysis of stable knockdown of GSTP1 in HCT116 cells. 
The cell cycle profile of individual HCT116
shGSTP1
 clones were analysed by flow cytometry. Prior to analysis, 
cells were seeded onto 6 well plates and grown in puromycin free media to 70% confluency. Cells were washed 
in PBS and fixed in 70% ethanol before stained with propidium iodide. Cell cycle profiles were analysed by 
flow cytometry. Values are represented as mean ± standard deviation.   
Genotype Doubling time (hrs) 
Untreated 23.43 ± 1.17 
Control shRNA 23.13 ± 4.8 
GSTP1 shRNA 31.96 ± 4.5* 
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4.15 Analysis of reduced and oxidised glutathione content after stable knockdown of 
GSTP1 in HCT116 cells 
Transient silencing of GSTP1 in HCT116 cells results in increases on reduced and disulphide 
glutathione levels (Figure 4.7). These parameters were also examined in stable HCT116 cell 
lines silenced for GSTP1. In contrast to transient knockdown of GSTP1, no difference in total 
glutathione concentrations could be determined in HCT116
shGSTP1 
cells (Figure 4.18A). 
However, there appears to be a marked increase in the proportion of oxidised glutathione in 3 
individual HCT116
shGSTP1
 clones (Figure 4.18B), suggesting that knockdown of GSTP1 
induces changes in the oxidation state of the cell. These data are comparable to that of 
transient silencing of GSTP1 in HCT116 cells which suggests a uniform mechanism in 
GSTP1-mediated cytoprotection in HCT116 cells. 
 
4.16 Protein S-glutathionylation in stably silenced GSTP1 HCT116 cells 
In relation to protein S-glutathionylation, the results generated from transient knockdown of 
GSTP1 led to the hypothesis that increased oxidation of glutathione may lead to increased 
disulphide exchange and, as a consequence, may have led to increased protein S-
glutathionylation. As a result of increased oxidation of glutathione in stably silenced HCT116 
cells, the level of protein S-glutathionylation was examined to test the disulphide hypothesis 
and examine the effect of GSTP1-mediated S-glutathionylation. HCT116 cells were treated 
with BSO as described previously, to maximise the resolution of proteins which are S-
glutathionylated. Upon treatment with BioGEE (0.4mM) there does not appear to be any 
difference in the level of protein S-glutathionylation between HCT116, HCT116
shcontrol
 and 
HCT116
shGSTP1
 cells treated with BSO as determined by Western blot analysis (Input, Figure 
4.19). Cells were also treated with the thiol oxidant, diamide, for 15 minutes after BioGEE 
incubation to induce protein S-glutathionylation and therefore determine if GSTP1-mediated 
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Figure 4.18. Analysis of total and oxidised glutathione levels in HCT116 cells stably 
silenced for GSTP1. 
HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells were analysed for total (A) and oxidised (B) levels of 
glutathione (n=3). For HCT116
shGSTP1
 cells, 3 individual clones were analysed in the assay. Values are 
represented as mean ± standard deviation.   
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S-glutathionylation was stress dependent. There was no apparent difference in the level of 
protein S-glutathionylation after diamide treatment across all cell lines. Biotinylated proteins 
were immunoprecipitated from cell lysates using streptavidin coupled Dynabeads, to 
determine any subtle differences in S-glutathionylated proteins. Cell lysates (500mg) were 
incubated with streptavidin-coated Dynabeads
®
 (40µl) at 4°C for 1 hour under gentle rotation 
before biotinylated proteins were separated from streptavidin beads by heating the samples at 
95°C for 5 min in a non-reducing sample buffer. Immunoprecipitation of biotinylated 
proteins from BSO and diamide treated cells demonstrates a difference in the composition of 
proteins S-glutathionylated after BSO and diamide treatment, with BSO enhancing the 
resolution of S-glutathionylated proteins to a greater extent than diamide. However, there is 
no apparent difference in the extent of biotinylation when compared to HCT116
shGSTP1
 cells 
(IP, Figure 4.19). The results demonstrate that stable knockdown of GSTP1 does not lead to 
decreased protein S-glutathionylation in HCT116 cells, even in the presence of the oxidant 
diamide, indicating that it is unlikely to catalyse protein S-glutathionylation in this context. 
However, the results do not resemble those observed in transiently silenced HCT116 cells, 
which may allude to the transient function of this modification or highlight compensatory 
mechanisms which may account for the stable loss of GSTP1. 
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Figure 4.19. Protein S-glutathionylation in HCT116 cells stably silenced for GSTP1.  
HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells were incubated with BSO (50µM) for 6 hours. Cell culture 
media was then replaced with fresh media containing BSO (50µM) and incubated for a further 12 hours before 
treated with 0.4mM BioGEE for 1 hour. As an alternative to BSO, protein S-glutathionylation was induced in 
cells after treatment with diamide for 15 minutes post BioGEE incubation. Lysates were prepared and 
immunoprecipitated (500mg) using streptavidin-coupled Dynabeads
®
 for 1 hour at 4°C. Proteins were separated 
from beads by boiling in 50µl non-reducing LDS buffer before 10µl was resolved on a SDS-PAGE gel. Gels 
were analysed by Western blotting using a streptavidin-HRP antibody (1:2000). Blots are representative of 3 
independent experiments. 
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4.17 GSTP1 regulation of mitochondrial proteins  
Transient silencing of GSTP1 in HCT116 cells resulted in increased S-glutathionylation of 
mitochondrial subcellular fractions but did not induce changes in mitochondrial integrity or 
structure (Figure 4.13). In HCT116 cells treated with the mitochondrial toxicant, rotenone, 
stable silencing of GSTP1 demonstrates a slight increase in cell sensitivity over a 72 hour 
cytotoxicity study (Figure 4.20). Although not significant there is a trend which suggests 
GSTP1 may play a role in the protection of mitochondria against rotenone treatment. 
However, it must be acknowledged that slight differences may, in part, be due to decreased 
cell numbers during the course of rotenone treatment due to decreased cell proliferation in 
HCT116
shGSTP1
 cells (Table 9). To examine the role of GSTP1 in the mitochondria in more 
detail, levels of oxygen consumption and glycolysis were determined in response to 
mitochondrial stress using the XF24 Analyser (Seahorse Biosciences). HCT116, 
HCT116
shcontrol
 and HCT116
shGSTP1
 cells were seeded at 20,000 cells per well onto a 24 well 
plate and incubated overnight. The following morning, cell media was replaced with 
unbuffered culture media and cells were incubated for 1 hour at 37°C in the absence of 
carbon dioxide. The rate of glycolysis and oxygen consumption was measured in response to 
DNP treatment. After 5 basal readings were taken, cells were treated with DNP (100µM) and 
the rate of oxygen consumption (OCR) and glycolysis (ECAR) measured. There was no 
difference in basal OCR and ECAR in two individual HCT116
shGSTP1
 cell lines compared to 
control cells (Figure 4.21), suggesting that GSTP1 is not required for basal mitochondrial 
function in HCT116 cells. After treatment with DNP, OCR and ECAR rates increased across 
all cell lines. However, there is no significant difference in the rate of OCR and ECAR in the 
absence of GSTP1, suggesting that in HCT116 cells, mitochondrial function does not appear 
to be intrinsically regulated by GSTP1. 
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Figure 4.20. Cytotoxicity assay examining the effect of the mitochondrial toxicant, 
rotenone, in the absence of GSTP1 in HCT116 cells. 
HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells were seeded into a 96 well plate at 1500 cells/well and treated 
with rotenone 24 hours later (n=4). After 72 hours incubation, cell viability was determined using the ATP 
assay. Values are represented as mean ± standard deviation. 
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Figure 4.21. Mitochondrial respiratory function of GSTP1 in response to 2,4-
dintrophenol (DNP). 
Oxygen consumption rates (A) and levels of glycolysis (B) were analysed in HCT116, HCT116 
shcontrol
 and 2 
individual HCT116
shGSTP1
 cell lines using the XF24 Analyser (n=3). Cells were incubated in unbuffered media 
for 1 hour prior to analysis. After 5 initial readings, DNP (100µM) was injected onto cells. Data show mean ± 
standard deviation. 
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However, a number of mitochondrial proteins have been identified as potential interacting 
partners with GSTP1 and therefore the role of GSTP1 could potentially be in the regulation 
of these proteins. Unpublished data from a Yeast two hybrid screen demonstrates GSTP1 can 
associate with a number of mitochondrial proteins (Table 10). Of particular interest is the 
strong association between GSTP1 and the mitochondrial protein electron transfer 
flavoprotein (ETFα). ETFα is an electron acceptor for a number of dehydrogenases and 
participates in catalysing the initial step of the mitochondrial fatty acid ß-oxidation (Furuta et 
al., 1981). To examine possible interactions between the two proteins, GSTP1 cloned from 
HCT116 cDNA was N-terminally tagged with GFP and transfected into HCT116 cells stably 
silenced for GSTP1. The GSTP1-GFP constructs contain silent mutations within the shRNA 
binding sequence, preventing silencing by shRNA whilst keeping the amino acid composition 
in the GSTP1 open reading frame intact. By performing the experiment as such, GFP-tagged 
constructs do not have to compete out endogenous GSTP1 and therefore a clean 
immunoprecipitation can be achieved at physiological concentrations. In addition, a non-
catalytic GSTP1 construct harbouring a Y7F mutation was cloned into GFP to assess non-
catalytic properties of GSTP1.  
 
What is particularly interesting is that GSTP1 present within HCT116 cells contains a 
polymorphism in the GSTP1 gene, a I105V substitution (*B polymorphism). In the context of 
colon carcinoma cell lines, it is not known whether this polymorphism contains any 
functional properties different to that of wild-type GSTP1. As described in the ‘Introduction’ 
chapter, I105V has been found to possess less catalytic activity than wild-type GSTP1 
towards CDNB in vitro, but has more catalytic activity towards certain epoxide containing 
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compounds. To control for the effects of the polymorphism in HCT116 cells, a V105I 
substitution was cloned into HCT116 GSTP1 which reverts GSTP back into its wild-type 
conformation (*A), as described by its GST nomenclature. For the purpose of this study, 
GSTP1 constructs labelled as GSTP1*B refer to polymorphic GSTP1 which is endogenous to 
HCT116 cells, whereas GSTP1*A refers to wild-type GSTP1. GSTP1
Y7F 
constructs have 
been cloned against HCT116 GSTP1 and therefore also contain the *B polymorphism.  
 
 
Table 10. Yeast two hybrid screen of genes associated with human GSTP1. 
A yeast 2 hybrid screen was performed using human GSTP1 as bait. Results kindly provided by Aileen 
McLaren. 
Number of hits Gene 
25 Electron transfer flavoprotein (ETFα) 
12 Metallothionein 2 
5 NADH dehydrogenase (ubiquinone) iron-sulphur protein 6 
1 NADH-ubiquinone oxidoreductase chain 1 
1 Ancient ubiquitous protein 1 (AUP1) 
1 Plasminogen 
1 Fas binding factor 
1 Na+/K+ ATPase, ß subunit 1 
1 Sorting nexin 3 (SNX3) 
1 Novel gene 
1 X-linked anhidroitic ectodermal dysplasia protein 
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HCT116
shGSTP1
 cells were seeded into 60mm culture dishes and grown until 70% confluent. 
Cells were transfected with 3µg of GFP-tagged GSTP1 using LTX PLUS as described in the 
‘Materials and Methods’. The amount of GFP-tagged construct to be used was determined by 
transfecting serial concentrations of GFP-tagged GSTP1 and comparing its expression to that 
of endogenous GSTP1 from HCT116 cells. The concentration of GSTP1 transfected closely 
resembles the physiological expression of GSTP1 as determined by Western blot analysis 
(data not shown). Cells were incubated for 24 hours before harvested in a mild NP-40 lysis 
buffer to maintain protein-protein interactions. GFP-tagged GSTP1 (2mg/ml) was 
immunoprecipitated from HCT116
shGSTP1
 lysates using GFP-Trap
®
 -M beads (30µl). Proteins 
were resolved on a SDS-PAGE gel and analysed by Western blot analysis. Figure 4.22 
demonstrates that transfection of GFP-tagged GSTP1 results in expression of a GSTP1 
protein which corresponds to the molecular weight of a fusion between GSTP1 and GFP. 
This is evident from the lower migration of a GFP transfected plasmid compared to the 
higher migration of GFP-GSTP1 fused construct on the Western blot. The presence of 
GSTP1 protein in HCT116
shGSTP1
 cells expressed as a fusion between GSTP1 and GFP 
demonstrates that the silent mutations introduced into the open reading frame have 
successfully prevented silencing of the transfected construct, as no GSTP1 protein can be 
detected in GFP only transfected cells or in untreated HCT116
shGSTP
 cells. At resting levels, 
the expression of ETFα does not appear to differ after transfection of any GSTP mutational 
construct suggesting its expression is not transcriptionally regulated by GSTP1. 
Immunoprecipitation of GFP at resting levels results in a clean pull down of GSTP1 from 
HCT116
shGSTP1
 cells. Unfortunately no apparent ETFα could be co-immunoprecipitated with 
any polymorphic or catalytic variant of GSTP1, suggesting that ETFα is not post-
translationally regulated by GSTP1.  In order to determine whether a protein interaction could 
be detected after cellular stress, cells were treated with cisplatin (50µM) or etoposide (25µM) 
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for 6 hours in order to induce apoptosis in HCT116
shGSTP1
 cells. Treatment with either 
compound did not induce transcriptional changes in ETFα expression upon transfection with 
GFP-tagged constructs. ETFα expression could not be detected after co-immunoprecipitation 
of GFP after treatment with either apoptosis inducing agents, indicating that, in HCT116 
cells, GSTP1 is unlikely to regulate ETFα.  
 
 
Figure 4.22. Immunoprecipitation of transfected GFP-tagged GSTP1 constructs from 
HCT116 cells.  
HCT116
shGSTP 
cells were transfected GFP-tagged GSTP1 constructs harbouring *A or *B polymorphism or Y7F 
(non-catalytic GSTP1) mutation. Each construct contained silent mutations within the shRNA binding region to 
allow expression of GSTP1. After transfection (24 hours), cells were treated with cisplatin (50µM) or etoposide 
(25µM) for 6 hours. Cells were harvested and lysates (2mg/ml) were incubated with GFP-Trap
®
 beads for 2 
hours at 4°C to immunoprecipitate GFP-tagged constructs. Proteins isolated from beads were resolved on a 
SDS-PAGE gel and analysed by Western blotting. Blots are representative of 3 independent experiments. 
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In summary, GSTP1 does not appear to be intrinsic in catalysing the S-glutathionylation of 
proteins in HCT116 cells which is in contrast to previously published data (Townsend et al., 
2008a). In fact, transient knockdown of GSTP1 in HCT116 cells induces the S-
glutathionylation of a number of proteins; however, this phenotype was not apparent in cells 
stably silenced for GSTP1 and therefore may not be a universal function of GSTP1. Although 
the S-glutathionylation of a number of mitochondrial proteins was increased when GSTP1 
was silenced transiently, no mitochondrial function could be attributed to GSTP1 in 
subsequent studies. Despite this, GSTP1 may have a role in mediating sulfhydryl homeostasis 
and redox control as transient or stable silencing of GSTP1 increases levels of glutathione 
disulphide in HCT116 cells. As previously demonstrated, GSTP1 is involved, although not 
necessary, in the proliferation of HCT116 cells (Dang et al., 2005); this phenotype is 
examined further in Chapter 5. 
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5. Chapter 5: Identification of GSTP1 mediated cytoprotection 
through chemical inhibition and microarray analysis 
 
Introduction 
Chapter 4 examined the function of GSTP1 in relation to a specific post translational 
modification in the human colon carcinoma cell line, HCT116. Although GSTP1 did not 
appear to have a clear role in protein S-glutathionylation in HCT116 cells, it was evident that 
silencing GSTP1, transiently or stably, induced differences in phenotype particularly in 
relation to cell proliferation and oxidative stress. This chapter aims to assess the different 
pathways mediated by GSTP1 through the use of chemical inhibition and microarray 
analysis. The chapter will also examine the role of GSTP1 in determining cellular resistance 
to a range of anticancer compounds in order to identify potential pathways of GSTP1-
mediated resistance. 
 
Results 
5.1 GSTP1 mediates resistance to ethacrynic acid but not to platinum compounds 
Initial experiments were designed to validate the use of HCT116
shGSTP1
 cells as a viable tool 
in cytotoxic assays using a well-characterised GSTP1 substrate, ethacrynic acid. Ethacrynic 
acid (EA) binds to the Cys47 residue on GSTP1, thereby affecting its ability to bind to other 
substrates (Phillips and Mantle, 1993). Inhibiting GSTP1 with EA increases the sensitivity of 
tumour cells to cisplatin (Wang et al., 2007) and can induce apoptosis in human Jurkat T cells 
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(McCaughan et al., 1994). Although proven unsuccessful in clinical trials due to its diuretic 
effects, analogues of ethacrynic acid have been synthesised and show anti-proliferative 
effects in tumour cells associated with inhibition of GSTP1 (Yang et al., 2010).  In this study, 
IC50 curves using EA were generated to determine the effect of GSTP1 knockdown in 
HCT116 cells and used as a positive control for other anticancer agents. The hypothesis 
assumes that GSTP1 knockdown cells would be more sensitive to EA treatment, owing to the 
specificity of EA for GSTP1. A number of HCT116
shcontrol
 and HCT116
shGSTP1 
clone cells, 
generated as described in Chapter 4, were incubated with EA over a 72 hour period. As 
predicted, treatment of HCT116 cells with EA induces cell death in a dose-dependent manner 
which is greatly enhanced in the absence of GSTP1, as evident from a left-hand shift in the 
IC50 curves in EA-treated HCT116
shGSTP1
 cells (Figure 5.1). EA treatment was tested in 
multiple GSTP1 shRNA clones and therefore the effect appears to be indicative of the 
absence of GSTP1 and not as a result of cell transduction. The large difference in IC50 as a 
result of specifically targeting GSTP1 is a positive control which provides confidence in 
pursuing further cytotoxicity studies targeting specific pathways or regulatory processes 
dependent on GSTP1.  
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Figure 5.1. IC50 curves of ethacrynic acid treated HCT116 cells stably silenced for 
GSTP1. 
HCT116 (n=3), HCT116
control
 (n=3) and HCT116
shGSTP1
 (n=6) cells were seeded into a 96 well plate at 1500 
cells/well and incubated for 24 hours. Cells were incubated with different concentrations of ethacrynic acid 
(EA). Cell viability was determined using the ATP assay 72 hours after EA treatment. The IC50 values are 
shown in the table above. Values are represented as mean ± standard deviation. 
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Initial studies involving GSTP1 mediated signalling and compound resistance in HCT116 
cells examined the cytotoxicity of two well-characterised platinum compounds, cisplatin and 
oxaliplatin. GSTP1 can facilitate the GSH conjugation of platinum compounds and therefore 
overexpression of GSTP1 is thought to play a key role in platinum resistance in cancer 
chemotherapy (Goto et al., 1999). The hypothesis is that in HCT116 cells silenced for 
GSTP1, one would expect an increase in platinum sensitivity due to reduced conjugation with 
GSH. Contrary to this, cytotoxicity analysis of both platinum compounds in HCT116 cells 
did not yield any significant difference in IC50 curves when GSTP1 was silenced (Figure 5.2). 
Therefore in HCT116 cells, GSTP1 does not appear to play a role in mediating platinum 
resistance. The effect is probably not caused by a polymorphism of GSTP1 in HCT116 cells, 
as described in Chapter 4, as Peklak-Scott et al demonstrated that this polymorphism 
increased the conjugation of GSH to cisplatin 80-90% over its wild-type counterpart and that 
this increased rate of GSH conjugation to cisplatin did not increase the resistance of cells to 
cisplatin treatment, speculating that GSTP1 must protect cells from cisplatin by other means. 
(Peklak-Scott et al., 2008). The role of GSTP1 in mediating oxaliplatin resistance is 
somewhat contradictory. Despite a lack of correlation between GST activity and oxaliplatin 
treatment demonstrated by some groups (Arnould et al., 2003), others have suggested 
polymorphisms in GSTP1 (Ile105Val) may be of use in predicting survival of patients with 
advanced colorectal cancer whilst receiving 5-fluorouracil/oxaliplatin treatment 
(Stoehlmacher et al., 2002). If the latter was true in this study, HCT116
shGSTP1
 cells should 
show a marked reduction in resistance to oxaliplatin, which is not the case.  
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Figure 5.2. IC50 curves of cisplatin and oxaliplatin treated HCT116 cells stably silenced 
for GSTP1. 
HCT116 (n=3), HCT116
control
 (n=3) and HCT116
shGSTP1
 (n=6) cells were seeded into a 96 well plate at 1500 
cells/well and incubated for 24 hours. Cells were incubated with different concentrations of cisplatin (A) or 
oxaliplatin (B). Cell viability was determined using the ATP assay 72 hours after platinum treatment. The IC50 
values are shown in the tables above. Values are represented as mean ± standard deviation. 
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5.2 Elucidating GSTP1 mediated cytoprotection through a multi-compound 
cytotoxicity screen 
GSTP1 is often found to be overexpressed in cancer cells and is associated with resistance to 
a wide range of anticancer and chemical treatments. It is unknown what the role of GSTP1 is 
in mediating resistance against such compounds, as many are not known substrates for 
GSTP1. The effect of GSTP1 on the cytotoxicity of EA is clearly evident in HCT116 cells 
but is less prominent with platinum compounds. As established in Chapter 4, the mechanism 
of GSTP1-mediated cytoprotection appears independent of JNK activity and therefore new 
insights are needed to determine the molecular pathways mediated by GSTP1 in HCT116 
cells. In order to assess this, a cytotoxicity screen was performed using 31 compounds 
targeted against different molecular pathways and cellular processes. A full list of compounds 
and their modes of action/target are shown in Table 11. Differences in cytotoxicity between 
HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells may indicate as to the molecular pathways 
mediated by GSTP and provide novel insight into the metabolism of these compounds, 
highlighting a potential use for improved or targeted drug dosing depending on the GSTP1 
expression of a tumour.  
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Compound Mode of action/target 
Carmustine Alkylating agent – forms DNA crosslinks 
Cyclophosphamide Alkylating agent – forms DNA crosslinks 
Lomustine Alkylating agent – inhibits DNA synthesis 
Cisplatin Causes crosslinking of DNA 
Cladribine Adenosine deaminase 
Tosedostat Aminopepdidase  
Anastrazole Aromatase 
Azacitidine DNA methyltransferase 
Gemcitabine Ribonucleotide reductase 
Doxorubicin DNA topoisomerase II 
XAV939 Tankyrase 1 and 2 
Cyclopamine Smoothened 
GDC-0449 Smoothened 
CI-994 Histone deacetylase 1 and 3 
Vorinostat Histone deacetylase 1 and 3 
NVP-AUY922 Heat shock protein 90 
17AAG Heat shock protein 90 
Roscovitine Cyclin-dependent kinase 
Everolimus Mammalian target of rapamycin (mTOR) complex 1 
LY294002 Phosphoinositide 3-kinases 
Pim1 inhib2 Pim1 
PLX4032 BRAF 
Erlotinib Epidermal growth factor receptor 
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NVP-AEW541 Insulin-like growth factor receptor 1 
Vatalanib Vascular endothelial growth factor receptor 1 
Platelet-derived growth factor receptor 
Docetaxel Microtubule 
Navitoclax Bcl2/Bcl-xL 
ABT888 Poly (ADP-ribose) polymerase 
Thiotepa DNA 
Pazopanib Vascular endothelial growth factor receptor 1,2 and 3 
Platelet-derived growth factor receptor 
c-Kit 
 
Table 11. Compounds targeting a number of cellular pathways and targets were used in 
a cytotoxicity screen against HCT116 cells silenced for GSTP1. 
The table highlights each compound used in a cytotoxicity screen against HCT116
shGSTP1
 cells and its mode of 
action. Where possible, more than one compound was designated to a particular molecular pathway/target.  
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HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells were seeded at 1500 cells/well onto a 96 
well plate and incubated with the compounds listed in Table 11 for 72 hours followed by a 
cytotoxicity assessment using the ATP assay. Any edge effect of the 96 well plates on cell 
viability was taken into account by incubating the same concentration of drug onto different 
areas of multiple 96 well plates. The range of drug concentration used was optimised for each 
compound in untreated HCT116 cells as a preliminary screen to ensure accurate readings of 
IC50 values. IC50 values were then generated for each compound in HCT116, HCT116
shcontrol
 
and HCT116
shGSTP1
 cells and are highlighted in Table 12. Some compounds did not induce 
toxicity in HCT116 cells at the concentrations tested and so were omitted from the final 
analysis. These mostly included drugs such as anastrazole and XAV939, where the parent 
compound needs to be metabolised into its active component. As HCT116 cells do not 
contain a functioning cytochrome P450 system (Nakumura et al., 2003), it is understandable 
that these drugs did not produce a cytotoxic effect. Other compounds saw pronounced 
differences between untreated HCT116 cells and HCT116
shcontrol
 cells and therefore were also 
excluded. From the compounds tested, very few appeared to show any difference in 
sensitivity in HCT116
shGSTP1
 cells and of the drugs which did show differences in drug 
sensitivity, there are very few similarities in their mode of action. Doxorubicin, 17-AAG and 
GDC-0449 were taken for a second set of screening over an improved dose range.  
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 IC50 values (µM, plus 95% confidence intervals) 
Compound Untreated shRNA Control shRNA GSTP1 
GDC-0449 14.3 (11.2, 18.2) 17.2 (13.5, 22.0) 10.9 (8.5, 14.0) 
Carmustine 46.4 (35.2, 61.0) 29.8 (22.1, 40.1) 28.8 (24.5, 34.0) 
Lomustine 21.6 (18.0, 25.9) 17.6 (13.7, 22.7) 15.0 (11.8, 18.9) 
Navataclax 6.4 (5.7, 7.2) 3.5 (2.9, 4.1) 3.7 (3.1, 4.4) 
Gemcitibine 0.015 (0.014, 0.016) 0.014 (0.012, 0.016) 0.014 (0.011, 0.018) 
Cyclopamine 7.3 (6.6, 8.0) 7.9 (6.7, 9.2) 6.5 (4.8, 8.8) 
PLX0432 12.43 (9.4, 16.5) 17.0 (11.8, 24.4) 12.32 (7.6, 19.9) 
Erlotinib 1.6 (1.3, 1.9) 1.6 (1.3, 1.9) 1.4 (1.2, 1,7) 
17-AAG 0.092 (0.067, 0.013) 0.17 (0.11, 0.25) 0.043 (0.032, 0.058) 
Azacitidine 13.7 (9.4, 19.9) 11.7 (5.9, 23) 8.1 (5.9, 11.2) 
Doxorubicin 0.066 (0.05, 0.09) 0.11 (0.06, 0.23) 0.04 (0.03, 0.05) 
CI-994 4.6 (3.8, 5.6) 4.6 (3.9, 5.5) 3.8 (3.1, 4.7) 
LY294002 13.0 (9.6, 17.6) 10.4 (7.0, 15.4) 9.7 (7.2, 13.0) 
NVP-AEW5411 0.35 (0.31, 0.39) 0.31 (0.22, 0.43) 0.26 (0.22, 0.3) 
 
Table 12.  IC50 values from a panel of anticancer compounds against HCT116 cells 
silenced for GSTP1. 
HCT116, HCT116
control
 and HCT116
shGSTP1
 (n=4) cells were seeded into a 96 well plate at 1500 cells/well and 
incubated for 24 hours. Cells were incubated with a range of anticancer compounds for 72 hours before cell 
viability was determined using the ATP assay. Values are represented as mean of IC50 ± 95% confidence 
intervals. 
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In this second screen, only the Hsp90 inhibitor, 17-AAG cytotoxicity retained a significant 
increase in sensitivity, demonstrating a 2.25-2.6 fold increase in cytotoxicity sensitivity in 
HCT116
shGSTP1
 cells (Figure 5.3). Hsp90 chaperones a large of number of proteins involved 
in protein kinase signalling and transcription factors. 17-AAG is a geldanamycin analogue 
which binds to a conserved ATP site in the N-terminal domain of Hsp90, disrupting its 
chaperone complex (Whitesell and Lindquist, 2005, Whitesell et al., 1994). The extent to 
which GSTP1 may facilitate this is unclear as another Hsp90 inhibitor, the resorcinylic 
isoxazole amide NVP-AUY922, did not show any significant difference in cytotoxicity 
between HCT116
shGSTP1
 and control cells (Table 12) indicating that the effect of GSTP1 in 
mediating 17-AAG resistance may be drug specific. 17-AAG is metabolised primarily via the 
cytochrome P450 system (Egorin et al., 1998, Banerji et al., 2005) but can also be 
metabolised by NQO1 into its hydroquinone derivative (Guo et al., 2005). Whether changes 
in NQO1 activity as a result of GSTP1 silencing may account for differences in metabolism 
of 17-AAG has yet to be determined as GSTP1 has not been shown to aid directly in the 
metabolism of 17-AAG. 
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Figure 5.3. IC50 curve of 17-AAG treatment in HCT116 cells silenced for GSTP1. 
HCT116 HCT116
control
 and HCT116
shGSTP1
 (n=4) cells were seeded into a 96 well plate at 1500 cells/well and 
incubated for 24 hours. Cells were incubated with different concentrations of 17-AAG and cell viability was 
determined using the ATP assay 72 hours later. The IC50 values are shown in the table above in µM. Values are 
represented as mean ± standard deviation. 
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5.3 Gene expression analysis of GSTP1 silencing in HCT116 cells 
The cytotoxicity screen produced few compounds which showed differential toxicity when 
GSTP1 is silenced, proving difficult to identify novel cellular pathways associated with 
GSTP1 mediated cytoprotection. In addition to the cytotoxicity screen, mRNA profiles were 
determined from HCT116, HCT116
shcontrol
 and HCT116
shGSTP1
 cells using the Illumina
® 
HumanHT-12 v4 Expression BeadChip array. Microarray profiling of HCT116
shGSTP1
 cells 
may shed light on novel pathways associated with GSTP mediated cytoprotection and aid in 
determining a cellular mechanism behind the observations made in Chapter 4 related to cell 
proliferation and oxidative stress. The microarray profiling demonstrated good clustering of 
biological samples within each genotype (Figure 5.4A), whilst showing little variation in 
signal (Figure 5.4B). As a positive control, GSTP1 was found to be the most down-regulated 
gene in HCT116
shGSTP1
 cells. Unfortunately, we observe that the control plasmid has had an 
effect on gene expression when compared to untreated HCT116 cells as evident from the 
clustering analysis (Figure 5.4A). To account for differences in gene expression due to off 
target effects mediated by the control plasmid, gene expression profiles of 2 separate 
HCT116
shGSTP1
 clones were compared against both untreated HCT116 and HCT116
shcontrol
 
mRNA profiles to generate 4 sets of gene expression profiles. Gene sets were then compared 
against each other to look for similarly regulated gene profiles. In practice, this is achieved 
through a four-way comparison; untreated vs HCT116
shGSTP1
 clone 1, untreated vs 
HCT116
shGSTP1
 clone 2, HCT116
shcontrol
 vs HCT116
shGSTP1
 clone 1 and HCT116
shcontrol
 vs 
HCT116
shGSTP1
 clone 2 (Figure 5.5). By comparing the data as such, the level of false 
positives due to off-target effects by both control shRNA and individual GSTP1 shRNA 
plasmids are minimised. The gene expression profiles of untreated HCT116 cells against 
HCT116
shcontrol
 cells were also compared to the extent of any off target effects (Table 15). 
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Figure 5.4. Analysis of microarray profiling of HCT116 cells silenced for GSTP1. 
mRNA from HCT116, HCT116
shcontrol 
and two individual HCT116
shGSTP1
 clones were profiled by microarray 
analysis. Biological mRNA triplicates were taken from each genotype and amplified to aRNA before analysed 
using the Illumina® HumanHT-12 v4 Expression BeadChip array. A) Cluster analysis of samples shows 
accurate grouping of biological samples for each genotype. B) Boxplot intensity profiles demonstrate little 
variation in signal between samples tested.  
 
Typically, the cut-off value for biologically significant changes in gene expression is greater 
than a two-fold difference. However, in order to examine statistically significant changes in 
gene expression across the number of comparisons made, the cut-off for a change in gene 
expression was decreased to 1.2 fold.  This takes into account statistically significant changes 
in gene expression and not just biological changes. Initial analysis of the raw microarray data 
as shown in Table 13 and Table 14 shows a number of genes that differ in mRNA expression 
in HCT116
shGSTP1 
cells from HCT116 untreated or HCT116
shcontrol
 cells, although very few 
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genes show a large difference in fold expression from control cells. It must be acknowledged 
that some differentially expressed genes in HCT116
shGSTP1
 cells in comparison to 
HCT116
shcontrol
 mRNA may be as a result of off-target effects from the control plasmid. This 
is evident from examining gene expression profiles from HCT116
shcontrol 
and HCT116 
untreated mRNA profiles (Table 15). For example, CAV1 mRNA is decreased 3- to 4-fold in 
HCT116
shGSTP1 
cells when compared to HCT116
shcontrol
 cells but is upregulated 2.4-fold in 
HCT116
shcontrol 
cells compared to untreated HCT116 cells and therefore the actual difference 
in gene expression may not be physiologically significant. In order to circumvent this 
potential problem, gene expression profiles were compared against each other and similarly 
expressed (i.e. upregulated or downregulated) genes across each four-way comparison were 
identified (Table 16). For example, GSTP1 is downregulated in each of the four-way 
comparisons described in Table 16 and is therefore regarded as a significant result, acting as a 
positive control in this regard. Understandably, this protocol may lead to the loss of gene 
targets which may have a true effect but as a result in gene expression differences between 
control cells, have been omitted. For example, in HCT116
shGSTP1 
clone 1 cells, VGF is 
upregulated 2.6 fold in comparison to HCT116
shcontrol 
cells, 1.6 fold in comparison to 
untreated cells and is upregulated 1.5 fold in HCT116
shGSTP1
 clone 2 cells compared to 
HCT116
shcontrol
 cells. However, as it is not differentially expressed between HCT116
shGSTP1
 
clone 2 cells and untreated HCT116 cells, it was omitted from the final analysis.  
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Figure 5.5. Venn diagrams showing comparative gene expression analysis of GSTP1 
silencing in HCT116 cells. 
mRNA expression profiles from HCT116, HCT116shcontrol and 2 individual HCT116shGSTP1 clones were 
compared against each other in a four-way Venn diagram. The numbers in each segment depict the number of 
simultaneously upregulated genes (A) and downregulated genes (B) between each comparison. Unt, untreated 
HCT116 cells; cont, HCT116
shcontrol
; sh1, HCT116
shGSTP1 
clone 1; sh2, HCT116
shGSTP1
 clone 2.  
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In total, 36 genes were found to be similarly upregulated and 40 genes downregulated in 
HCT116
shGSTP1
 cells (Figure 5.5). The top 10 genes differentially expressed in HCT116
shGSTP1
 
cells are shown in Table 16, with their range in fold differences across each comparison 
shown. Very few genes had any significant fold change in mRNA expression across each 
comparison, with the exception of GSTP1, which serves as a positive control. From the data 
generated, it was difficult to assess the biological response to GSTP1 silencing in HCT116 
cells due to a lack of uniform gene sets conferring a similar biological response. Whilst 
silencing of GSTP1 appears to induce the upregulation of sulfotransferases and NQO1 
mRNA expression, the fold difference in mRNA expression may not be biologically 
significant. What may be important is the upregulation of these genes in relation to a general 
cellular pathway or process which is discussed later in the chapter.  
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Top 20 downregulated genes 
shGSTP1 clone 1 vs 
Untreated 
shGSTP1 clone 2 vs 
Untreated 
shGSTP1 clone 1 vs 
shcontrol 
shGSTP1 clone 2 vs 
shcontrol 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
GSTP1 -13.7016 GSTP1 -10.1243 GSTP1 -12.5088 GSTP1 -9.24294 
TRIB3 -3.06358 IFITM1 -2.42911 CYP24A1 -4.68101 CAV1 -4.0235 
PCK2 -2.91263 SQLE -2.02962 S100A10 -3.35066 CYP24A1 -3.40112 
DDIT3 -2.86761 TSC22D3 -2.00164 CAV1 -3.31936 CAV2 -3.11606 
TNFRSF6B -2.66571 TM4SF18 -1.94673 CPA4 -3.30832 CAV1 -3.09288 
ASNS -2.56581 MKX -1.84514 S100A10 -2.74879 CPA4 -3.02439 
MKNK2 -2.51069 UPP1 -1.83989 CAV2 -2.51733 CAV2 -2.77899 
DDIT4 -2.40636 TSC22D3 -1.79255 CAV1 -2.486 GPR110 -2.40488 
LOC652097 -2.29801 CNTNAP2 -1.72482 F3 -2.42727 F3 -2.26335 
TNFRSF6B -2.18582 RBCK1 -1.70943 KRT81 -2.38986 KRT81 -2.06352 
ASNS -2.17479 MKNK2 -1.70175 ATG12 -2.36186 F3 -2.05669 
ATG12 -2.17424 TM4SF18 -1.68122 LOC652097 -2.279 SQLE -2.028 
SLC2A3 -2.1417 ARHGEF2 -1.65596 LOC647349 -2.2714 PTPN1 -1.97687 
MKX -2.1393 LOC730167 -1.65155 NP -2.23517 GPR110 -1.97143 
IFITM1 -2.12686 TRIB3 -1.64458 BCAR3 -2.17099 GPR110 -1.95635 
LOC730167 -2.12377 PCK2 -1.62361 CAV2 -2.13388 BCAR3 -1.91522 
ARHGEF2 -2.1129 ANXA3 -1.61315 MKNK2 -2.13014 LOC728285 -1.88141 
PTK2 -2.09527 ADAM19 -1.60416 AP3S1 -2.09271 SLC1A3 -1.86505 
ID1 -2.09469 HSPH1 -1.58939 PTPN1 -2.06786 LOC647349 -1.73658 
S100A10 -2.09187 KLF2 -1.57796 F3 -2.01684 NP -1.73423 
 
Table 13. Top 20 downregulated genes in GSTP1 silenced HCT116 cells when compared 
to both untreated and control shRNA treated HCT116 cells. 
mRNA expression profiles from 2 individual HCT116
shGSTP1
 clones were compared against mRNA expression 
profiles from HCT116 (untreated) and HCT116
shcontrol
 cells (n=3). Probes that exhibited an adjusted P value of 
<0.05 are expressed. 
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Top 20 upregulated genes 
shGSTP1 clone 1 vs 
Untreated 
shGSTP1 clone 2 vs 
Untreated 
shGSTP1 clone 1 vs 
shcontrol 
shGSTP1 clone 2 vs 
shcontrol 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
Gene 
Fold 
difference 
SCG2 2.863652 RGS2 2.785131 FXR1 5.000266 ANXA10 5.371668 
HSPA1B 2.765232 0 2.031254 SCG2 4.300566 FXR1 4.795362 
SLC4A7 2.533093 HSPA1B 1.853671 FXR1 3.909493 RGS2 4.412696 
SYTL2 1.928746 SYTL2 1.686146 
LOC100132
797 
3.466396 FXR1 3.751463 
DNAJB1 1.895632 F2RL1 1.616699 ACSL5 2.829557 
LOC100132
797 
3.253591 
FAM122B 1.856638 SLC4A7 1.579626 S100A16 2.61553 ACSL5 2.703254 
DHRS2 1.851713 SNORA12 1.579433 VGF 2.609363 DDIT3 2.474316 
DNAJA1 1.827864 AKAP12 1.561662 RGS2 2.370608 0 2.314096 
F2RL1 1.818131 DNAJB1 1.533974 DHRS2 2.355288 TRIB3 2.285847 
SLC4A7 1.800397 ANKRD37 1.527654 HSPH1 2.095961 S100A16 2.26521 
DNCL1 1.779618 MIR1978 1.526641 ANXA10 2.095487 ACSL5 2.210474 
CASP4 1.76604 DYNLL1 1.521144 CASP4 2.056673 DDIT4 2.17986 
F2RL1 1.760198 GPR177 1.51515 PDE4B 1.971111 HAS3 2.158181 
DYNLL1 1.726351 HMGCS1 1.509488 ACSL5 1.95556 PCK2 2.009696 
GCLM 1.689124 LOC392437 1.498877 STXBP6 1.922043 ASNS 1.998808 
FABP6 1.670221 RDH10 1.490909 ALDH1L1 1.90011 SLC2A3 1.987838 
MRPL33 1.650463 DHRS3 1.484901 MCM5 1.890673 ALDH1L1 1.930505 
SEPX1 1.626125 TDP1 1.473749 SULT1A1 1.8503 
LOC100130
516 
1.841752 
LOC100129
673 
1.617534 RNY1 1.44571 SULT1A4 1.831269 MCM5 1.838512 
EPDR1 1.606632 PCBD1 1.445189 0 1.797543 SLC20A1 1.834155 
 
Table 14. Top 20 upregulated genes in GSTP1 silenced HCT116 cells when compared to 
both untreated and control shRNA treated HCT116 cells. 
mRNA expression profiles from 2 individual HCT116
shGSTP1
 clones were compared against mRNA expression 
profiles from HCT116 (untreated) and HCT116
shcontrol
 cells (n=3). Probes that exhibited an adjusted P value of 
<0.05 are expressed. 
Results Chapter 5 
 
172 
 
 
Genes upregulated in control shRNA vs 
untreated HCT116 cells 
Genes downregulated in control shRNA vs 
untreated HCT116 cells 
Gene Fold difference Gene Fold difference 
CPA4 3.724755 ANXA10 -2.09058 
HSPA1B 2.886556 TRIB3 -1.91045 
CAV1 2.840511 FXR1 -1.8274 
CYP24A1 2.692376 IFITM1 -1.74687 
CAV1 2.361086 PCK2 -1.70618 
CAV2 2.325084 DDIT3 -1.66086 
KRT81 2.277799 LOC100132797 -1.63645 
CAV2 2.233047 SLC2A3 -1.60846 
DNAJB1 2.04252 FXR1 -1.59934 
F3 1.986304 ASNS -1.56559 
DNAJA1 1.836899 ACSL5 -1.46811 
LOC728285 1.831077 MKX -1.37163 
F3 1.807781 HKDC1 -1.34448 
GPR110 1.750518 TSC22D3 -1.2278 
BCAR3 1.712693 PSAT1 -1.2203 
 
Table 15. mRNA expression profile comparison between control shRNA treated 
HCT116 cells and untreated HCT116 cells. 
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Of the genes identified, MAP kinase interacting serine/threonine kinase 2 (MKNK2 or 
MNK2) expression was validated in a rtPCR reaction as it appeared to be one of the more 
downregulated genes identified from the comparison analysis (Table 16). MKNK2 is a 
member of the calcium/calmodulin-dependent protein kinases (CAMK) serine/threonine 
protein kinase family and is activated primarily through the ERK Kinase signalling pathways 
(Fukunaga and Hunter, 1997, Waskiewicz et al., 1997). MKNK2 is involved in the 
phosphorylation of the eukaryotic initiation factor 4E (eIF4E) and therefore plays an 
important role in translation and proliferation (Waskiewicz et al., 1997, Joshi et al., 2009). 
Activation of eIF4E by MKNK2 results in enhanced tumour proliferation in human glioma 
cells, which is attenuated when MKNK2 is silenced (Ueda et al., 2010). Silencing of GSTP1 
significantly reduces the level of MKNK2 expression in HCT116 cells in two HCT116
shGSTP1
 
clones as determined by rtPCR (Figure 5.6). Although there is a statistically significant 
difference between untreated HCT116 and HCT116
shcontrol
 cells, indicative of an effect 
mediated by the negative control plasmid, the change in expression is not great, with 
MKNK2 expression 87% to that of untreated HCT116 cells and therefore may have little 
biological significance. These data supports the means by which the microarray was 
examined and leads to an interesting hypothesis in that a reduction in MKNK2 expression as 
a result of GSTP1 silencing could potentially lead to a reduction in eIF4E phosphorylation 
resulting in reduced cell growth and proliferation, which may explain the observed decrease 
in proliferation in HCT116
shGSTP1
 cells.  
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Genes upregulated in GSTP1 shRNA 
HCT116 cells 
Genes downregulated in GSTP1 shRNA 
HCT116 cells 
Gene Name Fold difference Gene Name Fold difference 
TSC22D1 
TSC22 domain 
family 
1.2 to 1.6 
GSTP1 
Glutathione S-
transferase Pi 1 
-9.2 to -13.7 
MIR1978 microRNA 1978 
1.4 to 1.5 
MKNK2 
MAP kinase 
interacting 
serine/threonine 
kinase 2 
-1.4 to -2.5 
RGS2 
Regulator of G-
protein Signalling 2 
1.5 to 4.4 
PTK2 
Protein tyrosine 
kinase 2 
-1.3 to -2.1 
SULT1A1 Sulfotransferase 1A1 
1.4 to 1.9 
KLF2 
Kruppel-like 
factor 2 
-1.3 to -2.1 
SULT1A4 Sulfotransferase 1A4 
1.3 to 1.8 
NP 
Nucleoside 
phosphorylase 
-1.5 to -2.2 
S100A16 
S100 calcium binding 
protein A16 
1.3 to 2.6 
ATP6V1B2 
ATPase, H+ 
transporting, 
lysosomal V1 
subunit B2 
-1.4 to -1.9 
TDP1 
Tyrosyl-DNA 
phosphodiesterase 1 
1.4 to 1.7 
CYP24A1 
Cytochrome 
P450 24A1 
-1.3 to -4.7 
FXR1 
Fragile X Mental 
Retardation 
1.4 to 5.0 
TM4SF18 
Transmembrane 
4 L six family 
member 18 
-1.2 to -1.9 
ZDHHC6 
Zinc finger, DHHC-
type containing 6 
1.3 to 1.5 
ACAT1 
Acetyl-
Coenzyme A 
acetyltransferase 
1 
-1.4 to -1.7 
NQO1 
NAD(P)H 
dehydrogenase, 
quinone 1 
1.2 to 1.8 
AP3S1 
Adaptor-related 
protein complex 
3, sigma 1 
-1.3 to -2.1 
 
Table 16. Gene expression data of mRNA profiles from GSTP1 silenced HCT116 cells 
mRNA expression profiles from 2 individual HCT116
shGSTP1
 clones were compared against mRNA expression 
profiles from HCT116 (untreated) and HCT116
shcontrol
 cells (n=3) in a four-way comparison as described in 
Figure 5.5. The profiles were collaborated and the table shows genes which were either upregulated or 
downregulated similarly across each set of comparisons. The values show the range in fold difference of gene 
expression across each comparison. Probes that exhibited an adjusted P value of <0.05 are expressed. 
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5.4 Enrichment analysis of microarray studies 
In addition to examining individual changes in mRNA expression, data generated from the 
microarray was enriched to determine common molecular pathways or processes as a result 
of GSTP1 silencing in HCT116 cells. Gene enrichment of the data is separated into two 
analysis - cellular processes and cellular pathways - with two HCT116
shGSTP1
 clones 
compared against HCT116
shcontrol
 and untreated HCT116 mRNA profiles. HCT116
shcontrol
 
ontology pathways were also compared against untreated HCT116 pathways to assess any 
off-target effects. A full list of statistically significant pathways and processes are provided in 
the Appendices (II, III, IV, V). Pathways and processes which did not prove statistically 
significant but occur across multiple comparisons (as described in Figure 5.5) are also 
included in the analysis. 
 
Although many cellular processes are altered in individual HCT116
shGSTP1 
clone comparisons, 
very few processes are consistently exhibited across all possible comparisons, i.e., show the 
same pathway and process changes in each HCT116
shGSTP1
 clone compared to both 
HCT116
shcontrol 
and untreated HCT116 cells. For example, silencing of GSTP1 in HCT116 
cells induces the upregulation of a number of cellular processes related to hypoxia and 
oxidative stress, with the induction of GSTK1, MGST2 and peroxiredoxin gene expression 
common across most comparisons. However, this process is not upregulated in one particular 
comparison, HCT116
shGSTP1
 clone 2 vs HCT116
shcontrol 
cells and therefore it is uncertain if this 
pathway is of biological significance. However, changes in oxidative response pathways may 
contribute to explaining why transient or stably silencing GSTP1 in HCT116 cells induces 
levels of glutathione disulphide, as no significant changes in the mRNA of any GCL subunits 
or GS could be detected from the microarray.  
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Figure 5.6. MKNK2 mRNA expression in GSTP1 silenced HCT116 cells. 
HCT116 HCT116
control
 and HCT116
shGSTP1
 cells (n=3) were analysed for MKNK2 expression using rtPCR 
(Taqman). RNA (1µg) was synthesised to cDNA, diluted 1:80 and used in a duplex Taqman reaction using 
probes targeting MKNK2 and 18S as an endogenous loading control. ∆∆Ct values were determined from the 
analysis and are displayed as percentage of expression in comparison to untreated HCT116 cells. Values are 
represented as mean ± standard deviation, where ***P <0.001 and *P <0.05. 
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Silencing of GSTP1 does lead to the induction of a number of genes related to protein folding 
and is common across all comparisons. This is evident from the upregulation of a number of 
Hsp genes such as Hsp90 and Hsp70 and, interestingly, the upregulation of glutaredoxin. 
However, protein folding can be categorised to a large number of compartments, such as the 
endoplasmic reticulum and cytoplasm and so it is difficult to assess whether this is a general 
event or specific to certain subcellular fractions. There is also some upregulation of these 
pathways in HCT116
shcontrol
 cells when compared against untreated HCT116 cells and 
therefore the effect may be less significant. Another interesting find from examination of the 
pathway analysis is the upregulation of a number of pathways relating to fatty acid and 
catecholamine metabolism. This is largely due to the upregulation of a number of 
sulfotransferases in HCT116
shGSTP1
 cells as described previously and in Table 16. Although 
these pathways are upregulated at varying degrees across all comparisons, they may suggest a 
common mechanism by which GSTP1 may mediate cell regulation.  
 
As described in Chapter 4, transient or stable silencing of GSTP1 results in reduced 
proliferation of HCT116 cells. Examination of the enrichment data demonstrates a reduction 
in a large number of pathways related to cytoskeleton development and cell adhesion in 
HCT116
shGSTP1
 cells. A list of the cellular processes related to cytoskeleton modelling is 
highlighted in Table 17. Although a reduction in cell adhesion pathways can be detected in 
HCT116
shcontrol
 cells in comparison to untreated HCT116 cells, there is a large coverage of 
cellular processes related to cytoskeletal modification in HCT116
shGSTP1
 cells that clearly 
demonstrate a reduction in processes associated with cell mobility. This is indicative of a 
mechanism which fits well with our observed data from Chapter 4 and with data previously 
published demonstrating the role of GSTP1 in cellular proliferation (Dang et al., 2005).  
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Down regulation of cellular processes in HCT116
shGSTP1
 cells 
shGSTP1 clone 1 vs 
Untreated 
shGSTP1 clone 2 vs Untreated 
shGSTP1 clone 1 vs 
shcontrol 
shGSTP1 clone 2 vs shcontrol 
Process 
P 
value 
Process 
P 
value 
Process 
P 
value 
Process 
P 
value 
Cytoskeleton 
- Spindle 
microtubules 
5.06E
-03 
Cytoskeleton 
,Regulation of 
cytoskeleton 
rearrangement 
2.44E
-06 
Cytoskeleton 
- Actin 
filaments 
8.54E
-06 
Cytoskeleton -  
Spindle microtubules 
1.03E
-05 
  
Cell adhesion - 
Integrin-mediated cell-
matrix adhesion 
3.61E
-05 
Cell adhesion 
- Integrin-
mediated cell-
matrix 
adhesion 
1.68E
-05 
Cytoskeleton -
Intermediate filaments 
5.95E
-05 
  
Cytoskeleton - 
Intermediate filaments 
2.17E
-03 
Cell adhesion 
- Cadherins 
9.31E
-05 
Cytoskeleton - 
Cytoplasmic 
microtubules 
7.85E
-05 
  
Cytoskeleton - Actin 
filaments 
3.36E
-03 
Cytoskeleton 
- Regulation 
of 
cytoskeleton 
rearrangemen
t 
1.23E
-04 
Cytoskeleton - 
Regulation of 
cytoskeleton 
rearrangement 
1.79E
-04 
  
Cytoskeleton - 
Cytoplasmic 
microtubules 
1.08E
-02 
Cell adhesion 
- Cell 
junctions 
3.71E
-04 
Cell adhesion - 
Integrin-mediated cell-
matrix adhesion 
2.68E
-04 
  
Cell adhesion - Cell 
junctions 
1.25E
-02 
  
Cytoskeleton - Actin 
filaments 
 
7.28E
-04 
 
      
Cell adhesion - Cell 
junctions 
 
4.16E
-03 
 
 
Table 17. Enrichment analysis of downregulated processes related to cytoskeleton 
remodelling in GSTP1 silenced HCT116 cells. 
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Cellular processes related to mRNA profiles from HCT116, HCT116
shcontrol
 and 2 HCT116
shGSTP1
 clones were 
examined using Metacore software (Genego) and examined for similar ontology pathways. The table 
demonstrates downregulation of cellular processes related to cytoskeleton remodelling in HCT116
shGSTP1
 cells. 
 
In summary, chemical inhibition and targeting of molecular pathways leads to the inclination 
that GSTP1 may mediate the effects of a Hsp90 inhibitor, 17-AAG. Despite a lack of 
uniformity with other Hsp inhibitors, the role of GSTP1 in relation to the efficacy of 17-AAG 
may be an important determinant in assessing resistance in tumours. Microarray analysis of 
cells silenced for GSTP1 showed a promising correlation between their reduced proliferation 
and a number of pathways relating to changes in cellular cytoskeletal processes which 
supports our observations made from previous chapters. Furthermore, reduced MKNK2 
activity in HCT116
shGSTP1
 cells may prove one mechanism by which cellular proliferation is 
attenuated.  
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Chapter 5 (Supplementary study): Regulation of GSTP1 by p53 
Introduction 
In light of recent data describing a p53 regulatory motif in the human GSTP1 gene, the 
induction of GSTP1 by p53 was examined in addition to analysing transcriptional responses 
in response to GSTP1 silencing. As p53 is a prominent transcription factor in mediating 
cellular homeostasis, analysis of the regulatory mechanism between p53 and GSTP1 may 
lead to a better understanding of how GSTP1 can affect cell function independent of drug 
metabolism. This subchapter aims to address the role of p53 in mediating GSTP1 expression 
and later discusses a number of hypotheses with regards to the relationship between p53 and 
GSTP1. 
 
5.5 p53 
The p53 tumour suppressor is a transcription factor that is involved in the regulation of a 
number of cellular processes and maintenance of genome stability, often regarded as the 
‘guardian of the genome’ (Lane, 1992). Normally p53 is tightly regulated through its 
degradation by MDM2, an E3 ubiquitin ligase (Haupt et al., 1997). Binding of p53 to MDM2 
in the nucleus inhibits its transcription function and results in its export to the cytoplasm 
where it can be ubiquitylated (Wu et al., 1993, Ito et al., 2002). MDM2 itself is positively 
regulated by p53 and thereby creating a negative feedback for its own degradation. p53 can 
become stabilised and activated under a number of stress response pathways such as DNA 
damage (Shieh et al., 1997), heat shock (Wang and Chen, 2003), hypoxia (An et al., 1998), 
mitochondrial respiration (Matoba et al., 2006) and through the inactivation of tumour 
suppressors such as the retinoblastoma protein (Haupt et al., 1995). Typically, p53 is 
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stabilised through the phosphorylation of a number of serine residues (Siliciano et al., 1997, 
Cox and Meek, 2010) but is also subject to other post-translational modifications such as 
acetylation (Gu and Roeder, 1997). Stabilisation of p53 results in the initiation of intrinsic 
stress response pathways, resulting in the activation of a large number of downstream targets 
related to cellular arrest and apoptosis such as p21 (el-Deiry et al., 1994) and PUMA (Nakano 
and Vousden, 2001), as well as the recruitment of transcription factors such as p300/CBP 
(Avantaggiati et al., 1997). As such, p53 can be regarded as one of the principal transcription 
factors in responding to intrinsic cellular stress. 
 
p53 is mutated in 50-70% of all human cancers, with mutations often leading to inactivation 
of apoptotic pathways and activation of novel gain of function mutations. Similar to GSTP1, 
the role of p53 in human tumours is complex and is involved in multiple cellular pathways 
related to proliferation and apoptosis. A number of studies have examined the potential link 
between p53 and GSTP1 in a number of cancers (Huang et al., 2009, Schumaker et al., 2008, 
Nakanishi et al., 1999) but no mechanistic link has been proposed. In examining a possible 
relationship between these 2 proteins, Gate et al crossed Gstp1/2
-/- 
mice onto mice on a p53 
null background (p53
-/-
) and demonstrated that GSTP1 did not affect the tumour frequency on 
p53
-/-
 mice, although, as described previously, GSTP1 did affect the tumour frequency in 
mice with wild-type p53 (Gate et al., 2005). It could also be hypothesised that regulation of 
JNK activation by GSTP1 may influence the transcription of p53 which is a downstream 
target of JNK (Fuchs et al., 1998). Activation of phosphorylated c-Jun forms part of the AP-1 
complex resulting in the transcription of a number of stress response genes, including GSTP1 
which contains an AP-1 site embedded into its antioxidant response element (ARE) in its 
promoter (Figure 1.3) (Xia et al., 1991, Moffat et al., 1994, Cowell et al., 1988). It is 
interesting to note that the human GSTP1 promoter also contains a p53 regulatory motif in 
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intron 4 which has shown to be transcriptionally active (Lo et al., 2008) and therefore, like c-
Jun, p53 may act in an auto-regulatory manner with GSTP1.  
 
This supplementary chapter aims to briefly describe the transcriptional interplay between p53 
and GSTP1 in light of recent findings demonstrating further p53 regulatory motifs in the 
GSTP1 gene. 
 
Results 
5.6 Identification of further p53 regulatory motifs in the GSTP1 gene 
Bioinformatic analysis of the GSTP1 gene confirmed the presence of a p53 regulatory motif 
in intron 4 (GGGCAAGCCT) of the human GSTP1 gene as well as revealing a further p53 
motif in the 3’ non-coding region of the human GSTP1 gene (AAACATGCTT), and 
putatively in exon 3 of the mouse Gstp1 gene (AGGCTTGCTC). In order to determine 
whether GSTP1 was transcriptionally reliant on p53, the expression of GSTP1 was initially 
examined in p53 null HCT116 cells (HCT116
p53-/-
, kindly provided by Dr. Bert Vogelstein). 
As demonstrated in Figure 5.7, Western blot analysis shows that deletion of p53 does not 
reduce the protein expression of GSTP1 in HCT116 cells. In contrast, deletion of p53 induces 
protein expression of GSTP1 and the expression of GSTM1. This phenotype is specifically 
mediated by the loss of p53 as deletion of p21, a downstream target of p53, does not have a 
similar effect. The increase in GSTP1 and GSTM1 protein expression correlates well with a 
decrease in HO-1 expression in HCT116
p53-/- 
cells, indicative of a reduced oxidative stress 
response. This effect may be mediated by p53 acting as a suppressor of Nrf2-dependent 
transcription of antioxidant response genes (Faraonio et al., 2006) and therefore a lack of p53 
may enhance the transcription and expression of genes such as GSTP1 and GSTM1, leading 
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to a decrease in cellular oxidative stress, evident by the decrease in HO-1 expression. Further 
evidence to suggest that p53 does not induce the transcription of GSTP1 is demonstrated in 
that transfection of p53 into HCT116
p53-/-
 cells does not increase the expression of GSTP1. 
HCT116
p53-/-
 cells were transfected with p53 (kindly provided by Dr. David Meek, University 
of Dundee) and GSTP1 expression was analysed 24 hours later. Despite our earlier 
observations in HCT116
p53-/-
 cells, we do not observe a repression in GSTP1 levels 24 hours 
after transfection which suggests that the inhibition of GSTP1 expression by p53 may not be 
fully conclusive (Figure 5.8). However there is a notable shift in the migration of p53 on the 
Western blot, possibly as a result of a polymorphism and therefore the transfected p53, 
although wild-type, may not be endogenous to HCT116 cells. It has been demonstrated that 
an Arg72Pro substitution of p53, common within the human population, may account for 
differences in transcription (Marin et al., 2000) and therefore may account for the lack of 
GSTP1 response in this study. 
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Figure 5.7. Deletion of p53 in HCT116 cells 
HCT116, HCT116
p53-/-
 and HCT116
p21-/-
 cells were analysed for the basal expression of GSTP1. Cell lysates 
(10µg) were resolved on a SDS-PAGE gel and analysed by Western blotting. The blots demonstrate an 
induction in GSTP1 and GSTM1 expression in HCT116
p53-/- 
cells, correlating with a decrease in HO-1 
expression. 
 
Figure 5.8. Transfection of wild-type p53 does not induce levels of GSTP1 in HCT116 
cells. 
HCT116
p53-/- 
cells were transfected with increasing concentrations of p53 and analysed for GSTP1 expression 24 
hours later. Cell lysates (10µg) were resolved on a SDS-PAGE gel and analysed by Western blotting.  
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5.7 Stabilisation of p53 does not alter the expression of GSTP1 in HCT116 cells 
So far the data has examined basal expression of GSTP1 in response to deletion of p53, 
whilst p53-dependent activation of GSTP1 may only be mediated through induction of p53 in 
response to stress. Therefore the expression of GSTP1 was examined in response to a number 
of compounds which stabilise levels of p53 in HCT116 cells. HCT116
WT
 and HCT116
p53-/- 
cells were incubated with actinomycin D, cisplatin or etoposide for 8 hours and the 
expression of p53 and GSTP1 examined by Western blotting (Figure 5.9).  As expected, each 
treatment stabilises the expression of p53 in HCT116
WT
 cells but not in HCT116
p53-/-
 cells. 
However, p53 stability does not correlate with activation of GSTP1. This experiment was 
also performed after 24 hours compound incubation and still no difference could be observed 
in the level of GSTP1 expression (data not shown). A notable increase in basal GSTP1 
expression can be observed in HCT116
p53-/-
 cells, correlating with our previous findings. 
Interestingly, a notable increase in NQO1 expression can be observed in HCT116
p53-/- 
cells, 
which may provide further evidence for the induction of an antioxidant stress response in the 
absence of p53. 
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Figure 5.9. Stabilisation of p53 does not induce GSTP1 expression in HCT116 cells. 
HCT116 and HCT116
p53-/- 
cells were incubated with a number of p53 stabilising agents and the level of p53 and 
GSTP1 expression determined by Western blot analysis. Cells were incubated with Actinomycin D (25, 50, 
100nM), cisplatin (10, 20, 40µM) or etoposide (25, 50, 100µM) for 8 hours before cell lysates were prepared 
and resolved (10µg) on a SDS-PAGE gel and analysed by Western blotting. 
 
Finally, examination of p53 stabilisation on the activation or repression of GSTP1 was 
determined using a tetracycline-controlled (Tet-On) inducible p53 cell system (SAOS2/p53). 
SAOS2 cells are an osteosarcoma cell line that are null for p53 but have been transformed 
with a Tet-On vector which expresses p53 in the presence of doxorubicin (cells kindly 
provided by Dr. David Meek, University of Dundee). As demonstrated in Figure 5.10, 
treatment of SAO2 cells with doxorubicin induces the level of p53 specifically in SAOS2 
cells transfected with the Tet-On system. However, induction of p53 does not lead to the 
activation of GSTP1 after 24 hours of doxorubicin treatment. Although the levels of GSTP1 
appear to be suppressed in the presence of doxorubicin, the resting level of GSTP1 is 
markedly reduced in SAOS2/p53 cells which suggest that there may be some leakage of the 
Tet-On system. SAOS2 cells were grown in the presence of Tet-free FBS media and 
therefore it is unlikely that the culture media was responsible for any possible leakage. It is 
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also worth noting that SAOS2 cells lack a functional retinoblastoma protein (Rb) and 
therefore cannot sequester the E2F1 transcription factor which mediates cell proliferation and 
apoptosis in a p53 dependent and independent manner (Shaw and Tegtmeyer, 1981).  
Therefore, this may mask any apparent effects mediated by p53 in SAOS2 cells. 
 
 
 
 
Figure 5.10. p53 induction in a p53-tet inducible SAOS2 cell line does not induce 
expression of GSTP1. 
SAOS2/p53 cells contain an tet-inducible p53 expression vector which increases p53 expression in the presence 
of doxorubicin. SAOS2 wild-type or SAOS2/p53 cells were incubated with increasing concentrations of 
doxorubicin for 24 hours before cell lysates were prepared and resolved (10µg) on a SDS-PAGE gel and 
analysed by Western blotting. 
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In summary, this brief chapter highlights that despite the identification of further p53 
regulatory motifs in the human GSTP1 gene, a crude analysis of their regulatory function 
suggests that GSTP1 is not transcriptionally active in response to p53. Although these data 
are in contrast to those of Lo et al, they support the observations made by Faraonio et al, in 
that p53 may act to suppress the antioxidant response pathway (Faraonio et al., 2006). 
However, further work is required in order to examine this precise mechanism in relation to 
GSTP1 function. 
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6. Discussion 
The data presented in this thesis begins to describe, for the first time, the non-catalytic 
functions of GSTP1 in an in vivo model and determine its role in defining resistance to a 
well-characterised hepatotoxin, acetaminophen (APAP). The results generated define novel 
mechanisms by which GSTP1 can mediate cell regulation whilst providing contradictory 
evidence to some mechanisms suggested in the literature. This discussion aims to corroborate 
the findings against the scientific literature whilst providing an outline of how GSTP1 is 
involved in mediating cell regulation. 
 
6.1 Phenotype of Gstp1Y7F mice and role of GSTP1 in mediating acetaminophen 
toxicity 
It is clear from the data generated that the Gstp1
Y7F
 mouse harbours a GSTP1 protein devoid 
of catalytic activity. Targeting of the Tyr7 residue in vivo yields a GSTP1 protein which is 
transcribed and expressed to the same extent as its wild-type counterpart but is essentially 
catalytically inactive. Gstp1
Y7F 
mice show no activity towards ethacrynic acid whilst 
recombinant protein studies demonstrate that the Y7F protein can still bind GSH and CDNB. 
There were no compensatory changes in other GSTs within the liver and any basal 
phenotypic differences as determined by organ weight appear to be sex-related rather than 
genetic; the reasons for this at present are unexplained. Basal ratios and concentrations of 
GSH:GSSG did not differ between Gstp1
Y7F
 or Gstp1
WT
 mice and no change was evident 
when compared to Gstp1/2
-/-
mice. These observations suggest that GSTP1 is not critical in 
murine development or in the regulation of basal redox control. These results support 
previous findings associated with the deletion of GSTP1 from mice at resting levels, although 
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some subtle differences are apparent. These are mostly related to mouse strain, such as 
differences in lung size in Gstp1/2
-/- 
mice generated on a 129xMF1 background (Henderson 
et al., 1998a), which were not evident on a C57Bl/6J background.  
 
In vivo studies of GSTP1 have previously demonstrated that this enzyme forms part of an 
integrated adaptive response in maintaining cellular homeostasis following chemical and 
genetic stress. Unlike most forms of insult, the presence of GSTP1 appears to potentiate the 
hepatotoxicity of APAP in mice and therefore we investigated whether the catalytic activity 
of GSTP1 is responsible for this phenotype. The use of a non-catalytic GSTP1 mouse model 
revealed that the hepatotoxicity associated with APAP is mediated through the catalytic 
activity of GSTP1, as APAP treatment of Gstp1
Y7F
 mice does not cause serum transaminase 
induction or hepatic centrilobular necrosis. As mice nulled for GSTP1 share a similar 
phenotype with mice harbouring a Y7F mutation, it is unlikely that a non-catalytic GSTP1 
has acquired novel protective functions in the protection of APAP induced toxicity. Therefore 
the toxicity associated with APAP is most likely potentiated by the catalytic activity of 
GSTP1.  
 
There are three stages in which the catalytic activity of GSTP1 may contribute to the hepatic 
necrosis associated with APAP administration. These are described at three distinct phases of 
NAPQI induced toxicity as shown in Figure 6.1. Firstly, GSTP1 may contribute to APAP-
induced hepatic necrosis through the rapid depletion of the hepatic GSH pool, as shown in 
step 1 in Figure 6.1. In Figure 3.10A we observe a marked decrease in the rate of GSH 
depletion over that in Gstp1/2
-/- 
or Gstp1
Y7F
 mice, correlating with a quicker increase in the 
production of glutathione disulphide formation after 40 minutes of APAP treatment (Figure 
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3.10B). The catalytic properties of GSTP1 may mediate the rapid conjugation of NAPQI to 
GSH, resulting in a faster depletion of hepatic GSH and lead to a quicker onset of subsequent 
mechanisms responsible for hepatic necrosis. The reduced rate of GSH depletion in other 
mouse lines may allow time for a comprehensive response in antioxidant and detoxification 
pathways which are not apparent in Gstp1
WT
 mice. However, it has been demonstrated using 
diethylmaleate that depletion of GSH itself is not sufficient to induce tissue damage (Mitchell 
et al., 1973) whilst others have shown wide variation of hepatocellular damage using a 
variety of GSH depleting agents (Kitteringham et al., 2000) and therefore further downstream 
mechanisms associated with NAPQI must account for the subsequent necrosis. This becomes 
apparent when examining the level of GSH depletion in Gstp1/2
-/- 
and Gstp1
Y7F
 mice, as 
despite a slower rate of GSH depletion, there is no difference in the level of GSH after 90 
minutes when compared to Gstp1
WT
 mice. As there does not appear to be any difference in 
the level of covalent binding of GSH to APAP or differences in cytochrome P450 2E1 
between genotypes (Henderson et al., 2000), GSTP1 mediated conjugation of NAPQI does 
not appear to be a likely mechanism by which GSTP1 potentiates hepatic necrosis. 
 
The second stage centres on the function of GSTP1 when GSH levels are minimal (point 2, 
Figure 6.1). At this time point, there are very few differences in phenotype across all 
genotypes as determined by MAP Kinase activation, GSSG levels and oxidative stress. 
Despite this, there are clear differences in these parameters, with the exception of oxidative 
stress, subsequent to GSH depletion. This, therefore, appears to be the key time point at 
which APAP resistance is mediated in the absence of a catalytically functional GSTP1. 
Despite few compensatory changes in hepatic protein expression at resting levels in Gstp1/2
-/- 
mice (Kitteringham et al., 2003), APAP-induced toxicity may elicit a stronger response in 
compensatory changes, particularly at a time point when GSH depletion is maximal and 
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oxidative stress is high. Future experiments would include proteomic analysis of mouse liver 
at the point of maximal GSH depletion. This would be complemented with the use of 
microarray profiling at this time point, as 40-90 minutes post-APAP dosing may be too early 
a time point to identify changes in protein expression, but would provide a detailed 
transcriptional response to APAP as well as an understanding of the biological processes 
taking place. Although the covalent binding of NAPQI does not differ between Gstp1
WT 
and 
Gstp1/2
-/-
 mice at non-toxic doses, it would be interesting to determine if the distribution of 
this metabolite is a factor in mediating differences to APAP toxicity through the use of 
radiolabelled APAP.  
 
The final stage involves the regulation of cellular pathways after GSH pools have been 
depleted (highlighted at point 3 in Figure 6.1). There are clear biochemical differences in a 
number of assays measured between Gstp1
WT
 and Gstp1/2
-/-
/Gstp1
Y7F 
mice 240 minutes after 
APAP dosing, including the activation of MAP Kinase pathways (Figure 3.11) and levels of 
hepatic GSH (Figure 3.10A). As the maximal level of GSH depletion is similar across all 
genotypes, it could be reasoned that functions of a catalytic GSTP1 contributing to cellular 
necrosis occur only after maximal depletion of GSH. Whether or not the mechanism by 
which GSTP1 potentiates this effect is a continuation of those discussed in the second stage 
(point 2, Figure 6.1) or is a separate function subsequent to GSH depletion is unclear. It 
would also be interesting to determine if the mechanism underlying the resistance mediated 
in Gstp1/2
-/-
 and Gstp1
Y7F
 mice is sustained throughout the entire time course or whether an 
acute functional response after GSH depletion is necessary to avoid toxicity.  
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Figure 6.1. Schematic figure outlining the route to hepatic necrosis from acetaminophen 
(APAP) overdose in mice. 
From the data generated in Chapter 3, APAP administration to mice (300mg/kg, oral dose) induces hepatic 
necrosis through a series of mechanistic pathways involving the catalytic activity of GSTP1. The precise 
mechanism in which the catalytic activity of GSTP1 mediates these effects is not yet determined but 3 
hypotheses have been suggested. There are numbered in the diagram and outlined in the text. 
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6.2 Mechanisms of GSTP1 mediated acetaminophen induced toxicity 
6.2.1 Oxidative stress and inflammation 
The stages highlighted in Figure 6.1, although alluding to the process of APAP-induced 
toxicity and the kinetics of GSTP1 association with APAP, do not provide an accurate 
account of the mechanism by which GSTP1 can potentiate APAP toxicity. It is therefore 
important to assess the likely mechanisms surrounding APAP toxicity and discuss the wider 
implications of GSTP1-mediated cell regulation in light of the data presented in this thesis. In 
contrast to many previous publications, the mechanism behind APAP toxicity appears to be 
independent of oxidative stress. There is no apparent difference in the levels of glutathione 
disulphide or HO-1 after 90 minutes APAP administration, the time points at which we begin 
to observe GSH regeneration and silencing of MAP Kinase pathway in Gstp1/2
-/- 
and 
Gstp1
Y7F
 mice (Figure 3.10B and Figure 3.11). After 24 hours of APAP treatment, HO-1 
expression could be observed surrounding the centrilobular regions in Gstp1
Y7F
 and Gstp1/2
-/-
 
mice and therefore the level of oxidative stress is not indicative of the severity of toxicity. 
This finding supports unpublished data from Gstp1/2
-/-
 mice crossed onto mice carrying a 
HO-1 reporter transgene treated with APAP (Vasey, Henderson, unpublished). LacZ is fused 
to the C-terminus of HO-1, induction of which results in the expression of both HO-1 and 
lacZ, which can be identified using ß-galactosidase staining. APAP treatment of these mice 
demonstrates ß-galactosidase staining around the centrilobular regions of Gstp1/2
-/-
 mice and 
around the ‘necrotic rings’ in Gstp1WT mice (Figure 6.2), which is in agreement with our 
observations of HO-1 induction by APAP.  
 
There are a number of studies highlighting an inflammatory response to APAP treatment 
which demonstrate an up-regulation of a number of pro-inflammatory markers and pathways 
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such as TNF (Blazka et al., 1995b) and IFNγ (Ishida et al., 2002). However, there are some 
contradictions to these observations (Boess et al., 1998), highlighting the complex nature of 
inflammation in APAP induced toxicity. The observation that GSTP1 can potentiate 
myeloproliferation in mice generated on a mixed background may provide an insight into 
potential inflammatory response which may account for these observations (Gate et al., 
2004). However, data generated but not published in this thesis show that, in C57/Bl6J mice, 
there is no difference in the level of myeloproliferation between Gstp1
WT 
and Gstp1/2
-/-
 mice, 
and therefore is unlikely to account for differences in APAP toxicity. Additionally, there are a 
number of studies which suggest that inflammation is suppressed in Gstp1
WT
 mice compared 
to Gstp1/2
-/-
 mice (Ritchie et al., 2009, Henderson et al., 2011) and therefore the mechanism 
behind APAP resistance in Gstp1/2
-/-
 mice is unlikely to be related to inflammation.  
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Figure 6.2. APAP treatment induces HO-1 expression in Gstp1
WT
 and Gstp1/2
-/-
 mice 
Gstp1
WT 
and Gstp1/2
-/- 
mice crossed onto mice harbouring a HO-1 lacZ reporter transgene were administered a 
single oral dose of 300mg/kg APAP and harvested 24 hours later. Livers were removed and frozen before cut 
into 15µm sections and stained using ß-galactosidase to determine the expression of HO-1. Data kindly provided 
by Dr. Douglas Vasey and Dr. Colin Henderson. 
 
6.2.2 GSTP1 mediated MAP Kinase regulation 
Similarly, the role of GSTP1 in inhibiting JNK activity does not appear to account for the 
differences in APAP toxicity. APAP treatment in mice has been shown to increase AP-1 
binding to DNA through the increased phosphorylation of c-Jun (Kitteringham et al., 2000) 
and is up-regulated during tissue necrosis but not hepatic inflammation (Blazka et al., 1996) 
leading to the release of inflammatory mediators (Blazka et al., 1995a). Despite a number of 
studies highlighting the role of GSTP1 in inhibiting the phosphorylation of c-Jun through 
JNK inhibition, no propagation of JNK activity could be observed in Gstp1/2
-/-
 mice 
Discussion 
 
197 
 
compared to Gstp1
WT
 mice after APAP administration and therefore does not adhere to the 
conventional theory that deletion of GSTP1 leads to increased JNK activation. However, the 
noticeable increase in JNK phosphorylation in Gstp1
WT 
mice agrees with many published 
data, highlighted in Chapter 3, that JNK activation is required for tissue necrosis in response 
to APAP treatment. The observation that ERK activation is also increased in Gstp1
WT 
mice, 
suggests a general activation of the MAP Kinase pathway, independent of specific GSTP1 
regulation of JNK.  It is also interesting that there is little difference in the level of JNK/ERK 
activation between Gstp1
WT
 and Gstp1
Y7F
 mice, despite a large difference in the sensitivity to 
APAP. Firstly, this highlights that the catalytic function of GSTP1 is not necessary in 
mediating signalling through MAP Kinase cascade. This is supported through a study by 
Adler et al who established that GSTP1 binding of JNK is established on residues other than 
Tyr7 (Adler and Pincus, 2004). It is also interesting that the localisation of ERK activation is 
similar in Gstp1
WT
 and Gstp1
Y7F
 mice i.e., centrilobular. This, along with the observation that 
HO-1 expression localises to similar regions, highlights an interesting observation in the 
specificity of the hepatic expression of these genes. Secondly, it also suggests that JNK/ERK 
activation may not be the dependent factors in establishing hepatic necrosis. There are a 
number of studies which show a decrease in NF-κB binding associated with APAP toxicity 
(Chia et al., 2010, Blazka et al., 1995a) suggesting that a multi-transcriptional response is 
responsible for the development of tissue necrosis in response to APAP. Therefore, despite 
their similar phenotype in mediating cell regulation, the catalytic function of GSTP1 is 
contributing to the toxicities associated with APAP independently of MAP Kinase regulation. 
 
Further evidence to support mechanisms of cell regulation other than JNK regulation by 
GSTP1 is demonstrated in HCT116 cells silenced for GSTP1, as evident in Chapter 4. 
Silencing of GSTP1 did not induce changes in the level of JNK phosphorylation or that of c-
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Jun, even after UV treatment, suggesting that GSTP1 must have cellular functions other than 
JNK inhibition. Adler et al demonstrated that the amino acid residues Ile105 and Ala114, 
mutations of which confer the different polymorphisms of GSTP1, are crucial for binding of 
GSTP1 to JNK (Adler and Pincus, 2004), while Holley et al demonstrated different levels of 
JNK activity between the 2 haplotypes GSTP1*A and GSTP1*C (Holley et al., 2007). Recent 
data also suggest that GSTP1 mediates its regulation of JNK through an interaction with 
activating transcription factor 2 (ATF2) (Thevenin et al., 2011). Differences in the affinity of 
the GSTP1*B polymorphism, identified in HCT116 cells, for JNK or ATF2 may explain a 
lack of JNK regulation mediated by GSTP1 in this cell line. Microarray analysis of cells 
stably silenced for GSTP1 did not show any significant changes in the expression of 
transcription targets downstream of JNK, such as c-Fos, c-Jun and ATF2, correlating with a 
lack of JNK mediated signalling. However, it is interesting to note that HCT116 cells are 
heterozygous for a mutation in KRAS (Brink et al., 2003), activation of which has been shown 
to regulate members of the MAP Kinase pathway (Dunn et al., 2011, Weinberg et al., 2010) 
and therefore it is feasible that KRAS activation could ameliorate any relationship between 
GSTP1 and JNK due to sustained oncogenic signalling.  
 
6.2.3 Novel functions of GSTP1 mediated signalling 
The recent identification of two novel functions of GSTP1 may provide a clear insight into 
APAP induced hepatotoxicity. Firstly, there are numerous studies relating acetaminophen 
induced toxicity with a deregulation in the chelation of iron and nitric oxide production. The 
reduction of peroxides by ferrous irons occurs via a Fenton mechanism, leading to the 
production of radical species which increase with APAP toxicity and interact with a number 
of lipids and proteins. The addition of an iron chelator to cultured hepatocytes prevents 
acetaminophen toxicity (Kyle et al., 1987) and it has been shown that incubation with the iron 
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donor 3,5,5-trimethyl-hexanoyl ferrocene increases APAP associated toxicities without 
inducing basal changes in ROS, mitochondrial function or oxidative stress (Moon et al., 
2010). A recent study by Lok et al has shown that GSTP1 binds to dintrisosyl-iron complexes 
(DNICs) in regulating intracellular levels of nitric oxide and iron release, preventing their 
efflux from cells via the multidrug resistance protein 1 (Lok et al., 2012) whilst another study 
by Cesareo et al demonstrated that Tyr7 was the key residue in targeting the iron atom 
(Cesareo et al., 2005). It could be hypothesised that the prevention of DNIC efflux in 
hepatocytes, as a result of GSTP1 sequestering, leads to the accumulation of iron and nitric 
oxide within the cell, which in turn contributes to hepatic necrosis through the generation of 
peroxide radicals such as peroxynitrite. In Gstp1/2
-/- 
and Gstp1
Y7F
 mice, DNICs are not 
sequestered by GSTP1 in the cell and therefore DNIC accumulation is attenuated. There are 
some concerns with this model as it has been proposed that DNIC regulation by GSTP1 acts 
to suppress the toxicities associated with DNIC as a NO carrier and has been demonstrated to 
increase the resistance of cells against GSNO in collaboration with MRP1 (Lok et al., 2012). 
Increased efflux of DNIC in Gstp1/2
-/- 
and Gstp1
Y7F
 mice may lead to increased extracellular 
nitric oxide release which could potentially lead to inflammation and toxicity, which are not 
observed in these mice after APAP treatment. It has been observed that inhibition of GSH 
prevents NO-mediated iron release through the DNIC complex (Watts and Richardson, 2001) 
and therefore any level of discrepancy between GSTP1-mediated sequestering of NO may be 
ameliorated when GSH levels are depleted due to APAP treatment. DNICs have also been 
shown to inhibit the activity of glutathione reductase via nitrosation (Boese et al., 1997) while 
the presence of GSTs protects glutathione reductase and restores its activity (Pedersen et al., 
2007). Therefore one would expect differences in the ratio of GSH:GSSG if glutathione 
reductase is unable to reduce glutathione disulphide. This may be evident 40 minutes after 
APAP treatment (Figure 3.10B) but the difference is soon lost 90 minutes after APAP 
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treatment  and therefore unlikely that the role of GSTP1 in mediating DNIC efflux is a 
coherent mechanism by which APAP sensitivity is propagated in vivo.  
 
The second mechanism of GSTP1 function related to APAP-induced toxicity examines its 
role in protein S-glutathionylation and GSH homeostasis. The inability of Gstp1
WT
 mice to 
regenerate hepatic GSH levels after APAP treatment appears to be the predominant factor 
contributing to hepatic necrosis. Increased hepatocyte death/injury after treatment with APAP 
would lead to a reduction in the number of viable cells able to synthesise GSH which may 
account for the inability of Gstp1
WT
 mice to regenerate hepatic GSH. The lack of hepatic 
injury in Gstp1/2
-/-
 and Gstp1
Y7F
 mice enables hepatocytes to regenerate GSH although the 
precise mechanism by which these mice develop APAP resistance remains unclear. Our in 
vitro data from HCT116 cells suggests that GSTP1 appears to play a role in GSH 
homeostasis as transient or stable silencing of GSTP1 results in increased glutathione 
disulphide formation. Despite a lack of change in redox state basally in vivo, it is clear that 
GSTP1 plays a role in redox regulation, particularly in response to stress. As a colon 
carcinoma cell line, HCT116 cells possess a number of activated oncogenic and stress-related 
signalling pathways which are not activated basally in vivo and therefore may account for the 
differences in redox state between models. A key experiment to assess the role of GSTP1 in 
the glutathione homeostasis would be to treat Gstp1
WT
, Gstp1/2
-/-
 and Gstp1
Y7F
 mice with a 
GSH-depleting agent which does not induce hepatic toxicity and evaluate the rate of GSH 
regeneration. In this way, the role of GSTP1 is specifically controlled for the regulation of 
GSH homeostasis and not in the detoxification of a hepatotoxin. In Gstp1
WT
 mice, a single 
i.p. dose of BSO (4mmol/kg) results in 60% depletion of hepatic GSH levels over a 4 hour 
period and fully regenerates after 24 hours without inducing changes in serum transaminase 
levels (data not shown). If the function of GSTP1 is intrinsically related to GSH homeostasis 
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and independent of hepatic toxicity, we should observe a quicker regeneration of hepatic 
GSH in the absence of a catalytically functioning GSTP1.  
 
As described previously in Chapter 4, GSTP1 has been shown to catalyse global protein S-
glutathionylation in response to oxidative and nitrosative stress and is dependent on its Tyr7 
residue to mediate this effect (Townsend et al., 2008a). Based on this finding alone, one 
would hypothesise that more proteins would be S-glutathionylated in Gstp1
WT
 mouse 
hepatocytes in response to APAP treatment than in Gstp1/2
-/-
 and Gstp1
Y7F 
mouse 
hepatocytes. S-glutathionylation is thought to be a protective mechanism against oxidative 
stress while the majority of S-glutathionylation reactions lead to reversible inhibition of 
protein activity. Therefore it is conceivable that if a protein critical in the regeneration of 
GSH synthesis, for example GCL, is S-glutathionylated, its catalytic activity may be inhibited 
and glutathione regeneration cannot occur. However, Yang et al demonstrated that S-
glutathionylation of cellular proteins decreases in areas of hepatic damage induced by APAP, 
with unaffected areas exhibiting high levels of protein S-glutathionylation (Yang et al., 
2012). In Chapter 4, it was demonstrated that transient knockdown of GSTP1 in HCT116 
cells, induced basal levels of protein S-glutathionylation. From these data, one could 
hypothesise that Gstp1/2
-/-
 and Gstp1
Y7F
mice retain high levels of protein S-glutathionylation 
in response to APAP treatment resulting in the protection of protein thiols from labile ipso 
NAPQI adduct formation. If the proposed GSTP1:DNIC model (see earlier) is correct, then in 
vivo nitric oxide unscavenged by GSTP1 may, instead of causing toxicity, act as an 
intermediate for S-glutathionylation through the S-nitrosylation of cellular proteins. 
Generation of mouse hepatocytes would provide an incredibly powerful tool in examining 
this potential mechanism by which GSTP1 mediates sensitivity to APAP, as the in vitro 
methods used to detect protein S-glutathionylation outlined in Chapter 4 could be applied. 
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BioGEE incubation of hepatocytes and subsequent mass spectrometric analysis would enable 
the identification of proteins specifically S-glutathionylated after APAP treatment. Not only 
would this further our understanding of the role of GSTP1 in mediating S-glutathionylation in 
response to stress, but may also provide a ‘footprint’ of proteins which are subject to S-
glutathionylation in mediating a response to APAP treatment as very few in vivo methods of 
examining S-glutathionylation have resulted in the identification of proteins modified in such 
a manner. 
 
6.3 GSTP1 does not act as a catalyst in protein S-glutathionylation in HCT116 cells 
The data presented here are in contrast to those published by Townsend et al (Townsend et 
al., 2008a), on the role of GSTP1 in the S-glutathionylation of cellular proteins as transient 
silencing of GSTP1 increased basal levels of protein S-glutathionylation in HCT116 cells. 
This is possibly due to the induction of glutathione disulphide formation within the cell, 
leading to increased protein S-glutathionylation through disulphide exchange. The 
observation that HCT116 cells stably silenced for GSTP1 showed increased glutathione 
disulphide formation but no change in protein S-glutathionylation suggests that this 
mechanism may not be universal. However, the observation that glutathione disulphide levels 
are increased in both transient and stable cell lines demonstrates that GSTP1 has a functional 
role in glutathione homeostasis in vitro. Despite a reduction in protein S-glutathionylation in 
the presence of an iNOS inhibitor, some recent data suggest that there may be a role for 
nitrosylated proteins to act as a precursor to S-glutathionylation in this context. Using a 
biotin-switch protocol, in which nitrosylated bonds are reduced using ascorbate and 
subsequently labelled with a thiol-specific biotin reagent (Jaffrey and Snyder, 2001, Forrester 
et al., 2009), we can show that there is an increase in the amount of nitrosylated proteins in 
HCT116 cells transiently silenced for GSTP1 (Appendices VI) although further work is 
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required to verify this. Another possibility is that a reduction in the deglutathionylation of 
cellular proteins allows for the accumulation of S-glutathionylated proteins in response to 
GSTP1 silencing, such as the inhibition in the activity or transcription of glutaredoxin. 
However, the observation that glutaredoxin mRNA is upregulated in stable GSTP1 silenced 
HCT116 cells suggests that this may not be the case. It is possible that GSTP1 itself may act 
to reduce S-glutathionylation through the removal of thiol groups from proteins. As described 
in the Introduction, the N-terminal fold domain of GSTP1 contains a βαβαββα motif, similar 
to that of the thioredoxin family of enzymes, and therefore it is conceivable that GSTP1 may 
possess similar reduction properties which are conserved through evolution. However, it is 
unclear what the kinetics of such a reaction would be and what type of co-factors would 
contribute to the reaction. Similarly to the glutathione disulphide model, as no difference in 
S-glutathionylation was observed in stable knockdown cells such a mechanism may not be 
universal.  
 
A more likely mechanism for the transient induction of S-glutathionylation is related to 
changes in the oxidation state of the cell. Treatment of BSO in HCT116 cells induced a 1.5 
fold increase in ROS production in HCT116 cells silenced for GSTP1, leading to a large 
increase in protein S-glutathionylation. Although we could not detect any changes in NQO1 
or HO-1 induction in GSTP1-silenced cells, protein S-glutathionylation is a transient 
response to prevent oxidation of cysteine groups and therefore it is feasible that the S-
glutathionylation of cellular proteins occurs before a stress response signal is observed. 
Kinetically, this is favourable as less energy is required for the conjugation of thiol groups 
with a glutathionyl anion compared to the transcription and translation of new proteins. One 
can account for the observations of Townsend et al through this mechanism as PABA/NO, 
the compound used to induce nitrosative stress and S-glutathionylation in their study, is more 
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cytotoxic to Gstp1
WT
 MEFs than to Gstp1/2
-/- 
MEFs (Townsend et al., 2006) and therefore the 
increase in protein S-glutathionylation may be as a result of increased cytotoxicity and not as 
a function of GSTP1. However, the fact that GSTP1 can facilitate the conjugation of GSH 
with other xenobiotic compounds suggests that it may facilitate the conjugation of GSH in 
certain conditions. If this is true, an interesting question is whether GSTP1 can solely 
facilitate this process or if this is a function of all cytosolic GST classes; if there are 
differences between GST classes, what accounts for these differences? 
 
Protein S-glutathionylation in this thesis has shown to protect cells from the alkylating effects 
of N-ethylmaleimide and contributes further to the concept that S-glutathionylation plays a 
functional role in the protection of thiol groups. Interestingly, p53 has also been shown to be 
S-glutathionylated in the presence of oxidative stress, conferring a functional change in vitro 
which reduces its ability to bind to DNA (Velu et al., 2007). This observation has been 
supported in vivo, where S-glutathionylation of p53 in Alzheimer’s disease is thought to 
prevent its formation as a tetramer due to the high level of oxidative species often associated 
with the disease (Di Domenico et al., 2009). The data provided in Sub-chapter 5, may allude 
to a cellular function of this mechanism. Despite identifying further p53 regulatory motifs in 
the 3’ non-coding region of the human GSTP1 gene, and putatively in exon 3 of the mouse 
Gstp1 gene, we could not find any evidence in HCT116 or SAOS2 cells that the motifs are 
transcriptionally active. In the absence of p53, we observe an increase in a number of ARE-
regulated genes which is agreeable with those observations made by Faraonio et al (Faraonio 
et al., 2006). One could hypothesise that in times of oxidative stress, S-glutathionylation 
results in the inactivation of p53, allowing for the activation (via Nrf2) of a number of 
antioxidant response genes in order to combat cellular stress, without inducing cellular arrest 
or apoptosis. If there are conditions in which S-glutathionylation is catalysed by GSTP1 or 
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indeed reduced, this may have serious implications associated with p53 cell regulation, 
particularly in cancer where GSTP1 is often over-expressed, or where pharmacological 
agents act to inhibit GSTP1 function.  
 
6.4 GSTP1 as a potential regulator of the Hsp90 pathway 
The hypothesis relating protein S-glutathionylation to p53 function was difficult to interpret 
in our in vitro culture system as stable knockdown of GSTP1 did not induce changes in 
global protein S-glutathionylation. Additionally, knockdown of GSTP1 did not appear to 
induce large differences in sensitivity to a number of cytotoxic compounds in HCT116 cells 
with only a few compounds increasing the sensitivity of HCT116
shGSTP1
 cells. The increased 
sensitivity of these cells to the Hsp90 inhibitor 17-AAG is complex to describe, especially as 
a number of Hsp90 related pathways appear upregulated in HCT116
shGSTP1
 cells and another 
Hsp90 inhibitor, NVP-AUY922, did not show any difference in cytotoxicity. However, a 
relationship between GSTP1 and Hsp90 may exist as a result of their regulation from a 
family of serine protease inhibitors known as Maspin. Maspin has been shown to upregulate 
the expression of GSTP1 through inhibition of histone deacetylase 1, resulting in 
demethylation of the GSTP1 promoter (Li et al., 2011). Subsequent expression of GSTP1 
confers resistance to oxidative stress induced by H2O2 as well as increases maspin-mediated 
HDAC1 inhibition. The Li group have also speculated that Maspin can inhibit HDAC1-
mediated Hsp90 deacetylation as Maspin has been found to bind to Hsp90 (Yin et al., 2005) 
and therefore a possible link may exist whereby the extent of Hsp90 deacetylation is 
dependent on the expression of GSTP1. The use of 17-AAG clinically may be difficult to 
justify in tumours containing low expression of GSTP1 as a phase II trial of patients with 
metastatic, hormone-refractory prostate cancer, demonstrated that 17-AAG did not appear to 
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decrease the levels of prostate-specific antigen (PSA), a marker of prostate cancer (Heath et 
al., 2008).  
 
6.5 GSTP1 localisation and function within the mitochondria 
Previous data generated from cancer cell lines overexpressing recombinant GSTP1 suggests 
that GSTP1 confers resistance to a number of mitochondrial toxins by reducing the oxidative 
stress within the mitochondria (Goto et al., 2009) and therefore may play a role in the 
protection of hepatocytes against APAP toxicity. Although some evidence generated from the 
microarray profiling suggested that HCT116
shGSTP1
 cells had higher basal levels of oxidative 
stress, H2O2 treatment of these cells did not show any significant difference in cytotoxicity 
from control cells (data not shown). The data presented here demonstrates that GSTP1 can 
localise to the mitochondria, although its function is still unclear. Although there is a slight 
trend provided in Chapter 4 demonstrating decreased resistance to rotenone treatment in 
HCT116
shGSTP1
 cells, there is little significant data provided in this thesis to support the role 
of GSTP1 in mediating protection of the mitochondria against toxins. The function of other 
GST classes within the mitochondria, such as GST Kappa (Harris et al., 1991) and GST 
Alpha (Raza et al., 2002) may compensate for the loss of GSTP1, especially as its expression 
within the mitochondria is very low compared to other cellular compartments. Further data 
demonstrates that the presence of a catalytic GSTP1 protein does not appear to confer 
resistance to rotenone in MEFs, although interestingly, MEFs expressing GSTP1 or its non-
catalytic derivative respire at a higher rate than compared to Gstp1/2
-/- 
MEFs. Despite 
respiring at a lower basal rate, mitochondria from Gstp1/2
-/- 
MEFs appear to be driven harder 
in the presence of a mitochondrial uncoupling agent, DNP, than mitochondria from Gstp1
WT 
or Gstp1
Y7F 
MEFs. The low level of glycolysis in Gstp1/2
-/-
 MEFs, even after induction with 
DNP suggests that GSTP1 localisation within the mitochondria may aid in MEFs 
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preferentially undertaking glycolysis than oxidative phosphorylation, and that this effect can 
be mediated non-catalytically. This is a difficult concept to prove from the data generated, as 
we could not repeat this finding in HCT116 cells silenced for GSTP1. As the technology and 
interpretation for establishing mitochondrial respiration and glycolysis is relatively new, 
more optimisation is required using a number of mitochondrial toxins to examine the exact 
mitochondrial function of GSTP1. There is evidence from Yeast two-hybrid studies to 
suggest that GSTP1 can interact with a number of mitochondrial proteins, particularly ETFα; 
however we could not find any evidence for this through immunoprecipitation of GSTP1-
tagged constructs. Further experiments utilising mass spectrometric profiling of 
immunoprecipitated proteins are required to establish the role of GSTP1 in the regulation of 
cellular proteins. This would be performed under a number of different cellular stressors such 
as mitochondrial, oxidative, ER and DNA damaging agents so as to establish how GSTP1 
regulates cell function in response to stress. 
 
6.6 Proliferation of HCT116 cells is mediated by GSTP1 
GSTP1 has previously been demonstrated to be an important factor in cellular proliferation. 
Transient or stable silencing of GSTP1 reduces the growth rate of HCT116 cells, and the 
mechanism by which this occurs is independent of JNK signalling. This function appears to 
be specifically mediated in tumour cells as primary Gstp1/2
-/- 
MEFs, in contrast, show a 
higher proliferation rate than their wild-type counterparts (Ruscoe et al., 2001). Therefore it is 
likely that growth signalling mediated by GSTP1 in tumour cells is a secondary mechanism 
to a change in cellular function in the development of cancer. The finding of a down-
regulation in MKNK2 expression in HCT116
shGSTP1
 cells may account for the reduced 
proliferation and a down-regulation of a large number of pathways related to cytoskeleton 
formation. Down-regulation of MKNK2 leads to a reduction of eIF4E phosphorylation 
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resulting in reduced mRNA translation and cell proliferation (Ueda et al., 2010). The 
microarray also identified Regulator of G-protein Signalling 2 (RGS2) as up-regulated in 
HCT116
shGSTP1 
cells. RGS proteins negatively regulate G-protein-coupled receptor signalling 
by binding to active G protein alpha subunits leading to reduced signal transduction (Chen et 
al., 2000a, Heximer et al., 1997). RGS2 has been shown to inhibit glucose-induced cAMP 
signalling (Tseng and Zhang, 1998) and regulates T-cell proliferation and IL-2 production 
(Oliveira-Dos-Santos et al., 2000). While studies show that RGS2 is overexpressed in certain 
types of cancer (Boelte et al., 2011) RGS2 mRNA expression has been found down-regulated 
in colon cancer and associated with poor survival (Jiang et al., 2010), highlighting a potential 
relationship between GSTP1 expression and the expression of RGS2. Together, these data 
suggest that GSTP1 plays a key role in the proliferation of cancer cells through the regulation 
of a number of proteins involved in cell growth, although the nature of the relationship 
between these proteins remains to be determined. 
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7. Conclusions 
The data presented in this thesis clearly demonstrate that the function(s) of GSTP1 extends 
well beyond enzymology and is independent of its catalytic activity. There are many 
examples from the literature of how GSTP1 can mediate cell function and it is clear from this 
thesis that the functions of GSTP1, other than drug metabolism, appear to be context- and 
stress-dependent. The development of an in vivo model to demonstrate the non-catalytic role 
of GSTP1 is of great importance in understanding how this enzyme regulates cellular 
processes. One of the strengths of the data presented is that, for the first time, a clear 
relationship has been demonstrated in vivo between the catalytic activity of GSTP1 and 
cellular toxicity, independent of drug metabolism. Interestingly, there appears to be overlap 
between the catalytic and non-catalytic roles of GSTP1 protein relating to mitochondrial 
function, oxidative stress and MAP kinase regulation in vivo, highlighting a diverse set of 
pathways by which GSTP1 can operate. However, these functions are limited to only a few 
specific stress conditions and so further work is required to assess the application of these 
mechanisms to other stressors and disease states such as cancer, where GSTP1 over-
expression is often associated. The use of hepatocytes derived from transgenic mice would 
provide a powerful tool in examining further roles of GSTP1 in applying novel in vitro assays 
to address in vivo functions. The limitations of the in vitro culture system used in this thesis 
are related to tumour and species type, therefore a universal function of GSTP1 may not be 
evident from the data presented. Despite this, a lack of conformity with a number of 
publications relating to GSTP1 function highlights the need to address cellular mechanisms 
other than those commonly associated with GSTP1 such as kinase regulation. There is much 
evidence provided in this thesis to suggest GSTP1 can mediate glutathione homeostasis 
although the extent to which GSTP1 is active in sulfhydryl homeostasis is unclear. The use of 
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novel in vitro assays has developed our understanding of the pathways mediated by GSTP1 
and the effect, either direct or indirect, this has on cell regulation. Lastly, the data presented 
in this thesis suggest a novel role for GSTP1 in cytotoxicity. The use of a non-catalytic 
GSTP1 mouse provides an exciting in vivo model to further the understanding of this protein 
in cellular defence and provides an innovative system for investigating cellular regulation by 
GSTP1 in the aetiology of disease and toxicity. 
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8. Appendices 
 
Target Dilution Clonality Source 
Actin 1:1000 Rabbit polyclonal Sigma 
ETF alpha 1:1000 Mouse monoclonal Abcam 
GAPDH 1:5000 Rabbit polyclonal Sigma 
GFP 1:2000 Rabbit polyclonal Santa-Cruz 
GSTA1 1:1000 Rabbit polyclonal 
Prof. John Hayes 
(University of Dundee) 
GSTM1 1:1000 Rabbit polyclonal 
Prof. John Hayes 
(University of Dundee) 
GSTP1 1:2000-1:5000 Rabbit polyclonal 
Dr Kenny Ritchie 
(John Moore University, 
Liverpool) 
HO-1 1:1000 Rabbit polyclonal Abcam 
LDH 1:1000 Goat polyclonal Abcam 
MnSOD 1:1000 Rabbit polyclonal Novus Biologicals 
NQO1 1:1000 Goat polyclonal Abcam 
p21 1:1000 Rabbit polyclonal Santa-Cruz 
p53 (DO-1) 1:1000 Mouse monoclonal Santa-Cruz 
p-ERK/ERK 1:1000 Rabbit polyclonal Cell signalling 
p-JNK/JNK 1:1000 Rabbit polyclonal Cell signalling 
p-Jun 1:1000 Rabbit polyclonal Cell signalling 
PrdxVI 1:1000 Rabbit polyclonal Cell signalling 
Streptavidin-HRP 1:1000-1:2000 Rabbit polyclonal Cell signalling 
 
Appendices I. A description of the antibodies used in this thesis.
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Genes upregulated in GSTP shRNA HCT116 
cells 
 
Genes downregulated in GSTP shRNA HCT116 
cells 
 
Gene Name Fold difference Gene Name Fold difference 
TSC22D1 TSC22 domain family 1.2 to 1.6 GSTP1 Glutathione S-transferase Pi -9.2 to -13.7 
MIR1978 microRNA 1978 1.4 to 1.5 MKNK2 
MAP kinase interacting 
serine/threonine kinase 2 
-1.4 to -2.5 
RGS2 Regulator of G-protein Signalling 2 1.5 to 4.4 PTK2 Protein tyrosine kinase 2 -1.3 to -2.1 
SULT1A1 Sulfotransferase 1A1 1.4 to 1.9 KLF2 Kruppel-like factor 2 -1.3 to -2.1 
SULT1A4 Sulfotransferase 1A4 1.3 to 1.8 NP Nucleoside phosphorylase -1.5 to -2.2 
S100A16 S100 calcium binding protein A16 1.3 to 2.6 ATP6V1B2 
ATPase, H+ transporting, 
lysosomal V1 subunit B2 
-1.4 to -1.9 
TDP1 Tyrosyl-DNA phosphodiesterase 1 1.4 to 1.7 CYP24A1 Cytochrome P450 24A1 -1.3 to -4.7 
FXR1 Fragile X Mental Retardation 1.4 to 5.0 TM4SF18 
Transmembrane 4 L six family 
member 18 
-1.2 to -1.9 
ZDHHC6 Zinc finger, DHHC-type containing 6 1.3 to 1.5 ACAT1 
Acetyl-Coenzyme A 
acetyltransferase 1 
-1.4 to -1.7 
NQO1 NAD(P)H dehydrogenase, quinone 1 1.2 to 1.8 AP3S1 Adaptor-related protein complex 3, -1.3 to -2.1 
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sigma 1 
ITGAE Integrin, alpha E 1.2 to 1.4 TM9SF4 
Transmembrane 9 superfamily 
protein member 4 
-1.4 to -1.6 
MGST2 Microsomal glutathione S-transferase 2 1.2 to 1.4 KLF6 Kruppel-like factor 6 -1.2 to -2.0 
NSMCE2 MMS21 homolog 1.2 to 1.6 BOP1 Block of proliferation 1 -1.3 to -1.5 
PTS 6-pyruvoyltetrahydropterin synthase 1.2 to 1.3 ZMYM6 Zinc finger, MYM-type 6 -1.2 to -1.5 
MGC39900 hypothetical protein MGC39900 1.3 AP1M1 
Adaptor-related protein complex 1, 
Mu1 
-1.4 to -1.6 
DBI Diazepam binding inhibitor 1.3 STK39 Serine threonine kinase 39 -1.4 to -1.5 
BCYRN1 Brain cytoplasmic RNA 1 1.3 to 1.6 PTPN1 
Protein tyrosine phosphatase, non-
receptor type 1 
-1.4 to -2.0 
TSTD1 
Thiosulfate sulfurtransferase-like 
domain 1 
1.2 to 1.4 PLAU Plasminogen activator, urokinase -1.5 to -1.6 
ZMAT3 Zinc finger, matrin type 3 1.3 to 1.5 ANXA3 Aannexin A3 -1.2 to -1.6 
PANK1 Pantothenate kinase 1 1.3 to 1.4 CARM1 
Coactivator-associated arginine 
methyltransferase 1 
-1.2 to -1.4 
ALDH1L1 Aldehyde dehydrogenase 1 1.3 to 1.9 BMP4 Bone morphogenetic protein 4 -1.2 to -1.8 
Appendices 
 
214 
 
RBM47 RNA binding motif protein 47 1.2 to 1.3 BCL2L1 
BCL2-like 1nuclear gene encoding 
mitochondrial protein 
-1.4 to -1.5 
TGIF1 TGFB-induced factor homeobox 1 1.3 to 1.4 DUSP5 Dual specificity phosphatase 5 -1.4 
FADS1 Fatty acid desaturase 1 1.2 to 1.4 CDT1 
Chromatin licensing and DNA 
replication factor 1 
-1.4 
S100A13 S100 calcium binding protein A13 1.2 to 1.4 GNPDA1 
Glucosamine-6-phosphate 
deaminase 1 
-1.3 to -1.6 
PIR Pirin (iron-binding nuclear protein) 1.2 to 1.3 PTPRA 
Protein tyrosine phosphatase, 
receptor type, A 
-1.2 to -1.4 
GCNT3 Glucosaminyl (N-acetyl) transferase 3 1.2 to 1.4 SLC1A3 Solute carrier family 1 -1.3 to -1.9 
OCIAD1 OCIA domain containing 1 1.2 to 1.3 VIL2 Villin 2 (ezrin) -1.2 to -1.7 
NR2F2 
Nuclear receptor subfamily 2, group F, 
member 2 
1.2 to 1.3 IDH3B 
Isocitrate dehydrogenase 3 (NAD+) 
beta 
-1.2 to -1.3 
GRINA 
Glutamate receptor, ionotropic, N-
methyl D-aspartate-associated protein 1 
1.2 to 1.3 C14orf173 
Chromosome 14 open reading 
frame 173 
-1.3 
ZCCHC14 
Zinc finger, CCHC domain containing 
14 
1.2 GMCL1 Germ cell-less homolog 1 -1.3 
HYAL1 Hyaluronoglucosaminidase 1 1.2 to 1.4 C1orf85 Chromosome 1 open reading frame -1.2 to -1.3 
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85 
  
 CCDC21 Coiled-coil domain containing 21 -1.2 to -1.3 
  
 KIAA0194 KIAA0194 protein -1.2 to -1.3 
  
 CMTM7 
KLF-like MARVEL 
transmembrane domain containing 
7 
-1.2 to -1.4 
  
 PES1 Pescadillo homolog 1 -1.2 to -1.3 
  
 SPRY1 
Sprouty homolog 1, antagonist of 
FGF signaling 
-1.2 
  
 CSNK1E Casein kinase 1 -1.2 to -1.3 
 
Appendices II. Gene expression data of mRNA profiles from GSTP1 silenced HCT116 cells. 
mRNA expression profiles from 2 individual HCT116
shGSTP1
 clones were compared against mRNA expression profiles from HCT116 (untreated) and HCT116
shcontrol
 cells 
(n=3) in a four-way comparison as described in Figure 5.5. The profiles were collaborated and the table shows genes which were either upregulated or downregulated 
similarly across each set of comparisons. The values show the range in fold difference of gene expression across each comparison. Probes that exhibited an adjusted P value 
of <0.05 are expressed. 
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GSTP1 clone 1 vs 
untreated 
P value 
GSTP1 clone 2 vs 
untreated 
P value 
GSTP1 clone 1 vs 
control plasmid 
P value 
GSTP1 clone 2 vs 
control plasmid 
P value 
Translation - Translation 
in mitochondria 
3.79E-05 
Protein folding - Response 
to unfolded proteins 
1.69E-07 
Response to hypoxia and 
oxidative stress 
 
1.06E-
03* 
 
Apoptosis - Endoplasmic 
reticulum stress pathway 
4.55E-05 
Protein folding - Folding 
in normal condition 
6.02E-05 
Protein folding - Folding in 
normal condition 
3.11E-04 
Immune response - 
Phagosome in antigen 
presentation 
 
2.33E-
02* 
 
Immune response - Antigen 
presentation 
1.25E-04 
Immune response - 
Antigen presentation 
2.62E-04 
Response to hypoxia and 
oxidative stress 
5.83E-04 
Protein folding - Response 
to unfolded proteins 
 
3.41E-
02* 
 
DNA damage - DBS repair 3.13E-04 
Cell cycle - Mitosis 2.84E-04 
Translation - Translation in 
mitochondria 
1.49E-03 
Apoptosis - Apoptotic 
mitochondria 
 
4.46E-
02* 
 
Protein folding - ER and 
cytoplasm 
1.01E-03 
Protein folding - 
Response to unfolded 
proteins 
3.05E-04 
Protein folding - Protein 
folding nucleus 
 
9.36E-
03* 
 
  
Signal transduction - Leptin 
signaling 
1.29E-03 
Immune response - 
Phagosome in antigen 
presentation 
1.12E-03 
Protein folding - ER and 
cytoplasm 
 
1.27E-
02* 
 
  
Signal transduction - WNT 
signaling 
1.54E-03 
Inflammation - Protein C 
signaling 
1.90E-03       
Response to hypoxia and 
oxidative stress 
2.21E-03       
Appendices 
 
217 
 
Transcription - mRNA 
processing 
2.53E-03       
 
Appendices III. Enrichment analysis of cellular processes upregulated in HCT116 cells silenced for GSTP1.  
The table shows statistically significant processes which are upregulated in HCT116
shGSTP1
 cells compared to HCT116 untreated or HCT116
shcontrol
 cells. * signifies processes 
which are not statistically significant but are common across other comparisons. 
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GSTP1 clone 1 vs 
untreated 
P value 
GSTP1 clone 2 vs 
untreated 
P value 
GSTP1 clone 1 vs 
control plasmid 
P value 
GSTP1 clone 2 vs 
control plasmid 
P value 
Cholesterol Biosynthesis 1.18E-05 Cholesterol Biosynthesis 1.33E-09 
Peroxisomal branched chain 
fatty acid oxidation 
 
5.68E-04 
 
Apoptosis and 
survival_Endoplasmic 
reticulum stress response 
pathway 
9.20E-07 
Immune 
response_Neurotensin-
induced activation of IL-8 
in colonocytes 
1.17E-04 
Mechanisms of CFTR 
activation by S-
nitrosoglutathione (normal 
and CF) 
3.75E-06 
Catecholamine metabolism 
/ Human version 
1.92E-03 
Immune 
response_Oncostatin M 
signaling via MAPK in 
human cells 
1.74E-04 
Mechanisms of CFTR 
activation by S-
nitrosoglutathione 
(normal and CF) 
5.05E-04 
CFTR folding and 
maturation (norm and CF) 
6.90E-06 
Triacylglycerol metabolism 
p.1 
2.89E-03 
Immune response_Antigen 
presentation by MHC class 
I 
2.50E-04 
CFTR folding and 
maturation (norm and 
CF) 
8.09E-04 
Apoptosis and 
survival_HTR1A signaling 
7.39E-05 
n-6 Polyunsaturated fatty 
acid biosynthesis 
4.97E-03 
Nicotine signaling in 
dopaminergic neurons, Pt. 2 
- axon terminal 
4.59E-04 
Apoptosis and 
survival_HTR1A 
signaling 
1.20E-03 
Neurophysiological 
process_Dopamine D2 
receptor transactivation of 
PDGFR in CNS 
4.53E-04 
n-3 Polyunsaturated fatty 
acid biosynthesis 
4.97E-03 
Immune response_Antigen 
presentation by MHC class 
II 
4.66E-04 
G-protein signaling_G-
Protein alpha-q signaling 
cascades 
2.46E-03 
Catecholamine metabolism 
/ Human version 
4.53E-04   
Development_Role of IL-8 
in angiogenesis 
5.81E-04 
Cytoskeleton 2.46E-03     Apoptosis and 6.39E-04 
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remodeling_RalA 
regulation pathway 
survival_Caspase cascade 
Catecholamine 
metabolism / Human 
version 
2.86E-03     
Triacylglycerol metabolism 
p.1 
7.33E-04 
NGF activation of NF-kB 3.04E-03       
 
Appendices IV. Enrichment analysis of cellular pathways upregulated in HCT116 cells silenced for GSTP1.  
The table shows statistically significant pathways which are upregulated in HCT116
shGSTP1
 cells compared to HCT116 untreated or HCT116
shcontrol
 cells. * signifies pathways 
which are not statistically significant but are common across other comparisons. 
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GSTP1 clone 1 vs 
untreated 
P value 
GSTP1 clone 2 vs 
untreated 
P value 
GSTP1 clone 1 vs 
control plasmid 
P value 
GSTP1 clone 2 vs 
control plasmid 
P value 
Aminoacyl-tRNA 
biosynthesis in cytoplasm 
3.54E-10 
Aminoacyl-tRNA 
biosynthesis in cytoplasm 
 
1.20E-05 
 
Cytoskeleton 
remodeling_Cytoskeleton 
remodeling 
4.88E-05 
Cytoskeleton remodeling_TGF, 
WNT and cytoskeletal 
remodeling 
 
1.59E-09 
 
Transcription_Ligand-
dependent activation of 
the ESR1/SP pathway 
6.08E-04   
Cytoskeleton 
remodeling_TGF, WNT and 
cytoskeletal remodeling 
5.95E-05 
Cytoskeleton 
remodeling_Cytoskeleton 
remodeling 
5.28E-06 
    
Cell cycle_Cell cycle 
(generic schema) 
1.56E-04 
Cytoskeleton 
remodeling_Keratin filaments 
5.50E-06 
    Cell adhesion_Gap junctions 1.56E-04 Cell adhesion_Gap junctions 1.54E-05 
    
Development_Role of 
HDAC and 
calcium/calmodulin-
dependent kinase (CaMK) in 
control of skeletal 
myogenesis 
3.98E-04 
Cytoskeleton 
remodeling_Neurofilaments 
 
5.38E-05 
 
    
Translation_Translation 
regulation by Alpha-1 
adrenergic receptors 
5.02E-04 
Cytoskeleton 
remodeling_Reverse signaling 
by ephrin B 
 
1.94E-04 
 
      
Cell adhesion_Endothelial cell 
contacts by junctional 
mechanisms 
6.98E-04 
 
Appendices 
 
221 
 
Cell adhesion_Histamine H1 
receptor signaling in the 
interruption of cell barrier 
integrity 
      
Cell adhesion_Chemokines and 
adhesion 
2.00E-03 
      
Cytoskeleton remodeling_Role 
of Activin A in cytoskeleton 
remodeling 
2.11E-03 
 
Appendices V. Enrichment analysis of cellular pathways downregulated in HCT116 cells silenced for GSTP1.  
The table shows statistically significant pathways which are upregulated in HCT116
shGSTP1
 cells compared to HCT116 untreated or HCT116
shcontrol
 cells. * signifies pathways 
which are not statistically significant but are common across other comparisons. 
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Appendices VI. S-nitrosylated proteins in HCT116 cells silenced for GSTP1. 
HCT116 cells were transiently transfected with 10nM siRNA targeted against GSTP1 or control siRNA and 
grown for 72 hours. Lysates were prepared from the cells and sulfhydryl groups blocked with S-Methyl 
methanethiosulfonate (MMTS). S-nitrosylated proteins were reduced with sodium ascorbate and labelled with 
Biotin-HPDP. Lysates (10µg) were resolved on a non-reducing SDS-PAGE gel and analysed by Western 
blotting. A streptavidin-HRP antibody (1:1000) was used for the detection of biotinylated proteins. 
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